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Summary
The majority of synaptic transmission occurring at mammalian central synapses
is mediated by glutamate acting on specific trans-membrane receptors. The discovery
that certain forms of synaptic plasticity believed to underlie different forms of learning
and memory were mediated by glutamate receptors led to the development of a series of
compounds that could facilitate this process, through the positive modulation of AMPA
receptors. These compounds, termed collectively AMPA potentiators, were originally
developed as cognitive enhancers but AMPA potentiators have also been shown to
enhance the expression of the neurotrophin BDNF. This has led to the prediction that
AMPA potentiation may be able to enhance cellular resilience and survival, stimulate
neurogenesis and promote synaptic integrity. In this thesis two principal aspects of
AMPA potentiation were addressed: their ability to induce structural plasticity in vitro
and in vivo and their ability to produce long-lasting, persistent changes in brain
biochemistry and neuronal development.
The effect of an AMPA potentiator on structural plasticity in vitro
The human neuroblastoma cell line SH-SY5Y was used as a model for in vitro
neuroplasticity. A statistically robust and reproducible method for measuring the
average length of neuritic processes was developed from first principles. The effects on
neurite growth of the AMPA potentiator LY404187 were investigated using this method.
LY404187 (0.1 -1/xM) significantly increased the average length of neurites only in the
presence of the receptor agonist s-AMPA (lOjtiM) and was dependent on AMPA
receptor activation. LY404187 also increased expression of the cytoskeletal protein
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neurofilament-heavy chain. LY404187 increased neurite length in a BDNF-dependent
manner as co-incubation of SH-SY5Ys with an antibody specific to BDNF blocked the
increase in neurite length.
The effect of an AMPA potentiator on structural plasticity in vitro
The ability of LY404187 to enhance structural plasticity was tested in in vivo.
Unilateral excitotoxic lesions of the entorhinal cortex in mice led to a loss of synapses in
the ipsilateral dentate gyrus. In order to establish whether LY404187 could promote the
regeneration on synapses in this model (0.5mg/kg s.c) was administered twice daily for
14 and 28 days. Immuno-histochemical analysis revealed that although the lesion was
successful in producing a significant ipsilateral loss in synapse density, LY404187
administration had no significant effect on structural plasticity.
The rate of neurogenesis in the dentate gyrus following lesioning and LY404187
administration was also measured. Immuno-histochemical detection of newly generated
cells within the subgranular layer of the dentate gyrus revealed no significant change in
the number of cells in either hemisphere 14 and 28 days following ECL with or without
administration of LY404187 (0.5mg/kg s.c).
Biochemical changes in vivo associated with chronic AMPA
potentiation
The ability of the AMPA potentiator LY450108 (0.5mg/kg s.c.) was tested for its
ability to induce long-lasting changes in mouse brain biochemistry and physiology.
Using a dosing paradigm aimed at identifying the chronic and long lasting effects of
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AMPA potentiation in vivo three studies were carried out to investigate multiple end
points: protein expression down stream of AMPA receptor potentiation, monoamine
neurotransmitter levels and hippocampal neurogenesis.
Two potential effectors of AMPA potentiator-mediated neuroplasticity are
ERK1/2 (MAP 44/42) and the transcription factor CREB. Using western blotting and
immunohistochemistry techniques, phosphorylation levels of these key proteins were
monitored in the hippocampus. LY450108 produced no significant change in the levels
of pERKl/2 in the whole hippocampus when measured by Western Blotting. Immuno-
histochemical detection of pERKl/2 and pCREB in individual cells of the denate gyrus,
CA1, CA2 and CA3 allowed for a more quantative assessment of protein
phosphorylation following AMPA potentiation. Statistical analysis showed that
LY450108 produced no significant changes in protein levels across all regions and time
points.
Adult neurogenesis is believed to be a crucial mediator of certain forms of
cognitive and behavioural plasticity. Recently it in the actions of common
antidepressants and forms a key area of the neurotrophin hypothesis of depression.
AMPA potentiators increase the expression of neurotrophins in the hippocampus where
they may regulate cell survival and development. AMPA potentiators have been shown
to increase the rate of neurogenesis in the hippocampus following chronic and acute
administration. Using BrdU as a marker for newly generated cells and NeuN as a
neuronal marker the rate of neurogenesis and neuronal development was measured.
Statistical analysis of BrdU+ cells in the subgranular layer of the hippocampus revealed
no significant change following administration of LY450108 across all time points. The
development of newly generated cells can be assessed by double labelling of BrdU+ cells
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with other cell-type specific markers. The percentage of BrdU+ cells that were also
positive for the neuronal marker NeuN was used as an assessment of the rate of neuronal
development in the dentate gyrus. Statistical analysis revealed no significant change in
the percentage of double labelled cells following administration of LY450108 across all
time points.
AMPA potentiators may have therapeutic potential in the treatment of
depression. They have been shown to be active in animal models of depression. They
also act as cognitive enhancers and have been shown to enhance BDNF expression and
neurogenesis, both of which have recently been implicated in depression and the
mechanisms of action of common antidepressants. All of the most commonly prescribed
antidepressants increase synaptic levels of monoamine neurotransmitters. In this study
the effect of chronic administration of LY450108 on the levels of NA, 5HT and DA and
their principal metabolites was investigated. High Performance Liquid Chromatography
allows for rapid resolution of the components of biological mixtures. Electrochemical
detection allows for highly sensitive (picogram) quantification of the concentration of
each component in real time. The levels of monoamines detected in these experiments
were consistent with published studies. Statistical analysis revealed no significant
change in the levels of any of the monoamines measured following administration of
LY450108.
AMPA potentiaton holds promise for the treatment for many CNS disorders.
This thesis provides support for this hypothesis by demonstrating that AMPA
potentiation can induce structural plasticity in a BDNF dependant mechanism. Although
the in vivo studies were inconclusive the consequences of chronic AMPA potentiator




1.1.1 Glutamate as a neurotransmitter
Although evidence for a role of glutamate in neurotransmission first appeared
over 50 years ago (Hayashi 1954) it was not until 20 years later, when significant
pharmacological, biochemical and immuno-histochemical evidence had been
accumulated, that glutamate became widely accepted as the primary excitatory
neurotransmitter in the mammalian brain (reviewed in Watkins 2000). Early
experiments carried out by Curtis and Watkins on the excitatory effect of exogenously
applied glutamate on cultured spinal neurons (Curtis, Phillis et al. 1959a; Curtis, Phillis
et al. 1959b) and subsequent structure-function studies, led to the "3-point receptor"
model describing the conserved structural requirements of different glutamate analogues
(Watkins 2000). However, the abundance of glutamate in the human brain, its role in
intermediary metabolism and protein synthesis, coupled with a lack of specific
antagonists for glutamate-induced excitation, delayed the acceptance of glutamate as a
neurotransmitter. The earliest evidence for the existence of multiple glutamate receptors
came from studies showing heterogeneous responses across different thalamic and spinal
nuclei to glutamate analogues (McLennan, Huffman et al. 1968; Duggan 1974;
McCulloch, Johnston et al. 1974). However these data were interpreted as showing
glutamate acting on different populations of excitatory synapses rather than through
different receptor subtypes. Glutamate receptor pharmacology during the late 1970s,
particularly in the UK, led to the synthesis and discovery of over 75 compounds with
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excitant properties similar to glutamate (for a review seeMcLennan 1983). Among
these, NMDA (Curtis and Watkins 1960), and the naturally occurring kainate and
quisqualate (Shinozaki and Konishi 1970; Shinozaki and Shibuya 1974), were the most
potent and had the most distinct excitatory profiles. However it was not until the
discovery of selective antagonists to these compounds were discovered, that the notion
of glutamate receptors involved in neurotransmission began to be more widely accepted.
The first conclusive evidence for the existence of multiple receptor subtypes came from
studies on the effects of Mg2+ and D-a-aminoadipate (DaAA) on NMDA-induced
excitation (Biscoe, Evans et al. 1977; Evans, Francis et al. 1978). This led to the
classification of glutamate receptors into three main groups, determined by their
response to various antagonists. Thus NMDA and L-aspartate responses were sensitive
to Mg2+ and DaAA, whereas both quisqualate and 1-glutamate-induced excitation was
sensitive to L-glutamic acid diethylester (GDEE) with kainate induced responses being
insensitive to either antagonist. This classification of NMDA, quisqualate and kainate
preferring receptors (Watkins and Evans 1981) has remained relevant to this day and is a
testament to the quality of two decades of pharmacological and electrophysiological
investigation.
Throughout the 1980s, a range of more specific pharmacological tools was
developed: the NMDA receptor antagonists, 2-amino-5-phosphono-valerate (2APV)
(Davies, Francis et al. 1981), MK-801 (Wong, Kemp et al. 1986) and PCP (Lodge and
Anis 1982), the highly selective agonist for GDEE sensitive receptors alpha-amino-3-
hydroxy-5-methyl-4-isoxazoleacetic acid (AMPA) (Krogsgaard-Larsen, Honore et al.
1980) and the selective antagonist CNQX (Honore, Davies et al. 1988). These
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developments supported the existent classification system and confirmed glutamate
receptors as the mediators of synaptic transmission in the central nervous system.
Advances in radioligand binding studies (Monaghan and Cotman 1982; Monaghan, Yao
et al. 1984; Olverman, Jones et al. 1984) and immuno-histochemical techniques
(reviewed in Iversen 1978 and Cuello 1978), were crucial to the acceptance of the
existence of multiple glutamate receptors involved in synaptic transmission.
As well as the established NMDA, quisqualate and kainate receptors, the
existence of another class of receptor, insensitive to NMDA and non-NMDA
antagonists, was being documented, (McLennan 1983). The observation that glutamate
was capable of inducing second messenger molecules, and mobilising intracellular Ca2+
and the cloning of a glutamate receptor with distinct biochemical properties (Sladeczek,
Pin et al. 1985; Nicoletti, Iadarola et al. 1986; Nicoletti, Meek et al. 1986; Sugiyama, Ito
et al. 1987) opened up the field of metabotropic glutamate receptor research.
During the early 1990s a number of groups began cloning and expressing
functional recombinant glutamate receptors in mammalian cells, this led not only to the
elucidation of their structure but also to the reclassification of glutamate receptors by
their molecular, rather than pharmacological, properties (Figure 1.1). cDNA encoding a
glutamate receptor similar to frog and chick kainate binding proteins designated GluR-
K1 (later shown to be GluRA) was first cloned by Hollmann and colleagues (Hollmann,
O'Shea-Greenfield et al. 1989). In 1990 three groups reported the cloning of functional
AMPA-type glutamate receptors (Keinanen, Wisden et al. 1990; Nakanishi, Shneider et
al. 1990; Sakimura, Bujo et al. 1990), but it was the work of Seeburg and colleagues that
was most comprehensive in its characterisation of the AMPA receptor subunits. They
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cloned four cDNAs that encoded proteins of approximately 900 amino-acids in length
and shared between 56% and 70% sequence homology (Keinanen, Wisden et al. 1990).
The patterns of mRNA expression in rat brain and their pharmacology when expressed
in Xenopus oocytes, indicated that they had cloned a family of AMPA-type glutamate
receptors. In the following years a rush to clone other glutamate receptors lead to the
generation of recombinant NMDA receptors (Moriyoshi, Masu et al. 1991), kainate
receptors (Werner, Voigt et al. 1991) and metabotropic glutamate receptors (Houamed,
Kuijper et al. 1991; Masu, Tanabe et al. 1991). Since the creation of recombinant
receptors the detailed molecular structure and the function of glutamate receptors has
been intensively studied (Hollmann and Heinemann 1994; Dingledine, Borges et al.
1999). Enormous advances have been made in the characterisation of the structure and
function of AMPA receptor subunits from the structural basis of calcium permeability
(Verdoorn, Burnashev et al. 1991), glutamate binding site structure (Armstrong, Sun et
al. 1998), mechanisms of receptor desensitisation (Sun, Olson et al. 2002) and
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Figure 1.1 Glutamate receptor classification
Glutamate receptor subtypes based on molecular classification. Receptors are divided
into metabotropic and ionotropic receptors depending on their permeability to ions or
their ability to activate second messenger system. There are three classes of ionotropic
receptors: NMDA (composed of NR1 and NR2A-D subunits), AMPA (composed of
GluRA-D/GluRl-4 subunits) and Kainate (composed of GluR5-7 and KA1-2 subunits).
All ionotropic receptor subunits have an external N terminal, 4 trans-membrane
domains, a re-entrant loop between TM 2/3 and an internal C-terminus. Subunits
assemble into homo- or hetero- tetramers. Adaptedfrom Dingledine (1999).
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1.1.2 AMPA receptor structure
Intense research following the cloning of AMPA receptors in 1990 led, in a short
space of time, to the characterisation of a number of major structural features of AMPA
receptor subunits that determined the biophysical properties of the associated ion
channels. Most of these features are either slice variants or RNA editing sites. The first
such feature was the so-called Flip/Flop site, a 38 amino acid sequence preceding the
fourth transmembrane region (IV) (Figure 1.2). Alternative splicing of the gene during
development changes the composition of this area by 9-11 residues, determining the
desensitisation dynamics of the receptor. Seeburg and colleagues showed that flip form
containing receptors desensitised less rapidly than flop forms, allowing greater ion flow
through the receptor (Sommer, Keinanen et al. 1990). Interestingly they proposed that
this form of alternative splicing may underlie some forms of synaptic plasticity. Studies
into the current-voltage relationship of recombinant receptors revealed that the GluRB
subunit had unique rectification properties and concluded, through site directed
mutagenesis studies, that the identity of the residue at position 586, located in the second
transmembrane region (II) determined the calcium flow through the receptors (Hume,
Dingledine et al. 1991; Verdoorn, Burnashev et al. 1991). GluRA, C and D subunits all
have a neutral glutamine (Q) residue at that point, whereas GluRB subunits have a
positively charged arganine (R). This difference between subunits was shown to be a
result of RNA editing following transcription of a glutamine encoding transcript
(Sommer, Kohler et al. 1991). It was also shown that most native receptors behaved like
GluRB containing recombinant heteromers although there were notable exceptions, in a
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subset of neurons in the hippocampus, retinal bipolar cells and Bergman Glia in the
cerebellum (Nakanishi 1992) indicating the important role GluRB subunits play in in
vivo synaptic transmission.
C-terminal splice variants add further variety to AMPA receptor structure.
GluRB and D display alternative splice forms that contain a longer and shorter C
terminal region respectively (Gallo, Upson et al. 1992; Kohler, Kornau et al. 1994).
Although the exact functional implications of this variability have not been elucidated,
GluR4c has been shown to be widely expressed in the human brain (Kawahara, Ito et al.
2004) and interactions between the C terminal region of GluRB subunit and intracellular
proteins, through the PDZ binding motif, have been implicated in the establishment and
expression of certain forms of synaptic plasticity (Collingridge and Isaac 2003; Malenka
2003). The first crystal structure of the glutamate binding site of AMPA receptors was
provided by Armstrong et al. (1998) and led in the ensuing years to greater
understanding of the mechanics of channel activation and the action of agonist and
partial agonists. In an elegant series of experiments, researchers in the lab of Gouaux
created a glutamate binding core comprising the SI and S2 domains of GluR2 linked by
a hydrophilic linker (Armstrong, Sun et al. 1998). The structure of this chimera bound
to kainate was resolved revealing a clam-shaped structure with glutamate bound at the
interface of the two regions. The kainate bound formation was shown to be at an
intermediate closure state between that of the glutamate-binding protein (QBP) open and
closed conformations. This and subsequent experiments with a range of antagonists and
full and partial agonists (Armstrong and Gouaux 2000) showed that the S1S2 domain
closed to different degrees depending on the bound ligand; KA produced a closure of
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12° whilst AMPA caused a shift in the domains of around 20°. They concluded from
their experiments that the extent to which the channel is opened depends on the extent of
the domain closure (Armstrong and Gouaux 2000; Erreger, Chen et al. 2004). The
competitive antagonist DNQX produced no change indicating that antagonists may
stabilize the binding region in the open conformation preventing any channel opening.
This work was carried forward by Jin et al which showed a correlation between the
potency of five agonists, 5-substituted willardines; a series of partial agonists that each
differed by just one atom, and the extent of domain closure of the ligand binding core
(Jin, Banke et al. 2003).
AMPA receptors are characterized by very rapid (millisecond) desensitisation
(Hollmann and Heinemann 1994; Jones and Westbrook 1996; Dingledine, Borges et al.
1999). Although this process had been very well defined using electrophysiological
techniques, it was not until recently that a mechanistic model explaining this
phenomenon was proposed. Sun et al. (2002) proposed that AMPA receptors behave as
a 'dimer of dimers' whereby the SI region of the glutamate binding regions of two
subunits interact regulating the opening and desensitisation of the channel. The
researchers proposed that following agonist binding the binding region closed whilst the
SI regions remained stable, transferring the strain associated with this shift to the
transmembrane channel-forming region of the subunits leading to the channel opening.
Following this there is a rearrangement of the dimer interface leading to a stable
desensitised state in which glutamate binding is no longer coupled to channel opening.
The agonist remains bound, the channel remains closed and the receptor remains
insensitive to glutamate (Sun, Olson et al. 2002; Erreger, Chen et al. 2004). This period
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of deactivation and desensitisation following receptor activation shapes the post synaptic
response to presynaptic glutamate release (Jones and Westbrook 1996). This feature of
AMPA receptors is not fixed. Structural features of GluRA-D subunits, such as the
flip/flop region, change the desensitisation dynamics of the receptor (Sommer, Keinanen
et al. 1990) and the auxiliary AMPA subunit Stargazin (see below) blocks
desensitisation and increases AMPA mediated currents in vivo (Yamazaki, Ohno-
Shosaku et al. 2004; Priel, Kolleker et al. 2005; Tomita, Adesnik et al. 2005). The
ability of a receptor to alter its response to agonist binding depending on intrinsic (splice
variation, auxiliary subunits) or extrinsic (strength and duration of synaptic activity)





Figure 1.2 Structure of the AMPA receptor GluR2/B subunit
Illustration showing the major structuralfeatures that regulate the receptor's activation
and desensitisation dynamics as well as its interaction with intracellular proteins that
govern receptor localisation and trafficking: a large extra-cellular N-terminal domain,
the clam shaped glutamate binding domain, four transmembrane domains (I-IV) and an
intra-cellular C-terminal domain, containing PDZ interacting domains. Key
determinants of ion channel properties: Flip/Flop region and Q/R splice site. The
glutamate binding region and the principal region involved in protein-protein
interaction. Other AMPA subunits contain all these features and share between 56%
and 70% sequence homology.
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1.1.3 AMPA receptor mediated synaptic plasticity
Research in the field of behavioural pharmacology has gone a long way over the
past 40 years to answer some of the fundamental questions surrounding the mechanism
underlying complex behaviour (Robbins and Murphy 2006). Elucidating the
mechanisms of synaptic plasticity, first postulated by Donald Hebb as being the main
substrate of memory formation (Hebb 1949), has dominated the research in this field.
As the role of glutamate as a neurotransmitter was being revealed and the
pharmacological tools became available to study its actions, the phenomenon of Long
Term Potentiation (LTP) and its role in memory formation became apparent
(Collingridge and Bliss 1995).
Synaptic plasticity is a highly complex field and has been reviewed in detail
elsewhere (Malenka 2003; Lynch 2004; Malenka and Bear 2004). There are, however, a
number of key features that are relevant to this thesis: The first is the fundamental
mechanism by which LTP is initiated. Repeated activation of AMPA receptors
depolarises the postsynaptic membrane that in turn releases the voltage dependent
magnesium block of NMDA receptors that gate the flow of Ca2+ into the cell. The rise
in intracellular calcium has a number of downstream effects, mediated in part by
CaMKII and CREB, that trigger the expression of LTP, partly through the process of
synaptic tagging (Frey and Morris 1997; Frey and Morris 1998; Henley 2001; Bredt and
Nicoll 2003; Malenka 2003; Cavazzini, Bliss et al. 2005). Key observations that helped
develop this model have shown that blockade of NMDA receptors suppresses LTP
formation in vitro (Collingridge, Kehl et al. 1983) and impaired certain forms of
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memory in vivo (Morris, Anderson et al. 1986). Second is the principal expression of a
potentiated synapse; the modification of AMPA receptor stoichiometry, density and
phosphorylation (Song and Huganir 2002). Proteins such as NSF (Dong, Zhang et al.
1999), GRIP (Dong, O'Brien et al. 1997; Dong, Zhang et al. 1999) and PICK1 (Xia,
Zhang et al. 1999) have all been shown to regulate the surface clustering of AMPA
receptors through interaction with the C terminus of GluR subunits and are involved in
the expression of LTP (Henley 2001; Malenka 2003). Evidence suggests that these
interactions may be transient and work in concert with other scaffolding proteins to
regulate AMPA subunit trafficking (Fukata, Tzingounis et al. 2005). Over the last few
years a family of proteins that have a much more intimate association with AMPA
receptors and regulate their localisation and their pharmacological properties has been
characterised. Stargazin or y-2 was first cloned as a putative calcium channel y-subunit
that was absent in mice carrying a spontaneous mutation, so called 'stargazer' mice
(Letts, Felix et al. 1998). These mice developed spontaneous seizures that led to their
characteristic rearing that gave them their name. Investigations into the development of
cerebellar granule cells revealed that stargazer mutant mice displayed synaptic responses
lacking an AMPA receptor mediated component (Hashimoto, Fukaya et al. 1999). This
observation was investigated further by Chen and colleagues who made the important
observation that stargazin interacts with AMPA receptors and regulates their synaptic
targeting (Chen, Chetkovich et al. 2000). They also demonstrated that stargazin did not
alter the calcium currents in the cell, concluding that the primary role of the protein was
to regulate AMPA receptor trafficking, rather than to act as a calcium channel (Chen,
Chetkovich et al. 2000). A family of stargazin-like proteins named y3, 4 and 8, that bind
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with AMPA receptors, were soon identified and named transmembrane AMPA receptor
regulatory proteins (TARPs). Recently TARPs have been shown to enhance AMPA
mediated currents in vivo (Yamazaki, Ohno-Shosaku et al. 2004) by reducing
desensitisation, accelerating recovery from desensitisation and slowing deactivation
(Priel, Kolleker et al. 2005; Tomita, Adesnik et al. 2005; Turetsky, Garringer et al.
2005). Evidence on the role of stargazin in regulating AMPA in vivo suggests that
potentiation of AMPA receptors may enhance physiological mechanisms (Nicoll,
Tomita et al. 2006; Tomita, Sekiguchi et al. 2006)
The receptor composition is also important to the expression of LTP, with the
synaptic delivery of GluRl/2 subunits a key step in this process. (Shi, Hayashi et al.
2001). The discovery of 'silent' synapses provided strong evidence for the role of
AMPA receptors in the expression of LTP. These synapses are devoid of synaptic
AMPA receptors but have NMDA receptors. LTP can be induced at these synapses by
the delivery of AMPA receptors to the synapse (Gomperts, Rao et al. 1998). The
phosphorylation of AMPA receptors during LTP has also been shown to modulate their
function (Benke, Luthi et al. 1998; Nicoll and Malenka 1999). These two aspects are
relevant to this thesis because AMPA potentiation can be hypothesised to induce the
induction of LTP and mimic or amplify aspects of its expression. Both these processes
might be important in providing cognitive enhancement.
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1.1.4 AMPA receptors and cognitive function
Following the seminal observation that NMDA receptors were essential for the
formation of hippocampal dependant memories (Morris, Anderson et al. 1986) a number
of studies showed that these mechanisms were also important in the formation of fear
conditioning in the amygdala (Miserendino, Sananes et al. 1990), stimulus-response
learning in the striatum (Packard and Teather 1997) and the acquisition of approach
behaviour in the nucleus accumbens (Di Ciano, Cardinal et al. 2001). Recently it has
become clear that although NMDA receptor function is crucial for the formation of
behavioural responses and memories, AMPA receptors are crucial for the formation and
retrieval of certain forms of memory (Day, Langston et al. 2003; Bast, da Silva et al.
2005). Thus blockade of AMPA receptors disrupts recall as well as encoding (Robbins
and Murphy 2006). The use of pharmacological intervention in behavioural tests using
rats has been paralleled by genetic studies using mice (Reisel, Bannerman et al. 2005;
Schmitt, Sprengel et al. 2005) and researchers have been able to dissect specific forms of
memory formation (Bannerman, Rawlins et al. 2006).
As pharmacological and genetic studies prove, disruption of AMPA and NMDA
receptors has profound effects on performance in certain established behavioural
paradigms. Synaptic disruption in humans is obviously less amenable to intervention.
However there are a number of key observations that show that the mechanisms
involved in memory and behaviour in humans are broadly similar to those seen in
experimental animals. In conditions such as Alzheimer's disease, that are characterised
by widespread and progressive loss of synapses in cortical and limbic areas, the loss of
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long term memories and cognitive functions are the most striking symptoms. The most
convincing evidence comes from patients who have taken drugs that specifically
interfere with glutamate receptor function. The compounds PCP and ketamine, which
both suppress the formation of LTP through their antagonism of NMDA receptors
(Stringer, Greenfield et al. 1983; Zhang and Levy 1992), also impair performance in
memory tests in humans that are comparable to conventional animal tests (Honey,
Honey et al. 2005; Rowland, Astur et al. 2005). At higher doses these compounds
produce profound schizophrenia-like symptoms that have been exploited to study the
mechanisms of this condition in animal models (Morris, Cochran et al. 2005).
In the brain 60% of all neurons, including all cortical pyramidal neurons and
thalamic relay neurons utilise glutamate as their primary neurotransmitter (Javitt 2004).
Modulation of glutamatergic synaptic transmission is involved in higher cognitive
processes many of which are severely affected in neuropsychiatry conditions such as
depression and schizophrenia. Neurodegenerative conditions such as Alzheimer's and
Parkinson's diseases are also characterised by the loss of synapses in cortical and sub¬
cortical areas. Synaptic transmission through glutamate receptors has therefore become
a popular target for therapeutic intervention. AMPA potentiators are currently in clinical
trials for the treatment of depression, anxiety, schizophrenia, mild cognitive impairment,
ADHD, Alzheimer's and Parkinson's disease. For each of these conditions there is
substantial evidence for impairment of glutamatergic transmission.
The modulation of synaptic transmission through glutamate receptors is critical
for the best studied form of synaptic plasticity, LTP. Most neuroscientists now believe
this process to be a fundamental substrate for learning and memory. Over the last
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decade there has been a parallel effort to synthesise compounds that can alter this
process with the view of creating viable clinical compounds for the treatment of age-
related and pathological cognitive disorders.
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1.2 AMPA receptor potentiators
1.2.1 Introduction
The role of glutamate receptors in the formation and expression of synaptic
plasticity and consequently in higher cognitive function provided the intellectual basis
for the development of positive modulators of AMPA receptors (Morris, Anderson et al.
1986; Lynch, Muller et al. 1988; Muller, Joly et al. 1988; Muller and Lynch 1988). The
central hypothesis predicts that positive modulation of AMPA receptors will facilitate
the induction of LTP by lowering the threshold for NMDA receptor recruitment. This
would lead to cognitive enhancement, with obvious clinical benefit (Lynch 2004).
During the early 1990s a number of compounds were shown to be capable of
potentiating AMPA receptor mediated currents. The plant lectin concanavalin-A was
the first compound shown to act as a positive modulator of quisqualate receptors at
mammalian synapses (Mayer and Vyklicky 1989). Soon after, the nootropic agents
aniracetam and piracetam were identified as AMPA potentiators (Ito, Tanabe et al.
1990), able to reverse chemically-induced memory impairment in rats (Lazarova-
Bakarova and Genkova-Papasova 1989) and improve memory in humans (Lee and
Benfield 1994). Finally the diuretic diazoxide, and particularly its derivative
cyclothiazide, was shown to potentiate AMPA receptor responses with much higher
potency than aniracetam (Yamada and Rothman 1992; Yamada and Tang 1993).
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1.2.2 Classes of AMPA receptor potentiator
These discoveries led to the synthesis of the principal classes of AMPA
potentiator. Gary Lynch and colleagues developed a series of aniracetam derivatives,
bezoylpiperidines, termed 'AMPAkines'. The prototypical AMPAkine, CX-516, was
shown to potentiate synaptic transmission in vitro with much higher potency then
previously described compounds. Crucially it could facilitate the induction of LTP (Arai,
Guidotti et al. 1996), cross the blood-brain barrier, potentiate central transmission and
facilitate memory formation with much higher potency then previously described
compounds such as aniracetam and piracetam (Staubli, Perez et al. 1994; Staubli, Rogers
et al. 1994).
The thiazide derivative cyclothiazide is the most well-characterised AMPA
potentiator and remains an important tool to investigate the mechanisms of AMPA
potentiation (Sun, Olson et al. 2002). It is not, however, clinically relevant due to its
poor brain penetration. However, IDRA-21, another thiazide, has been shown to
potentiate AMPA mediated transmission in vitro and in vivo (Bertolino, Baraldi et al.
1993; Zivkovic, Thompson et al. 1995)
The final major class of AMPA potentiator are the biarylpropylsulphonamides.
These were first synthesised by Eli Lilly (Omstein, Zimmerman et al. 2000) and have
been shown to be the most potent AMPA potentiators so far described. They are highly
selective potentiators of AMPA receptors and show good brain penetration and are
active in a number of animal behavioural models (Bai, Li et al. 2001; Baumbarger,
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Muhlhauser et al. 2001; Li, Tizzano et al. 2001; Vandergriff, Huff et al. 2001; Quirk and
Nisenbaum 2002).
Recently Lilly Neuroscience have described two further generations of AMPA
potentiator that have nanomolar potencies at recombinant AMPA receptor subunits
























Figure 1.3 Classes of AMPA potentiators
Chemical structures of representative members of the principal classes of positive
AMPA receptor modulators. (Kessler and Arai 2006)
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1.2.3 Pharmacology of AM PA receptor potentiators
Positive allosteric modulators of AMPA potentiators of different chemical
classes display a range of potency and efficacy. However, they share a number of key
features that give them their basic properties. Firstly they are unable, on their own, to
induce AMPA receptor activation. Secondly, upon binding of the agonist, the period of
channel opening is prolonged and the amplitude of current is increased (Figure 1.4).
Where they differ is in their binding regions and consequently, their mechanisms of
receptor potentiation. The exact nature of the binding site for allosteric modulators
remains uncertain. A number of studies have shown that AMPA potentiators show
selectivity between flip and flop variants of receptor subunits (Partin, Bowie et al. 1995;
Arai, Xia et al. 2002; Quirk and Nisenbaum 2003) and site mutagenesis has revealed that
the potencies of AMPA modulators are particularly sensitive to changes in the flip-flop
region. However the exact mechanisms of action appear to be distinct between different
classes of compound. AMPAkines appear to be more selective for flop over flip splice
variants (Kessler and Arai 2006), while biarylpropylsulphonamide compounds and
benzothiazides are more selective for flip over flop splice variants (Ornstein,
Zimmerman et al. 2000; Gates, Ogden et al. 2001; Miu, Jarvie et al. 2001). There are
also class differences between selective effects on the deactivation and desensitisation of
AMPA receptors. Aniracetam has been shown to slow desensitisation of AMPA
receptors, prolonging the opening time for the channel and increasing the peak current
flow (Isaacson and Nicoll 1991). Aniracetam is also more selective for flop variants of
GluR subunits (Xiao, Staubli et al. 1991). AMPAkines, although structurally related to
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aniracetam, have been shown to separate into two subfamilies that differ in their
respective actions (Arai, Kessler et al. 1996; Arai, Kessler et al. 2000; Arai, Xia et al.
2002). Biarylpropylsulphonamides are potent blockers of receptor desensitisation and
are more selective for flip isoforms (Miu, Jarvie et al. 2001). Work by Gouaux and
colleagues has proposed that cyclothiazide acts as an allosteric potentiator by binding at
the interface between binding domains of adjacent subunits of the receptor, stabilising
this interface and preventing desensitisation (Sun, Olson et al. 2002). Quirk and
colleagues hypothesised that LY404187 and other biarylpropylsulphoamides may work
in a similar fashion (Quirk and Nisenbaum 2003).
The differences in action, potency and subunit selectivity across different classes
of compounds is an important feature of AMPA potentiators and one that may be
exploited in clinical use. AMPA receptors are widely distributed across the brain and
have a range of developmental and topographical expression patterns both in splice
variants and subunit compositions (Hollmann and Heinemann 1994). It is reasonable to
assume that differential modulation of different populations of AMPA receptors may
have a range of behavioural and physiological consequences. Given the wide spectrum
of conditions potentially treatable by AMPA modulation this seems to be a strong area
of future drug development. Early evidence in imaging the effects on brain activity has
already shown that different compounds can have distinct patterns of action across
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Figure 1.4 Pharmacological actions of AM PA potentiators
a) LY404187 is able to enhance the amplitude of AMPA receptor currents only in the
presence of AMPA. This response in blocked by NBQX. b) LY404187 is able to
potentiate glutamate evoked currents in cerebellar granule cells with over 100 fold
higher more potency than older AMPA potentiators, c) The differential effects on two
aspects of AMPA receptor kinetics of two classes of AMPA potentiator. Cyclothiazide
blocks desensitisation but has little or no effect ofdeactivation. CX516 on the other hand
has a smaller effect on desensitisation but has a large effect on the rate of deactivation
of AMPA receptors. This phenomenon is seen across many AMPA potentiators each
having specific pharmacokinetic profiles. From Gates et al. (2001) and Lynch (2004).
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1.2.4 The AM PA potentiators LY404187 and LY450108
In this thesis I have studied the effects of two biarylpropylsulphonamide AMPA
potentiators, LY404187 and LY450108. The former is one of the best characterised of
Lilly's first generation of potentiators. LY404187 is -100 times more potent than
cyclothiazide at potentiating AMPA receptors in isolated cerebellar Purkinje neurons
(Figure 1.4), potentiates hippocampal AMPA receptor mediated currents at nanomolar
concentrations and is highly selective for GluRl-4 receptors with EC50 values ranging
from 0.22-5jtiM (Gates, Ogden et al. 2001; Miu, Jarvie et al. 2001). LY404187 shows
good brain penetration and can enhance synaptic transmission in rat prefrontal cortical
neurons (Vandergriff, Huff et al. 2001), increase glucose utilisation and c-fos activation
in rats (Fowler, Whalley et al. 2004). LY404187 has also been shown to promote the
expression of the neurotrophin BDNF in vivo (Mackowiak, O'Neill et al. 2002) and has
recently shown neurotrophic like properties in vivo (O'Neill, Murray et al. 2004) (Figure
1.6). Behavioural studies have shown that LY404187 is effective as a cognitive
enhancer in a water maze test and can reduce immobility in the forced swim test (Quirk
and Nisenbaum 2002). In vivo studies have shown that LY404187 is effective at
enhancing BDNF expression, potentiating central synapses and promoting structural
plasticity at doses of between O.lmg/kg and lOmg/kg (Quirk and Nisenbaum 2002).
LY450108 has been less well described in the literature. It was initially
developed as a clinical candidate and human pharmacokinetic studies have recently been
made available (Jhee, Chappell et al. 2006). Although extensive pharmacological
comparisons between LY450108 and LY404187 are not available, they have both been
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shown to enhance the expression of BDNF in vitro and have been shown to have
comparable neurotrophic effects in 6-OHDA lesion models of Parkinson's Disease
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Figure 1.5 In vitro actions of LY450108
(Upper) LY450108 can induce the expression of BDNF in cortical neurons at
concentrations between 1 and 10 pM. (Lower) The potentiation of native AMPA
receptors in various cell types by LY450108 (pM range) is comparable to that of
LY404187 (Quirk and Nisenbaum 2002). Figures taken from conference abstract
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Figure 1.6 In vivo actions of LY404107 and LY450108
(a) Data showing the effect of AMPA potentiation on the firing rate of prefrontal
cortical neurons in vivo. Both LY404187 (left) and LY450108 (right) enhance the rate of
firing in these cells with a 100-fold higher potency than CX516 (Quirk and Nisenbaum
2002) (b) Neurotrophic effect of LY404187 and LY450108 in a rat 6-OHDA lesion
model. Images are representative of a series of studies performed by O'Neill et al
showing that AMPA potentiation can promote the recovery of TH immunoreactivity in
the caudate nucleus following partial lesions of the nigro-striatal tract. The authors
concluded that AMPA potentiation could enhance sprouting ofsurviving dopaminergic




i to ino looo loom
Dosc(ug/k& i.v.)







1.2.5 AM PA potentiators as cognitive enhancers
AMPA potentiators were first conceived as cognitive enhancers and their ability
to enhance memory and cognition remains by far their most well-documented feature.
In strong support of the central hypothesis for AMPA potentiators AMPAkines have
been shown to facilitate LTP induction (Staubli, Perez et al. 1994), promote memory
formation (Staubli, Rogers et al. 1994) and olfactory learning (Larson, Lieu et al. 1995),
reverse age-related memory impairments in rats (Granger, Deadwyler et al. 1996),
improve working memory in non-human primates (Buccafusco, Weiser et al. 2004;
Porrino, Daunais et al. 2005) and improve performance in recall tasks in humans
(Ingvar, Ambros-Ingerson et al. 1997; Lynch, Granger et al. 1997).
AMPA potentiators have since been shown to have cognitive enhancing effects
in many behavioural paradigms. The evidence shows that these compounds can enhance
the formation of short term memory and show activity in certain behavioural models that
are predictive of antidepressant properties (Li, Tizzano et al. 2001; Alt, Nisenbaum et al.
2006), there are also effects in human trials of schizophrenia (Marenco, Egan et al.
2002) although published research remains limited (Tuominen, Tiihonen et al. 2005).
AMPA potentiators also have an added feature that makes them interesting as
potential therapeutic agents; they enhance expression of the neurotrophin BDNF. This
property of AMPA potentiators has been demonstrated in vitro (Lauterborn, Lynch et al.
2000; Legutko, Li et al. 2001; Lauterborn, Truong et al. 2003) and in vivo (Mackowiak,
O'Neill et al. 2002) and is thought to underlie the neurotrophic effects seen in both
systems (O'Neill, Murray et al. 2004; Wu, Zhu et al. 2004; O'Neill, Murray et al. 2005).
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Additionally, AMPA potentiation has been shown to enhance the rate of neurogenesis in
the sub-granular layer of dentate gyrus (Bai, Bergeron et al. 2003). These observations
have led to speculation that, as well as providing cognitive enhancement, AMPA
potentiators may promote a long term neurotrophin-mediated therapeutic benefit in a
number of neurological conditions (O'Neill, Bleakman et al. 2004; Alt, Nisenbaum et al.
2006).
1.2.6 AMPA potentiators and neurotrophins
The seminal observation that mouse sarcomas implanted into developing chick
embryos caused nerve fibres from adjacent dorsal root ganglia to grow into the tumour,
led to the isolation of a soluble low-molecular weight protein later identified as NGF
(reviewed in Levi-Montalcini 1987). The subsequent work of Viktor Hamburger, Rita
Levi-Montalcini and Stanley Cohen throughout the 50s laid the foundation for the study
of the so-called neurotrophic factors. These are proteins capable of promoting cell
survival, growth and synaptic plasticity throughout the developing and adult CNS and
PNS. Many families are included in this group, including TGF-p, FGF, IGF, EGF, BMP
and PDGF (Lessmann, Gottmann et al. 2003). The most important member of this
group however is the neurotrophin family, which includes, in mammals, NGF, BDNF,
NT-3 and NT-4/5. Each of these proteins signals through its cognate receptor, one of a
family of cell-surface receptors with intrinsic tyrosine kinase activity, the so-called Trk
(Tropomyosin Receptor Kinase) receptors: NGF has high affinity for Trk-A, BDNF has
high affinity for Trk-B and NT-3 has high affinity for Trk-C, NT-4/5 has affinity for
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Trk-B. There is also a degree of promiscuity, with NT4/5 also binding Trk-B. All
neurotrophins also bind with a lower affinity to the p75 neurotrophin receptor
(Rodriguez-Tebar and Barde 1988; Gentry, Barker et al. 2004).
Upon ligand binding, these receptors dimerise and auto-phosphorylate at
specific intracellular tyrosine residues. This promotes the binding of small effector
molecules that initiate signalling cascades resulting in a large number of physiological
responses from cell survival, apoptosis, mitosis and neuritic outgrowth (Segal and
Greenberg 1996; Bibel and Barde 2000; Segal 2003). Although neurotrophins are all
essential for development of the CNS and PNS, as evidence with knock-out mice shows
(Crowley, Spencer et al. 1994; Ernfors, Lee et al. 1994; Ernfors, Lee et al. 1994;
Conover, Erickson et al. 1995), it is impossible to make many generalisations about the
role of neurotrophins as any given protein will have multiple, often contradictory,
actions across different regions or at different times during development (Lessmann,
Gottmann et al. 2003). One example is the action of NGF and the low affinity
neurotrophin receptor p75. NGF stimulates cell survival through Trk-A but can trigger
cell death through p75. Other examples include the truncated forms of Trk receptors and
the function of pro-form of neurotrophins (Segal 2003). As well as regulating
developmental processes such as cell survival and axonal growth, the demonstration by
Lohof and colleagues (1993) that neurotrophins (excluding NGF) could modulate
synaptic transmission at the Xenopous neuromuscular junction opened up the study of
the role of neurotrophins, particularly BDNF, in synaptic homeostasis and the
modulation of transmission at mature synapses (Poo 2001).
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Neurotrophins are capable of eliciting a range of physiological responses upon
binding to their specific Trk receptor and are essential for the establishment and
maintenance of a fully functional nervous system. In relation to the present study
however, it is the role of neurotrophins in regulating axonal growth and promoting
recovery and plasticity in the adult nervous system that will be explored in more detail.
The link between AMPA receptor activation and neurotrophin expression is well
established (Zafra, Hengerer et al. 1990). The demonstration by Lauterborn that AMPA
potentiation could induce the promotion of BNDF was in itself not surprising, but had
very important repercussions in the field (Lauterborn, Lynch et al. 2000). This first
demonstration of BNDF expression using AMPA potentiators has since been reproduced
in vivo and in vitro using a number of other AMPA potentiators (Legutko, Li et al. 2001;
Mackowiak, O'Neill et al. 2002; Lauterborn, Truong et al. 2003). One controversial
aspect of this effect concerns the duration of the enhanced expression of BDNF.
Lauterborn and colleagues showed that in organotypic hippocampal slice cultures BDNF
expression returned to normal levels during 24 hours of continuous exposure to an
AMPA potentiator. The explanation for this effect was that prolonged exposure to the
AMPA potentiatior led to the degradation of the AMPA receptor complex (Lauterborn,
Lynch et al. 2000). They subsequently showed that levels could be maintained at a
higher level for a period of days if the compound was administered on alternate days
(Lauterborn, Truong et al. 2003). However Mackowiack et al showed that in vivo
BDNF mRNA levels were elevated even following two weeks of twice daily
administration. These two observations can be reconciled when one takes into account
differences in exposure to AMPA potentiators in the two systems. In vivo AMPA
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potentiators tend to be metabolised very quickly and levels in the brain return within
hours (O'Neill, Murray et al. 2005; Jhee, Chappell et al. 2006). Therefore, twice daily
dosing could equate to the kind of on/off administration that can bypass degradation of
AMPA receptors. At high doses some AMPA potentiators lose their potency displaying
bell shaped response curves that could be explained by degradation of the AMPA
receptor complex.
AMPA potentiator-induced expression of BDNF has been shown to be mediated
both directly and indirectly by AMPA receptor recruitment of intracellular kinases. The
non-receptor tyrosine kinase Lyn (Hayashi, Umemori et al. 1999) which associates with
GluR2 subunits, was shown to activate MAP kinase pathways that lead to increased
transcription of the neurotrophic factor in vitro (Wu, Zhu et al. 2004). Lyn's activation
of MAP kinases was independent of Ca2+ influx through VGCC, indicating that Lyn
may be activated by conformational change within the receptor subunit (given that
GluR2 containing receptors are calcium impermeable) (Burnashev, Monyer et al. 1992;
Hollmann and Heinemann 1994). Lyn's role in other aspects of AMPA receptor
mediated neuroplasticity such as LTP and neurite growth has yet to be investigated but
remains an interesting addition to the multiple pathways activated by AMPA receptor
activity.
BDNF transcription is regulated by CREB, which can be phosphorylated by
AMPA receptor activation (Perkinton, Sihra et al. 1999; Schurov, McNulty et al. 1999;
Wu, Deisseroth et al. 2001). As well as BDNF, CREB also regulates the expression of a
range of anti-apoptotic and neurotrophic genes such as Bcl-2 (Carlezon, Duman et al.
2005). Recent work indicates that other neurotrophins such as VEGF are also enhanced
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by AMPA potentiation (Lakics 2006). What emerges is a profile of neurotrophic factors
that can all be induced by AMPA potentiators.
One of the most well-characterised inducers of apoptosis is excitotoxicity (Olney
and Ho 1970; Choi 1992) through glutamate receptors. Any mechanism that enhances
glutamatergic transmission might be expected to exacerbate excitotoxicity. However
Dicou and colleagues demonstrated that administration of CX516 was neuroprotective
against ibotenate-induced cortical damage (Dicou, Rangon et al. 2003). A study on the
neuroprotective effect of AMPA potentiation from the excitotoxic effects of high
concentration of AMPA, corroborates this evidence (Wu, Zhu et al. 2004). The
potentiation of AMPA receptors could specifically promote neurotrophic pathways
rather than excitotoxic ones.
The neuroprotective effects of AMPA potentiation were also demonstrated in the
6-OHDA model of Parkinson's Disease (O'Neill, Murray et al. 2004; O'Neill, Murray et
al. 2005). Histological and behavioural assessment of rats that had 6-OHDA-induced
lesions of the nigro-striatal tract, and had been administered AMPA potentiators
revealed significant improvement in drug-treated groups. The authors found evidence
that the sprouting of nerve terminals in the striatum following the lesion was promoted
following AMPA potentiator administration. Importantly they found that the compound
was effective not only as a neuroprotectant (when administered during the degenerative
phase) but could also induce histological changes when administered some time after the
surgical insult, indicating neurotrophic mechanisms (Figure 1.6). This ability to induce
structural change in vivo was a key finding and along with some evidence for the neurite
growth-inducing properties of cyclothiazide (Fushiki, Matsumoto et al. 1995), were until
34
recently the only evidence supporting the neurotrophic effects of AMPA potentiators
that has been suggested in a number of recent reviews (Limatola 2004, Alt et al 2005).
1.3 AMPA potentiators and Structural plasticity
1.3.1 Neuroplasticity
Over the last 50 years our understanding of the brain's ability to adapt to its
environment has changed greatly. We now know that the adult brain retains a large
degree of plasticity, from synaptic plasticity, to the proliferation of stem cells, to large
scale rearrangement of cortical networks and behavioural plasticity. Although most
neuroscientists have a good working understanding of what neuroplasticity is in relation
to their field, definitions vary: "the ability of the nervous system to change the
effectiveness of [synaptic] transmission" or "structural, biochemical and molecular
changes...supporting behavioural plasticity" (Cotman and Berchtold 2002)
The word plasticity was first used in relation to humans in 1890 by William
James. He was the first to recognise that the most important feature of human behaviour
is the ability to carry out meaningful change (James 1890, Cotman 2002). In 1969
Geoffrey Raismann first used the word to describe structural changes when describing
sprouting in the septal nucleus or adult rats following lesions (Raisman 1969). Our
understanding of the phenomenon has expanded to encompass a number of
physiological and pathophysiological processes in the brain. There is a vast body of
literature dealing with "neuroplasticity" (>17,000 hits on PubMed). One of the most
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common definitions of neuroplasticity defines it as the substrate for the brain's adaptive
response to its environment. Neuroplasticity is, therefore, the brain's primary function
(as an extension of its role in maintaining homeostasis). A recent review divides
plasticity into "fast", "medium" and "slow" processes (Peled 2005). This particular view
is the most relevant to this thesis as it provides a useful framework in which to place the
potential actions of AMPA potentiators.
This thesis is a study of how certain forms of plasticity can be promoted via
glutamate synaptic transmission in order to halt or reverse certain pathological processes
in some of the most common neurological conditions, via the induction of neurotrophin
expression and long term structural and biochemical changes.
1.3.2 Principles of neurite growth
Elucidating the mechanisms by which neurons initiate, extend and retract their
processes and ultimately how they select and establish meaningful synaptic connections
with other neurons, is one of the most persistently relevant and challenging areas of
neurobiology. Progress in this field has clinical as well as purely academic implications;
the development of novel treatments for spinal chord injury (Schwab 2002), Parkinson's
(Gash, Zhang et al. 1998; Lindvall, Kokaia et al. 2004) and Alzheimer's (Teter and
Ashford 2002) and depression (Manji, Quiroz et al. 2003), all rely in some aspect on
promoting structural neuroplasticity, whilst abhorrent neuronal sprouting is thought to
underlie the pathology of some forms of epilepsy (Lamer 1995).
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The great neuroanatomist Cajal first proposed that the CNS was made up of
neurons which extended fibres from the soma and made synaptic connections with
neighbouring cells. This view, the 'neuronal doctrine', led to the field of study
dedicated to the resolution of the mechanisms regulating this process (Levi-Montalcini
and Hamburger 1951; Sperry 1963; Tessier-Lavigne and Goodman 1996; Jones 1999;
Nikolic 2002). In the intervening century an extensive list of neurite growth-regulating
factors has been compiled (Chilton 2006) and the task of describing this process is best
approached "bottom-up", as so many distinct pathways converge at key regulatory
stages. Neurite growth is a specialised form of cell motility where only one part of a
polarised cell is involved. It is essentially a process of highly organised cytoskeletal
reorganisation. Although cell types differ in the rate, regulatory cues and timing of
neuritogenesis, the process has three main events; the initial budding, the formation of
neuritic processes and finally the development of polarity with axons and dendrites (da
Silva and Dotti 2002). The majority of evidence suggests that the principle driving force
of this process is the actin cytoskeleton (Meyer and Feldman 2002). The principal site
of this cytoskeletal reorganization is the growth cone, a highly specialised structure at
the leading end of developing neurites first characterized by Cajal. The growth cone is a
structure present at the leading edge of growing neurites that comprises large fan-like
structures called lamelipodia and thin protruding processes called filopodia. The
structure has adapted to sense the extracellular environment for molecules that direct the
growth of the neurite (Kolodkin 1996; Korey and Van Vactor 2000). Growth cones are
rich in filamentous actin (F-actin) which is constantly being polymerised at the leading
edge of the growth cone in the filopodia, retrogradely transported and depolymerised in
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the back of the cone (Suter and Forscher 1998). The rate of de-polymerisation can be
regulated by an array of guidance cues, both secreted and cell-membrane bound
(Tessier-Lavigne and Goodman 1996; Korey and Van Vactor 2000). One such
mechanism suggests that actin polymerisation can be regulated by interactions between
actin cytoskeleton and membrane bound receptors that grasp the extracellular matrix.
The result is a shift towards polymerization and forward motion of the filopodia, a
process called the "clutch" hypothesis (Mitchison and Kirschner 1988; Suter and
Forscher 1998). Ultimately the regulation of neurite growth is much more complex, but
the key regulators and intracellular cascades mediating this process are now beginning to
be elucidated. All major signals that regulate growth cone dynamics converge at the
level of actin polymerisation (Dickson 2002; Gillespie 2003). The main up-stream
molecules that regulate this process are the Rho GTPase family of molecules (Nikolic
2002). Evidence for the role of these molecules in regulating the cytoskeleton first came
from experiments in yeast (Adams, Johnson et al. 1990; Johnson and Pringle 1990) but it
was the experiments of Ridley and colleagues using Swiss 3T3 fibroblasts that first
showed that GTPases could directly regulate actin polymerisation (Ridley and Hall
1992; Ridley, Paterson et al. 1992). Racl, RhoA and Cdc42 are the principal members
of this family (Nikolic 2002). In neurons Cdc42 has been shown to induce neurite
growth and RhoA to inhibit neurite growth whilst Racl has been shown to promote and
inhibit neurite growth (Eaton, Auvinen et al. 1995; Luo 2000). Rho GTPases switch
between active GTP-bound and inactive GDP-bound states under the regulation of
guanidine exchange factors GEFs and GTPase activating proteins. The principal
downstream targets have been identified as ROCK, Cdk5, N-WASP and Pak (Luo
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2000). These kinases regulating actin assembly act principally through LIMK and its
phosphorylation of ADF/cofilin. ADF/cofilin is a member of the family of actin-binding
proteins that regulate the rate of actin de-polymerisation, the rate-limiting step in the
treadmilling cycle of actin dynamics (Carlier, Laurent et al. 1997; Paavilainen, Bertling
et al. 2004). Although multiple organism and cell-specific regulators of actin
polymerisation exist, these principal molecules are evolutionarily conserved and are
fundamental mediators of many processes involving cytoskeletal reorganization.
Neurons are highly polarised cells often with extremely complex dendritic or axonal
processes; throughout development and adulthood extracellular signals act on neurons to
attract, repel, promote or inhibit neurite extension and branching. All these signals act by
regulating the activation state of Rho GTPases which in turn regulate the rate of actin
de-polymerization. These signals can be mediated by cell-cell interactions such as the
semaphorins, diffusible molecules such as netrins or both, as is the case with ephrins.
For the purpose of this thesis an in-depth assessment of these molecules is not relevant
and many excellent reviews exist. The studies described in this thesis are concerned
with the interactions between neurotrophins, synaptic activity and neurite growth.
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1.3.3 Synaptic activity and structural plasticity
A potential mechanisms by which AMPA potentiators may treat neurological
disorders is through the regulation of neurite growth by neurotrophins. Although early
patterning of the CNS is mainly guided by molecular interactions between growing
neurons, ECM and target-derived guidance cues (Tessier-Lavigne and Goodman 1996),
there is a "critical" period of development extending into young adulthood were
abnormal sensory experience as well as spontaneously generated electrical activity can
radically affect the development of neuronal networks (Katz and Shatz 1996). The work
of Hubel and Weisel in the late 1950 and 1960s (Wiesel and Hubel 1963; Hubel and
Wiesel 1970; Hubel, Wiesel et al. 1977) on the visual system of cats and monkeys
established the theory of a critical period during which sensory experience drives the
formation of cortical circuitry. Thus, monocular deprivation induces a shift in the
distribution of cortical cells responsive to the un-deprived eye of kittens (Hubel and
Wiesel 1970), afferent activity is required to maintain dendritic stability in auditory
nuclei (Deitch and Rubel 1984), NMDA blockade disrupts retino-tectal development in
Xenopus tadpoles (Cline and Constantine-Paton 1989), glutamatergic signalling
regulates dendritic development in vivo (Rajan and Cline 1998), visual activity promotes
dendritic development in vivo (Li, Van Aelst et al. 2000) and sensory deprivation alters
the dynamics of dendritic development in the rat barrel cortex in vivo (Lendvai, Stern et
al. 2000).
Although a central role of synaptic activity has been established in the
development and refinement of cortical circuitry, the actions of glutamate are varied and
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often conflicting. Application of glutamate inhibites neuritogenesis in cultured
embryonic rat motor neurons (Metzger, Wiese et al. 1998), whilst depolarization of
PC 12 cells enhances neurite growth in response to NGF (Howe 2003) and KA can
induce neuritogenesis in vitro (Tsai, Chiu et al. 2002). In other examples, actin motility
was inhibited in cultured rat hippocampal neurons by Ca2+ entry through VGCC and
AMPA/Kainate receptors (Chang and De Camilli 2001).
Glutamate receptors can elicit a range of physiological responses so it is not
surprising that the same holds true for the regulation of cytoskeletal dynamics. The
majority of research in this area has been aimed at the role of afferent and spontaneous
synaptic activity in regulating dendritic growth and development (Katz and Shatz 1996;
Wong and Ghosh 2002). One of the principal mechanisms through which synaptic
activity can shape dendrites is through elevation of intracellular calcium via VGCC,
NMDA and AMPA receptors that regulate RhoGTPase activity through CaMKII (Wu
and Cline 1998; Li, Van Aelst et al. 2000) or through CREB-mediated transcription via
CaMKIV (Redmond, Kashani et al. 2002) and MAPKs (Wu, Deisseroth et al. 2001).
There is also evidence for calcium independent activation of MAPK pathways via
AMPA receptors via Lyn kinase (Hayashi, Umemori et al. 1999) G-proteins (Wang and
Durkin 1995; Wang, Small et al. 1997). Although fast regulation of actin polymerization
can be mediated directly through RhoGTPase activity via glutamate receptors, long-term
structural change and homeostasis is mediated primarily through BDNF and Wnt
signalling (Konur and Ghosh 2005). BDNF expression is linked to glutamatergic
activity via calcium signalling and CREB phosphorylation (Zafra, Hengerer et al. 1990;
Ghosh, Carnahan et al. 1994; Shieh, Hu et al. 1998; Tao, Finkbeiner et al. 1998) There
41
is very little evidence regarding the effect of AMPA receptor potentiators on neuritic
growth. Fuskiki and colleagues showed moderate neurite growth in mouse CGN using
the weak AMPA receptor potentiator aniracetam (Fushiki, Matsumoto et al. 1995).
However the possibility that AMPA potentiation could induce neuritic plasticity has
been suggested in a number of recent publications (O'Neill, Bleakman et al. 2004;
O'Neill, Murray et al. 2004; O'Neill, Murray et al. 2005; Alt, Nisenbaum et al. 2006).
Given the roles of synaptic activity and neurotrophins in the developing cytoskeleton it
is not surprising that positive modulators of AMPA receptors could enhance neuritic
development. The implications of these observations may be of critical therapeutic
importance in a number of neurological disorders.
1.3.4 Structural plasticity in mood disorders
There is growing evidence to suggest that a number of mood disorders display
some structural pathology that may contribute to the etiology of the disorders and may
provide targets for pharmaceutical intervention (Manji, Quiroz et al. 2003). Studies
have shown changes in hippocampal volume in a range of conditions including bipolar
disorder, autism, PTSD and epilepsy. One particularly relevant case is that of major
depressive disorder, which has been classically viewed and treated under the monoamine
hypothesis of depression put forward over 40 years ago (Schildkraut 1965). Recent
evidence has emerged implicating the neurotrophin BDNF and the generation of new
neurons in the causes and possible treatment of depression (Duman, Malberg et al.
2000). AMPA potentiators are currently under investigation for the treatment of mood
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disorders due to their ability to enhance BDNF expression, neurogenesis and their
activity in classical animal models of depression (Bai, Li et al. 2001; Li, Tizzano et al.
2001; Bai, Bergeron et al. 2003; Alt, Nisenbaum et al. 2006).
1.3.5 Structural plasticity, BDNF and neurogenesis in depression
Depression affects approximately 120 million people worldwide. It is the leading
cause of disability worldwide. It costs an estimated $83 billion per annum on the US
economy (Gilbody, Sheldon et al. 2006) and by 2020 is expected to become the second
largest contributor to the global burden of disease (WHO, 2006). The observation that
imipramine (used in anti-histamine research) and iproniazid (an early anti-tubercular
drug) could treat the symptoms of depression laid the foundations for 40 years of
modern psychopharmacology. The discovery that both compounds increased central
levels of noradrenaline led to the so called "Monoamine hypothesis of depression"
(Schildkraut 1965; Coppen 1967). This theory, although it revolutionised the treatment
of depression, does not explain a number of key observations. Chief amongst these is the
phenomenon of the therapeutic lag associated with SSRI (selective serotonin uptake
inhibitors) (Berton and Nestler 2006). Although central levels of monoamines are
enhanced acutely following tricyclic or MAO inhibitor administration, alleviation of
symptoms are not usually observed before a period of weeks (Sachar and Baron 1979).
The development of sophisticated brain imaging techniques has revealed abnormalities
in blood flow, glucose metabolism, reduced grey matter volume and enlarged ventricles
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in a number of limbic and prefrontal cortical areas of depressed patients (Beyer and
Krishnan 2002; Drevets, Bogers et al. 2002; Drevets, Price et al. 2002; Strakowski,
Adler et al. 2002). Post-mortem studies on brain tissue have also found reduced cortical
volumes and reduced neuronal and glial densities and volumes in a number of brain
regions (Manji, Quiroz et al. 2003). It has been proposed that changes in brain
physiology and structure may be due to prolonged exposure of the brain to circulating
glucocorticoids. Glucocorticoids have been shown to regulate a number of plastic
responses in the hippocampus, including the magnitude of LTP (McEwen 1999).
Glucocorticoids can produce reversible atrophy of the dendrites of CA3 pyramidal
neurons and suppressed neurogenesis (McEwen and Sapolsky 1995; Gould, McEwen et
al. 1997). Dendritic atrophy is correlated with impairments in cognitive tasks and,
importantly, both structural and behavioural impairments are reversed by treatment with
the antidepressants tianeptine and phenytoin (Watanabe, Gould et al. 1992; Luine,
Villegas et al. 1994; Conrad, Galea et al. 1996). In humans, stress has long been
associated with the onset or exacerbation of depression (Anisman and Zacharko 1992;
Post 1992) and approximately half of all depressed individuals have elevated
Hypothalamus-Pituitary-Adrenal (HPA) activation (Holsboer, Gerken et al. 1986) which
can be reversed following successful depression treatment (Rubin, Phillips et al. 1995).
The link between stress and depression is far from clear however, as many people suffer
from extreme or prolonged stress and do not develop depression.
Over the last decade Ronald Duman and colleagues at Yale have built a body of
evidence supporting a role for CREB-induced BDNF expression and neurogenesis in the
underlying pathology of depression as well as in the mechanisms of action of common
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antidepressants (Duman, Heninger et al. 1997; D'Sa and Duman 2002). Electro
convulsive therapy (ECT) is probably the most effective treatment for serious depression
and has been used for over 60 years. Levels of Trk-B and BDNF have been shown to be
elevated following ECT (Ernfors, Bengzon et al. 1991) and central infusion of BDNF
has antidepressant effects (Siuciak, Lewis et al. 1997). Duman and colleagues showed
that common antidepressants and electro convulsive seizures all increase BDNF mRNA
(Nibuya, Morinobu et al. 1995). Furthermore they showed that antidepressants can
enhance expression of CREB (Nibuya, Nestler et al. 1996), a transcription factor that
regulates the expression of a number of anti-apoptotic and trophic factors including Bcl-
2 and BDNF (Shieh, Hu et al. 1998; Tao, Finkbeiner et al. 1998; Finkbeiner 2000;
Carlezon, Duman et al. 2005). Importantly they showed that the effects on BDNF were
only apparent following chronic and not acute administration of antidepressants.
Subsequent studies showed that the expression of CREB and BDNF had antidepressant
properties (Chen, Shirayama et al. 2001; Shirayama, Chen et al. 2002). Further support
comes from a post-mortem study in which subjects treated with antidepressants at the
time of death had higher levels of CREB (Stewart, Chen et al. 2001) and BDNF (Chen,
Dowlatshahi et al. 2001) in the hippocampus than non-treated patients.
Duman and colleagues have also shown that antidepressant and ECS can induce
neurogenesis (Malberg, Eisch et al. 2000) as well as showing that expression of CREB
can enhance cell proliferation (Nakagawa, Kim et al. 2002). Correlation however does
not imply causation and in a follow-up study Malberg et al. showed that the
antidepressant effects seen in an animal model of depression (inescapable shock) were
abolished in animals that had received low-dose x-ray radiation, which reduces the rate
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of neurogenesis (Malberg and Duman 2003). This was supported by another study
which showed that neurogenesis was required for antidepressant-like effects (Santarelli,
Saxe et al. 2003).
Although these studies provide much pre-clinical support for a cellular theory of
depression based on the actions of BDNF and neurogenesis, a number of studies suggest
that caution must be exercised. A recent study has suggested that in some areas of the
brain BDNF may be necessary for the expression of stress-induced learned helplessness
(Berton, McClung et al. 2006). Elsewhere, inducing learned helplessness in rats had no
effect on cell proliferation in the hippocampus and reducing the rate of neurogenesis did
not pre-dispose animals to developing learned helplessness (Vollmayr, Simonis et al.
2003). Clearly there remains much work to be done and an explanation of depression
simply involving levels of BDNF is at odds with our current understanding of multi¬
system biology. However, the evidence suggesting that deficits in certain forms of
plasticity contribute to the development of mood disorders is compelling and provides a
framework to develop truly novel therapies.
AMPA potentiators, with their ability to penetrate the brain and increase
expression of BDNF (Lauterborn, Lynch et al. 2000; Legutko, Li et al. 2001;
Mackowiak, O'Neill et al. 2002; Lauterborn, Truong et al. 2003) and enhance rates of
neurogenesis (Bai, Bergeron et al. 2003) are excellent candidates for the treatment of
depression and other mood disorders (Skolnick, Legutko et al. 2001; Skolnick 2002; Alt,
Nisenbaum et al. 2006).
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1.3.6 AMPA potentiators in other CNS disorders
Schizophrenia is a promising target for glutamatergic-based intervention (Javitt
2004). Evidence for the involvement of glutamatergic transmission in the symptoms of
schizophrenia includes the discovery that the potent psychotomimetic phencyclidine
(PCP) was an NMDA antagonist. Trials with the PCP analogue ketamine have
confirmed that single doses of NMDA antagonists can induce transient psychosis,
cognitive impairment and motor disruption similar to those seen in schizophrenia
(Glantz, Gilmore et al. 2006). Decreased NMDA receptor function may be one of the
consequences of the development of schizophrenia but growing evidence from studying
brain volumes, synaptic markers and neuropil markers suggests that synaptic disruption
through unregulated apoptosis is involved (Glantz, Gilmore et al. 2006). Schizophrenia
is in fact a condition that develops over time and can become progressively worse.
There is evidence showing reduction in cell layer volumes in the anterior cingulate
cortex and evidence of apoptosis and DNA fragmentation (Benes 2003). As well as
potentially promoting structural plasticity that is deficient in some schizophrenia, AMPA
potentiators may alleviate the synaptic deficits associated with structural degeneration
and glutamatergic dysfunction (Lynch 2004). Two small scale trails using the AMPA
potentiator CX516 revealed minors improvement in positive symptoms (Johnson, Luu
et al. 1999; Marenco, Egan et al. 2002).
Alzheimer's disease (AD) is a progressive age-related neurodegenerative disease
that affects approximately 4.5 million people in the United States (Lledo, Alonso et al.
2006). Given that AD is characterised by progressive cognitive decline and cell loss in
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cortical areas, AMPA potentiators may be well suited for alleviating some of the
symptoms and possibly slow down the progression of the disease (Lynch 2004). There
is evidence showing that the AMPA potentiator CX516 is able to enhance memory
formation in aged adults (Ingvar, Ambros-Ingerson et al. 1997). Therefore enhancing
glutamatergic transmission may help alleviate some of the cognitive impairment seen in
AD patients (Lynch 2004). Cognitive function could also be enhanced by the
facilitation of synaptic transmission by BDNF (Levine, Dreyfus et al. 1995). As with
other conditions the possibility that enhanced levels of BDNF may help to promote cell
survival and neuritic plasticity means that these therapies may help perhaps slow the
progression of AD.
AMPA potentiators exhibit a range of physiological properties that are
potentially of therapeutic value in a wide range of cognitive disorders. Through their
acute ability to enhance synaptic transmission and facilitate the formation of memories
and their potential neurotrophic actions on the structural integrity of dendrites and
synapses, AMPA potentiators may be able to offer not only symptomatic relief but also
potentially treat the underlying pathology of many common CNS disorders (figure 1.7).
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Figure 1.7 Clinical potential of AMPA potentiators
With their ability to promote synaptic transmission, induce certain forms of structural
plasticity, increase the rate of neurogenesis and facilitate the formation of new
memories, thus acting as cognitive enhancers, AMPA potentiators have the potential to
be beneficial in a wide range ofconditions (see textfor references).
49
1.4 Aims of the Thesis
The aim of this thesis was to investigate the mechanisms of AMPA potentiators-
induced neuroplasticity. I used a number of in vitro and in vivo techniques to examine
multiple physiological, structural and biochemical measures of neuroplasticity. The
specific aims of the three studies presented in this thesis are stated below.
1. Develop a statistically sound and reproducible, adequately powered in vitro
model of neuroplasticity in SH-SY5Y human neuroblastoma cells. The primary
endpoint is the change in the average length of neurites in response to AMPA
potentiator administration. The secondary endpoint will be the changes in
neurofilament expression measured by Western blotting. This model will be used
to measure the effects and mechanisms of the AMPA potentiator LY404187 on
neurite growth.
2. Measure the effect of subcutaneous administration of LY404187 on the
formation of new synapses and the rate of neurogenesis in the hippocampal
following unilateral partial lesions of the entorhinal cortex.
3. Monitor the persistence of biochemical and physiological changes induced by
chronic administration of LY450108. Multiple endpoints will measure the
biochemical signals associated with AMPA potentiation, the rate of neurogenesis
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and neuronal development and the levels of the principal monoaminergic
neurotransmitters in the neo-cortex, striatum and hippocampus.
2. Materials and Methods
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2.1 Assessment of neurite growth
2.1.1 Introduction
Understanding the processes that regulate the growth and development of
neurons is critical to our understanding of brain function and key to developing new
clinical therapies. A powerful tool in this research is the study of neurite growth and
development in vitro. From its early days in the study of neurotrophins (Levi-Montalcini
1987) to the sophisticated, real-time assays of today (Lohof, Quillan et al. 1992; Wang
and Poo 2005) it has remained a popular and accepted method for elucidating the
processes of neurite development. However, as yet there is no accepted standard
measure of neurite outgrowth in vitro in particular when assessing population wide
changes in average neurite length. The heterogeneity of cell populations and their
processes renders automation of neurite measurements elusive. Existing techniques are
either costly (Ramm, Alexandrov et al. 2003; Price, Oe et al. 2005) or use
approximations of neurite length using stereological techniques (Ronn, Ralets et al.
2000). There is no consensus about which measure to use, with different groups using
increases in average neurite length (Price, Yamaji et al. 2003), percentage of cells
bearing neurites (Howe 2003), longest neurite per cell (Bamdad, Voile et al. 2004) and
the percentage of cells bearing "long" neurites (Troller, Raghunath et al. 2004). In
addition, some reports use pre-differentiated cells; a variety of treatments include
retinoic acid (Adlerz, Beckman et al. 2003; Ruiz-Leon and Pascual 2003),
tribromophenol (Rios, Repetto et al. 2003), aphidicolin (Price, Yamaji et al. 2003) and
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staurosporine (Prince and Oreland 1997) with other groups reporting robust outgrowth in
un-pre-treated cells (Shea, Cressman et al. 1995; Sanchez, Sayas et al. 2001; Tucholski
and Johnson 2003; Trailer, Raghunath et al. 2004).
For the purpose of our studies we selected an extensively used, human,
neuroblastoma cell line that expressed AMPA receptors; SH-SY5Ys.
2.1.2 SH-SY5Y cells as a model of neurite growth
SH-SY5Ys are neuroblastoma cells of sympathoadrenal lineage that can be
differentiated into cells with a neuronal phenotype in culture (Abemayor and Sidell
1989; Christnacher and Sommer 1995). SH-SY5Ys express AMPA receptor subunits
(Figure 2.1) (Christnacher and Sommer 1995), BDNF and Trk-receptors (Olivieri, Otten
et al. 2003; Ruiz-Leon and Pascual 2003) and have been used extensively as in vitro
models of neuronal differentiation and neurite growth (Encinas, Iglesias et al. 2000;
Ivankovic-Dikic, Gronroos et al. 2000; Simpson, Bacha et al. 2001; Price, Yamaji et al.
2003; Jamsa, Hasslund et al. 2004; Daniel, Mudge et al. 2005). In culture they display
numerous cell phenotypes with around 30% percent of cells displaying a neuronal
phenotype. Untreated SH-SY5Ys displaying a neuronal phenotypes are similar in
appearance to SH-SY5Ys that have been treated with retinoic acid, although they are
less numerous. Retinoic acid and NGF share common pathways in the induction of
neuritic length (Corcoran and Maden 1999) and the co-administration of retinoic acid
and BDNF induces extensive differentiation in SH-SY5Ys. AMPA activation leads to
increases in BDNF (Zafra, Hengerer et al. 1990; Legutko, Li et al. 2001; Mackowiak,
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O'Neill et al. 2002) and the choice was made not to pre-differentiate the SH-SY5Y cells
so as not to interfere, a priori, with mechanisms that might be involved in the increase of
neurite length following AMPA potentiation.
2.1.3 Cell culture
SH-SY5Y cells (ECACC No. 94030304) were cultured in Dulbecco's modified
Eagle's medium (DMEM) with 10% heat-inactivated foetal calf serum (FCS) (Gibco),
2mM L-glutamine and 1% penicillin/streptomycin mix. Cells were cultured for up to 6
weeks (<passage 20 in accordance with ECACC guidelines). Optimum culture
conditions were established using a range of seeding densities and incubation times. In
neurite growth experiments, cells were plated in NUNC 6-well dishes at a density of 1 x
105 cells / well 24 hours prior to testing. Medium was replaced with fresh DMEM (2%
FCS, 2mM L-glutamine) and appropriate compounds applied for 72hrs. All compounds
were stored at -20°C in stock aliquots and fresh dilutions were made on each
experimental day. After 72 hrs, cells were fixed using 4% PFA for 2 hrs before being
processed for data collection.
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2.1.4 Measuring neurite length
Neurite growth was assessed by taking a series of digital images of fixed cells
and measuring the average length of all neuritic processes using the image analysis
software Image J (NIH freeware) (Figure 2.1). The experimenter, blinded to treatment
group, selected fields at random under a microscope and captured phase-contrast images
at 200x magnification from each well (Leitz Laborlux microscope with Polaroid CCD
camera running Polaroid DMC2 software). SH-SY5Ys have a heterogeneous population
of cell phenotypes, which display a range of cell body shapes and process number and
length. Because of high numbers of non-differentiated cells present in a population of
SH-SY5Ys, images were only captured if they contained dispersed, neurite bearing cells.
The system was checked for image compression and calibrated before use by taking
horizontal and vertical images (200x) of a standard graticule. Neurites were traced
manually and the length calculated. Neurites that extended past the edge of the field,
crossed other neurites, touched other cells were not measured. All neurites were
measured from the cell body to the extremity of the neurites. Branches, extending from
neurites were not measured and all process shorter than 20jam (average width of cell
body) were not included in further analysis.
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Figure 2.1 Manual tracing of neuritic processes in SH-SY5Ys
Processes were traced manually using Image J software. The length of the line is
automatically calculated (in this case 102pm). All processes longer than 20pm were
measured and used in statistical analysis.
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2.1.5 Sampling, Power and Statistical analysis
Power analysis was used to ensure accurate sampling size in neurite growth
experiments. The distribution of neurites yielded an average standard deviation of
20/rm. The minimum detectable difference was set at 5jum (10% increase in length over
control cells). The power and probability were set at the standard 0.8 and 0.05 levels.
The test was designed to estimate the minimum sample size for ANOVA with 5 groups
the size of a typical experiment. Calculations were carried out using Sigma Stat
software package and yielded a predicted sample size of 379. The distribution of
neurites in a population of SH-SY5Ys failed a normality test (K-S Dist. = 0.104, p =
0.002)) (Figure 2.2). Because of this, data was pooled into one population of 350-400
neurites collected over 4 experimental days and 8 independent wells and analysed using
a Kruskal-Wallis analysis of variance on ranks followed by comparisons to vehicle
treated cells using Dunn's post hoc analysis, as the group sizes were not equal across
treatment groups. Significance was set at 95% confidence, p<0.05. For BDNF antibody
and CNQX studies additional, multiple Mann-Whitney comparisons were run as a post-
hoc test following analysis of variance. In this study p-values were corrected for
multiple comparisons using the Bonferroni procedure. For purposes of clarity we have
presented all neurite growth data as the mean average neurite length for the entire
population in each group. Comparisons between the two methods for presenting the data
are shown in Figure 3.1.6.
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Neurite Length (^/m)
Figure 2.2 The distribution of neurite lengths in SH-SY5Ys
Frequency distribution analysis of neurites longer than 20pm collected from a
population of SH-SY5Ys. The distribution of neurites failed a normality distribution test




Since its development, Western blotting has become one of the most commonly
used techniques in biology (Burnette 1981). Western blots, named to differentiate from
Southern blots (DNA) and Northern blots (RNA), rely on the separation of proteins of
different mass on an acrylamide gel (SDS-PAGE) and the detection of the protein of
interest using antibodies raised against protein specific epitopes. Although proteins can
now be manipulated and imaged with a high level of temporal and spatial resolution and
that Western blotting remains a semi quantitative measure. Nevertheless its technical
simplicity, low cost and robustness ensure that it remains the best method for measuring
large changes in levels of a protein of interest. The quality of the final blot depends in
large part on the amount of protein present and the separation but primarily on the
specificity and selectivity of the antibody.
2.2.2 Cell culture and protein extraction
In Western blot experiments cells were seeded at a density of 1 x 106 per 9cm
dish and incubated in DMEM (2% FCS, 2mM L-glutamine) containing the appropriate
compound. Following incubation, SH-SY5Y cells were washed with ice-cold PBS and
lysed in 500/xl NP40 lysis buffer (150 mM NaCl; 50 mM Tris-HCl pH 7.4; 10 mM
EDTA; 0.6% Nonidet P40; 1 mM Na3V04; 10% glycerol; 10 jug/ml pepstatin; 1 mM
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phenyl methyl sulfonyl fluoride). Cell lysates were incubated on ice for 30 mins before
removing cell debris by centrifugation (15300g/10min/4°C) and protein concentrations
determined using a modified Lowry method (Bio-Rad D2 Protein Assay kit; Bio-Rad
Laboratories, Hemel Hempstead, UK).
2.2.3 Western Blotting protocol
10 ng of protein in standard loading buffer (25 mM Tris-HCl (pH 6.8); 0.8%
SDS; 1% 2-mercaptoethanol; 4% glycerol; 0.01% bromophenol blue) was loaded on a 4-
12% Tris glycine gel and separated by SDS-PAGE (200 mV for 45 min). Proteins were
transferred to a PVDF membrane (Millipore (UK) Ltd, Watford, UK), and incubated in
Tris Buffered Saline (TBS)-Tween (50 mM Tris-HCl; 150 mM NaCl; 0.05% v/v Tween-
20) containing 5% albumin w/v for lhr. Sequentially, membranes were probed with
primary antibody; neurofilament (1:2000 anti-200kDa Neurofilament Heavy - Ab7795,
Abeam), Trk (1:500, B-3 sc-7268, SantaCruz), P-actin (1:5000, Sigma, UK) and
peroxidase-conjugated IgG (1:30000; Sigma, UK) before detecting with Enhanced
Chemiluminescence Detection system (ECL plus; Amersham Biosciences UK Ltd.,
Little Chalfont, UK). Between each step membranes were washed three times for 5
mins with TBS-Tween. Chemiflourescence levels were corrected for background,




The data obtained from the NF western blot was not amenable to standard
statistical analysis due to the small sample size and the large variance (see results for
further details). This finding influenced the design of subsequent western blot
experiments. When studying the effect of LY450108 on the levels of pERK in the
hippocampus larger group sizes were used. In this experiment (Figure 3.3.1) data was
analysed by ANOVA followed by post hoc Student t-test with Bonferroni corrections.
































Figure 2.3 Schematic representation of Western Blotting methodology
Schematic representation of western blot methodology. Refer to text for full details of
experimental protocol.
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2.3 Investigations of the effects of AM PA potentiators in vivo
2.3.1 Housing conditions
Male adult C57BL/J mice (~20-25g) were housed in cages, randomised for drug
treatment, in groups of six as long as possible throughout the study. Throughout the
studies all procedures complied with Home Office regulations and condition and weight
of the animals was controlled daily.
2.3.2 Drug treatment
Animals were administered twice daily injections of LY404187 or LY450108 via
s.c injections. Each animal was weighed daily and given the appropriate volume to
ensure 0.5mg/kg compound delivery at lOml/kg injection volume. The vehicle for
LY404187 was 10% ethanol, 3.75% hydroxypropyl-p-cyclodextrin and the vehicle for
LY450108 was CMC. The drugs were made daily from frozen stocks. The study using
LY404187 was performed at the University of Edinburgh and the dosing was carried out
by the author. The study using LY450108 was carried out in the laboratories of Eli Lilly
and dosing was performed by Dr. Tracey Murray.
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2.3.3 Entorhinal Cortex Lesions
Surgical procedures described in Chapter 4 were all performed by Dr. Jill Fowler.
Lesions of the perforant path, either by excito-toxic cell death or mechanical
sectioning of axons, results in synapse loss on dendrites of granule cells of the dentate
gyrus. This is followed by an extended period of reactive synaptogenesis leading to an
almost complete recovery of synapses occupancy on granule cells (van Groen, Miettinen
et al. 2003). This model has been used extensively to investigate the processes of
synapse degeneration and the plastic responses from gene expression to neurite
sprouting and growth. The two main strengths of this model are that it allows the
processes of degeneration and regeneration to be monitored in a topographically distinct
area which is distant from the lesions site and that unilateral lesions allow for an internal
control in the contralateral hemisphere.
Male adult C57BL/J mice (~20-25g) were housed in cages, randomised for drug
treatment, in groups of six as long as possible throughout the study. Throughout the
studies all procedures complied with Home Office regulations and condition and weight
of the animals was controlled daily.
Animals were anesthetised in a perspex box using 3% halothane in a mixture of
nitrous oxide and oxygen (70:30). Once anaesthetised, animals were transferred to a
stereotaxic frame (David Kopf) and a face mask was placed over their snout and the
halothane reduced to 1.5-2% for the remainder of the procedure. Rectal temperature was
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monitored throughout the surgery keeping internal temperature around 37°C with the aid
of heating lamp and a heated mat.
A midline incision was made in the scalp and the skin and muscle was retracted
exposing the occipital bone down to the base of the skull. A 2[i\ Hamilton syringe was
mounted to on the frame and the coordinates, determined from Bregma, were set at: AP
4.72mm and L 4.75mm and 17° from vertical. A hole through the skull, exposing the
dura, was made using a dental drill. Forceps were used to peel back the dura exposing
the dorsal surface of the cortex. The syringe was lowered onto the surface of brain and
lowered a further 3mm. Ibotenic acid (a-amino-3hydroxy-5-isoazoleatic acid) lOmg/ml
was then injected into the entorhinal cortex at a rate of 0.1/xl/min until a total volume of
0.5/xl was injected. 10 minutes elapsed following the injection to allow diffusion of the
acid from the syringe tip. The syringe was removed and the skin was sutured, the
animals were administered 200/xl of saline and placed under observation until fully
recovered.
2.3.3 Perfusion fixation
Animals were deeply anaesthetised with 5% halothane in a nitrous oxide and
oxygen mix (70%:30%). Animals were then transferred to a mat fitted with a face mask
over their snout and kept under heavy anaesthetic. When animals no longer responded to
foot pinch an incision along the ventral midline and the skin and connective tissue was
removed exposing the ribcage. The ribcage was raised and a butterfly needle was
inserted into the left ventricle of the heart. Phosphate buffer (PB) containing 1% heparin
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was then pumped at a rate of 3mls/min until the solution ran clear. Paraformaldehyde
was then run through the animal until animal was fixed (~7mins). The head was
removed and placed in paraformaldehyde for 24 hours. The skull was then removed and
the brain placed in paraformaldehyde for a further 2 hours and finally placed in PB until
processed for histology.
2.3.4 Paraffin embedding and tissue sectioning
3mm thick blocks of tissue were cut through the fixed brains using a cast metal
mouse brain matrix. For the study investigating in vivo sprouting following ECL tissue
blocks were taken through the entorhinal cortex and the hippocampus. The tissue used
in this study was processed manually passing the tissue through progressive alcohols and
into xylene. For the study investigating the effects of chronic administration of
LY450108, tissue was taken from the hippocampus and processed automatically using a
Vacuum Infiltration Processor, (VIP5, Bayer diagnostics, Newbury). Both sets of tissue
were then manually embedded in paraffin blocks. 10/xm sections were made through the
entorhinal cortex and every tenth section used for histological assessment. 7p,m thick
sections were collected through the hippocampus. The sections were taken from the
hippocampus at the level of the habenular nuclei.
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2.3.5. Quantification of entorhinal cortex lesion volume
For the ECL study sections through entorhinal cortex were stained with
haematoxylin and eosin to visualise the damaged tissue and quantify the volume of
lesioned brain. The tissue was processed as follows: 3x 2mins Xylene, 3x 2mins 100%
ethanol, lmin 70% ethanol, 2min FEO, lOmins Gill's Haematoxylin, 2x 5mins H2O,
4mins Aqueous Eosin, 5mins Wash, lmin 70% ethanol, 3x 2mins 100% ethanol, 3x
2mins Xylene.
10 planes through the entorhinal cortex were taken from Paxinos and Watson's
Mouse Brain Atlas (1986) and were used as a template on which to map out the lesioned
area on each plane following examination using 5x light field microscopy (Figure 2.4).
The distinction between lesioned and normal tissue was possible due to the well
circumscribed lesions. These areas were then transferred to MCID software (3D-MCID)
where the images were calibrated and 3D volumetric reconstructions were generated
from which the approximate lesion volumes could be calculated (Figure 2.5). A priori
exclusion criteria were set for animals which displayed lesions that spread into any area
of the hippocampal formation and those which had no lesioned tissue or had lesions
restricted to the needle tract. Such animals were excluded from all further analysis. Data
were analysed with the appropriate statistical test and significance was set at p<0.05
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Figure 2.4 Coronal Sections through entorhinal cortex
(Overleaf) 10 coronal plates through the entorhinal cortex taken from a mouse brain




Figure 2.5 3-D reconstruction of entorhinal cortex lesions
3-D reconstruction of lesion (red) in the posterior 3mm of the entorhinal cortex (blue).
The reconstruction allowed an estimate of the total volume ofthe lesion.
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2.3.6 Immuno-staining of mounted sections
Mounted sections were de-waxed and processed for immuno-staining using the
protocol described below (Figure 2.7). Antigen retrieval steps were incorporated for
BrdU, NeuN, ERK 1/2 and CREB immuno-staining to improve the signal (30mins
Citrate buffer 100°C. PT-Moudule, Lab Vision). For each antibody, blocking steps were
carried out according to the manufacture's instructions. For NeuN an additional
blocking step was performed using a specific "Mouse on Mouse" (M.O.M) blocking
agent (Vector Laboratories). Optimum working dilutions and incubation times were
determined using serial dilution curves (Table 2.6). All sections were incubated with
primary antibody overnight at 4°C. The specificity of each antibody was assessed using
primary antibody negative controls. Double labelling of BrdU and NeuN was performed
by co-incubation of both antibodies at 4°C overnight. Appropriate secondary antibodies
were used at manufacturer-recommended dilutions (Vector ABC kit, Vector
laboratories, Peterborough). BrdU, pERK 1/2 pCREB and synaptophysin antibodies
were developed using horseradish peroxidase conjugated secondary antibodies and DAB
as the chromagen substrate. NeuN used Alkaline Phosphatase conjugated secondary
antibody and Vector-Blue (Vector Laboratories) as the chromagen substrate (Table 2.6).
This allowed a more diffuse staining pattern than that obtained using DAB, which was
required during double labelling experiments.
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Antibody Species Concentration Conjugate Chromagen
BrdU Rat 1:100 HRP DAB
NeuN Mouse 1:100 AP VectorBlue
pERK 1/2 Rabbit 1:100 HRP DAB
pCREB Rabbit 1:100 HRP DAB
Synaptophysin Rabbit 1:300 HRP DAB
Table 2.6 Antibody dilutions for immuno-histochemical studies
Source, species, working dilutions and developing conditions for primary antibodies. All
secondary antibodies were used at the manufacturer's recommended dilutions.
73
2.3.7 Quantification of immuno-staining
The staining pattern for BrdU, pERK 1/2 and pCREB was easily amenable to
quantification by counting the number of positive cells per slide. The average number of
positive cells over 2 sections per animal was used as the end point. pERK 1/2 + cells
were readily counted in the dentate gyrus and CA1, CA2 and CA3 regions while the
number of diffusely stained pCREB cells in the CA1, CA2 andCA3 regions was such
that reliable quantification of these cells was not possible. BrdU+ cells were clearly
visible in the subgranular layer of the dentate gyrus and double labelled cells were
clearly identifiable under high magnification due to the nuclear stain of BrdU and the
predominantly cytosolic staining of NeuN
Synaptophysin immunoreactivity was assessed by measuring the optical density
at 10 points along the middle molecular layer of 3 regions of the dentate gyrus; dorsal,
medial and ventral. Readings for background OD were taken from the corpus callosum
and subtracted from the DG readings (see section 3.2 for details).
2.3.8 Statistical analysis
Entorhinal cortex lesions and synaptophysin degeneration
The pilot experiment was aimed at determining the time course of synaptophysin
degeneration in the dentate gyrus. To determine whether there was any significant
difference in the ratio of ipsilateral and contralateral synaptophysin levels over time the
data were analysed by ANOVA followed by post hoc Student's t-test with Bonferroni
corrections for multiple comparisons.
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In the LY404187 study we set out to determine whether administration of LY404187
(0.5mg/kg) had any significant effect on synaptophysin levels in the denate gyrus at 14
and 28 days post lesion. To determine whether there was any significant difference in
lesion volume between LY404187 (0.5mg/kg) or vehicle treated groups at 14 or 28 post
lesion, independent, two-tailed unpaired Student's t-test were performed on both data
sets. To determine whether there was any significant difference in synaptophysin
immuno-reactivity between LY404187 (0.5mg/kg) or vehicle treated groups,
independent, two-tailed unpaired Student's t-test were performed on both data sets. To
determine if there was any significant correlation between the size of the lesion and the
levels of synaptophysin independent linear regression analysis was performed on each
dataset. The final end point of the study was the level of neurogenesis in the dentate
gyrus. To determine whether there was any significant difference in the number of BrdU
positive cells in the sub-granular layer between LY404187 (0.5mg/kg) or vehicle treated
groups, independent, two-tailed unpaired Student's t-test were performed on both data
sets. All data are presented as either raw data of mean ±SEM. Significance was set at
p<0.05.
Biochemical changes associated with LY450108
We set out to determine whether chronic administration of LY450108 can induce
significant changes in number of pERK and pCREB +ve cells. We carried out ANOVA
followed by post hoc Student t-test with Bonferroni corrections for multiple comparisons
on both data sets. Data are presented as raw data or mean ±SEM. Significance was set at
p<0.05.
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We also set out to measure whether chronic administration of LY450108 can alter the
rate of neurogenesis and neuronal development in the sub-granular layer of the dentate
gyrus. To determine whether 3 days, 10 days or 17 days LY450108 administration
(0.5mg/kg) can induce changes in the number of BrdU +ve cells multiple independent
two-tailed unpaired Student t-tests were carried out on each data set. To determine
whether 3 days, 10 days or 17 days LY450108 administration (0.5mg/kg) can induce
changes in the ratio of NeuN+/BrdU+ cells to NeuN-/BrdU+ cells, multiple
independent two-tailed unpaired Student t-tests were carried out on each data set. All
data are presented as raw data. Significance was set at p<0.05.
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Figure 2.7 Schematic representation of Immuno-histochemistry
methodology
Standard protocol for immuno-staining of paraffin embedded sections: 7pm sections
were taken through the hippocampus at the level of the lateral habenulae and processed
as follows. See textfor details ofeach step.
Step 1: Sections were incubated in citrate bufferfor 30mins at 100°C to remove paraffin
wax and antigen retrieval (see-text) Step 2: Endogenous peroxidases were quenched
using 0.3% H2O2 for 30mins. Step 3: Sections were blocked with serum from
appropriate animal for 1 hour. Step 4: Sections were incubated in primary antibody
over night at 4°C. Step 5: Sections were incubated in secondary antibody for 30mins at
RT. Step 6: Sections were incubated with ABC horseradish-peroxidase or alkaline
phosphatase complex. Step 7: Sections were developed using DAB for ~6mins or Vector
Blue for 15mins Sections were washed 3x 5 mins with PBS between all steps (except 3
and 4).
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2.6 Monoamine analysis by High Pressure Liquid Chromatography
2.6.1 Introduction
The use of chromatography as the principal technique for the separation,
identification and quantification of components of mixtures became widespread in 1930s
and 40s despite having been first used by the Russian botanist Micheal Tswett at the
beginning of the 20th century. The basic principal of liquid chromatography is the
process of separating and purifying substances dissolved in a mixed solution by slow
passage through or over a surface of adsorbing material, making use of differences in
absorbtion of the constituents to separate the components either as (coloured) bands or
spots or by differences in speed of travel when washed through the adsorbing material.
High Pressure Liquid Chromatography (or High Performance Liquid Chromatography)
passes a solvent containing the mixture (mobile phase) under high pressure through a
column of tightly packed beads (solid phase) to separate components either by size
exclusion, affinity separation, ion-exchange or polarity. HPLC represented a significant
improvement on previous liquid chromatography techniques allowing the rapid and
sensitive separation of a mixture into its components. The separated components are
then passed through a detector (UV, Refractive index or fluorescence) and identified in
real time. The resolution of the system is dependent upon the extent of interaction
between the solute components and the stationary phase which can be manipulated
through different choices of both solvents and stationary phases. As a result, HPLC
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acquires a high degree of versatility and can easily separate a wide variety of chemical
mixtures.
2.6.2 Reverse-phase HPLC with electrochemical detection
Reverse phase HPLC is one of the most common forms of the technique wherein
the mixture of interest is dissolved in a polar solvent, in this case acetonitrile, and passed
through a column of hydrophobic beads. The polarity of the individual components in
the mixture will determine the retention time in the column and thus allow for separation
along the whole column. The components then pass through the detector electrode
which measures the current resulting from oxidation/reduction reaction of the analyte.
Since the level of the current is directly proportional to the analyte concentration, this
detector could be used for quantification. Although this form of detection is not very
versatile its sensitivity to levels of phenols, catecholamines, nitrosamines, and organic
acids is in the picomole (nanogram) range. By calibrating the detection software to
concentration ranges of a number of catecholamines involved in the metabolism and
catabolism of the principle monoaminergic neurotransmitters the experiment was
designed to detect changes in the levels of these important compounds in key areas of




Figure 2.8 Schematic representation of HPLC methodology
The sample is loaded into the loop and run through for 20mins. The detector then gives
readout of the concentration for each compound. The process of electrochemical
detection (measuring redux currents) means that the system can be a closed loop where
each compound can only be detected once.
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2.6.3 Experimental protocol
Standard curves for each compound of interest were established by injecting
50/xl PCA (60%) containing a mixture of the compounds at 2ng/jttl, 0.5ng/jal and
0.125ng/jul through the column. The mixture contained Noradrenaline, DOPAC,
Dopamine, 5HIAA, HVA, 5HT and the internal control NW-5HT. Each compound was
identified as a separated peak with a distinct retention time.
Tissue from the neocortex, striatum and hippocampus was dissected from fresh
mouse brain and snap-frozen in isopentane on dry ice and stored at -70°C until use. The
wet weight of each sample was measured before being sonicated for 10s in ~ 100/xl 60%
perchloric acid (PCA) containing 0.1ng//xl NW-5HT. The sample was then spun down
and the supernatant was run through the column (50/xl). Concentrations were then
obtained for each compound of interest and the final concentration of compound per mg
of tissue was calculated.
2.6.4 Statistical analysis
In these experiments we aimed to measure whether chronic administration of
LY450108 (0.5mg/kg) produced significant changes in the levels of aminergic
neurotransmitters and their principal metabolites in three areas of the brain. The data
was analysed by performing three, independent, two tailed unpaired Student t-tests for
each time point. This test was performed for each metabolite in the cortex, hippocampus




3.1 LY404187 and neurite growth
3.1.1 Aims
The aims of this study were to establish a model for the measurement of neurite
growth in the human neuroblastoma cell line SH-SY5Y. This model was then used to
investigate the effects on neurite growth of the AMPA potentiator LY404187.
3.1.2 Establishment of neurite growth assay
The methods employed in the measurement of neurite growth are numerous and
varied. To establish a reproducible and statistically sound assay we carried out pilot
studies to determine the ideal working protocol for a number of experimental parameters
Differentiation of SH-SY5Ys
SH-SY5Y cells are a highly heterogeneous cell type. Figure 3.1.1 shows a
typical field captured from cultured SH-SY5Y cells after 72 hours in culture. Using a
variety of differentiation factors it is possible to increase the number of neuronal type
cells and enhance considerably the average length of neurites. However in any given
population of SH-SY5Y cells under standard culture conditions, there is a clear sub-
population of cells that display neuronal phenotypes and a number of studies have been
published that use pre-differentiated SH-SY5Ys. Experiments were carried out using
retinoic acid (RA) to induce differentiation in these cells (data not shown). However I
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decided against using RA for two reasons. First, although the number of neuronal cells
was increased in RA treated cells, the phenotype of these cells was indistinguishable
from the neuronal cells present in SHSY5Y cells under standard conditions (Figure
3.1.2). Second, there is evidence suggesting that RA and NGF exert their effects though
the same mechanism of action. I had hypothesised that LY404187 may exert its effects
of neurite growth through BDNF, therefore the decision was taken not to involve
multiple growth factor pathways when they were under investigation.
Sampling
In view of the heterogeneity of SHSY5Y cells, it was important to determine that
an accurate sample was being taken. By measuring the average neurite length from a
population of cells collected from successive, randomly selected fields, I determined the
number of fields that were required to ensure that any additional fields did not alter the
average of the whole sample. Figure 3.1.3 summarises the data from three independent
experiments each representing approximately 100 neurites in total. I determined from
this study that between six and eight fields were necessary to ensure accurate population
sampling. To balance the need to ensure accurate population sampling and the logistical
issues of time and information storage whilst also ensuring adequate population sizes, in
all subsequent experiments 8 fields per well were taken.
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Figure 3.1.1 Heterogeneous populations of SH-SY5Ys
SH-SY5Ys display multiple phenotypes after 72hrs in culture. Round with multiple short
processes (black arrow), Cells with fewer processes but no polarity (red arrow),
neuronal-type cell with one or two long, thin processes and flattened cell body (white




Figure 3.1.2 Differentiation of SH-SY5Ys
SH-SY5Ys treated with a) RA lOOnMfor 72 hrs and b) untreated for 72hrs. In both
differentiated, neuronal-like cells are present, displaying long neuritic processes.
Figure 3.1.3 Population sampling for neurite growth assay
Population sampling for neurite growth assay. Data are presented as means ±SD (n>3).
The number of fields which need to be collected to ensure adequate sampling was
determined by measuring the standard deviation in the value for the average neurite
length from sequential fields. See textforfull explanation of results.
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Seeding density
SH-SY5Y cells divide every -14 hours, thus any experiment lasting more than
24 hours may be hampered by over confluence in the culture dish. We therefore set out
to determine the suitable seeding densities. Figure 3.1.4 shows images captured from
cells that have been seeded at different densities and left for 24 hours. The images are
representative of multiple fields. The pilot study showed that a starting density of
100,000 cells/well led to healthy cells that were not to confluent to allow accurate
measurement of neurite length. An NGF treated group was included to ensure that any
neurotrophic/differentiating factor would not affect the confluency of the cells.
Incubation times
I next determined the suitable time course for the experiment. I wanted to allow
the compound I was studying the necessary time to enhance the length of neurites but
without leading to over confluent cells. I carried out a pilot study, using NGF as an
inducer of neurite growth, that assessed the change in neurite length at 3, 5 and 7 days
incubation. The results, shown in Figure 3.1.5, indicate that across three equally
powered time points, each representing over 450 neurites only the group at 3 days
reached significance (ANOVA, p<0.05). In subsequent experiments all drug treatments








Figure 3.1.4 Seeding densities of SH-SY5Ys
Seeding SH-SY5Ys at a range ofdensities indicated that 100,000 cells/ well was the best
at providing dispersed, healthy, neurite bearing cells. At 1000 cells per well cells would
often die and lift off the plate. At 10,000 cells per well, although cell death was much





Figure 3.1.5 Incubation times for SH-SY5Ys
Data are presented as mean ±SEM (n>450, p<0.05). Different incubation times were
used to determine an appropriate incubation time to assess neurite growth. NGF
increased neurite length at each time point but the change was statistically significant
only at 3 days with groups ofequal size.
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3.1.3 The effect of FK506 on neurite growth
To test our model we carried out a large, fully powered study to measure changes
in average neurite length following incubation of SH-SY5Y cells with FK506.
FK-506 (tacromilus) is an immunosuppressant used in the prevention of allograft
rejection in transplants of organs such as livers and kidneys (Gold 1997). It is also
active in the nervous system and has been shown to induce neurite outgrowth, via the
activation of MAPK pathways, and potentiate the actions of NGF (Price, Yamaji et al.
2003). Its established neurotrophic role and ready availability made it an ideal
compound with which to test the SH-SY5Y neurite growth model.
Treatment of SH-SY5Y cells with FK506 for 72 hrs induced a concentration
dependent increase in average neurite length (Figure 3.1.6) with concentrations of 1/xM
and lOjiiM producing statistically significant increases compared to vehicle treated cells.
Due to the large number of neurites scatter graphs (Figure 3.1.6), although representing
the entire data set, are not best at conveying the shift in average length. For this reason
data from subsequent studies are presented as mean neurite lengths.
Figure 3.1.7 shows frequency distribution and cumulative frequency graphs to
illustrate alternative ways of presenting the large data set. These graphs, presenting the
same data as graphs in Figures 3.1.6, reveal a rightward shift in the distribution of
neurites across the whole population, suggesting that FK506 promotes the growth of
neurites of all lengths. These modes of presenting the data are useful as they reveal
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Figure 3.1.6 The effect on neurite growth of FK506
FK506 induces a concentration dependent increase in the average neurite length in SH-
SY5Y cells following 72 hours incubation. The same data are presented as mean neurite
length ±SEM (upper) and as a scatter graph (lower), veh- vehicle. n>350, p<0.05.
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Figure 3.1.7 Frequency distribution of SH-SY5Ys treated with FK506
Frequency distribution graphs of neurites from SH-SY5Ys cells treated with FK506
] fiM. Both graphs reveal a rightward shift in the distribution of neurites from FK506
treated cells. Open circles and bars = vehicle, Closed circles bars = FK506 ljiM
(n>350, p<0.05)
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3.1.4 The effect of LY404187 on neurite growth
Following confirmation of the model's sensitivity and robustness the effects of
AMPA receptor potentiator LY404187 on neurite length were investigated.
AMPA alone does not enhance neurite growth in SH-SY5Y cells
Application of s-AMPA (the active stearic isomer of AMPA) alone did not
enhance neurite length at any concentration tested (Figure 3.1.8) (ANOVA, p>0.05). At
the highest concentration tested the average length was dramatically accompanied by
widespread cell death. The toxicity was due to the actions of s-AMPA as no effect was
seen in the vehicle treated cells (1:1000 PBS). As well as excluding any neurotrophic
actions of AMPA alone the results also suggest that SH-SY5Ys expressed functional
glutamate receptors which mediated the excitotoxic insult (Choi 1992).
LY404187 alone does not enhance neurite growth in SH-SY5Y cells
Administration of LY404187 alone also produced no increase in average neurite
length. At the highest concentration tested the compound caused a decrease in the
average neurite length (ANOVA, p>0.05) (Figure 3.1.9). There was no apparent
increase in cell death at this concentration and these observations may reflect some cross




Figure 3.1.8 The effect on neurite growth of s-AMPA
Data are presented as mean ±SEM (n>350, p<0.05). s-AMPA does not promote neurite
growth at any of the concentrations tested. lOOpMfor 72 hours led to widespread cell





Figure 3.1.9 The effect on neurite growth of LY404187
Data are presented as mean ±SEM (n>350, p<0.05). LY404187 does not promote
neurite growth at any concentrations tested. 1 OpMfor 72 hours led to a significant
reduction in neurite length. Veil— vehicle
LY404187 in the presence of s-AMPA induces neurite growth
LY404187, in the presence of s-AMPA, when administered at concentrations
which alone do not induce neurite growth (0.1 and ljuM), led to a significant increase in
neurite length (Figure 3.1.10) (ANOVA, p<0.05). Frequency distribution analysis
reveals that the increase in average neurite length, although numerically subtle (<10%)
represents a pronounced rightward shift in the distribution of shorter neurites (<80jum)
(Figure 3.1.11).
Neurite growth induced by LY404187 in attenuated by CNQX
Co-incubation with the AMPA receptor antagonist CNQX (10/xM) attenuated the
enhancement in average neurite length induced by LY404187 (Figure 3.1.12) (ANOVA
with Bonferroni post hoc. test, p<0.05). CNQX (lOjaM) did not significantly alter the
average length of cells in the absence of LY404187 and s-AMPA (ANOVA with





Figure 3.1.10 The effect on neurite growth of LY404187 in the presence of
s-AMPA
Data are presented as mean ±SEM (n>350, p<0.05). Co-administration of s-AMPA
(O.lpM) and the AMPA potentiator LY404187 (0.1-lpM) for 72hrs significantly
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Figure 3.1.11 Frequency distribution of SH-SY5Ys treated with LY404187
Frequency distribution graphs of neurites from SH-SY5Ys cells treated with LY404187
(0.1 pM) and sAMPA (0.1 pM). Both graphs reveal a rightward shift in the distribution
of neurites from LY404187 and s-AMPA treated cells. Open circles and bars - vehicle,





Figure 3.1.12 The effect of CNQX on LY404187-induced neurite growth
Data presented as mean ±SEM (n>350, p<0.05). Incubation of SH-SY5Y with CNQX
(lOpM) attenuated the increase in neurite length following co-incubation with s-AMPA
(O.lpM) and LY404187 (0.1pM). Open bars= vehicle, Closed bars = CNQX (lOfxM)
3.1.5 The effect of LY404187 on the expression of neurofilament protein
Along with a morphological assessment we also performed biochemical analysis
of the effect of LY404187 on SH-SY5Y cells (Figure 3.1.13). Western blot analysis for
the cytoskeletal protein neurofilament-heavy chain (NF-H) revealed a similar pattern of
response in SH-SY5Ys to that measured by neurite growth. s-AMPA alone failed to
enhance NF-H immunoreactivity, as measured by the intensity of a 200kDa band, the
predominant band in the blot. LY404187 in the presence of s-AMPA consistently
enhanced NF-H in four separate replicate experiments. Although in all studies co¬
administration of LY404187 and s-AMPA induced the largest increase in NF-H a less
reproducible but evident increase was seen with administration of LY404187 alone. In
all treatment groups NF-H immunoreactivity was decreased by co-incubation with
CNQX (10/xM). Equal loading was confirmed by the relative intensity of actin blots
across wells (42kDa band).
Taken together with the structural data these results indicated that AMPA























Figure 3.1.13 The effect of LY404187 on neurofilament expression
Data are presented as mean ±SEM fold increase in chemiluminescence normalised to
Vehicle+CNQX treated cells, (n=4). Representative Western blots showing
neurofilament heavy chain expression levels from control (upper) and CNQX (lOpM)
treated cells (middle). Equal loading was confirmed by blotting for f-actin (lower).
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3.1.6 The comparative effects of multiple compounds on neurite growth
Because I had established a new method for the measurement of neurite length in
vitro we carried out a study comparing the magnitude of increase in neurite length seen
following incubation with LY404187 in the presence of s-AMPA with that of other well
characterised compounds. The neurotrophic factors BDNF and NGF as well as the
differentiating factor RA were used to induce neurite length in SH-SY5Ys. The
concentrations used were chosen from larger studies using these compounds carried out
in parallel to the studies described in this document (Milne and Voss unpublished
observations). Each compound was dissolved in a different vehicle (DMSO, ethanol,
glycerol and PBS). I therefore carried out independent, concurrent and equally powered
experiments to compare the magnitude of the effects of each compound. Figure 3.1.14
shows the results from these studies. The data were analysed by Student t-tests on the
average lengths from each experiment. The data indicate that NGF and RA induce a
30% increase in average neurite length while BDNF and LY404187 in the presence of s-
AMPA enhance neurite length by approximately 10%.
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LY404187
Figure 3.1.14 Comparison of neurite growth induced by LY404187, NGF,
BDNF and RA
Data presented as mean ±SEM neurite length (n>400, p<0.05). Increases in neurite
length following BDNF (lOng/ml), NGF (lOng/ml) and retinoic acid (RA) (0.1pM)
treatment are compared to AMPA (0.1pM) + LY404187 (0.1pM) (A+LY) treated cells.
3.1.7 The effect of LY404187 on the expression of Trk receptor protein
AMPA receptor potentiators have been shown to increase expression of BDNF
mRNA and protein in vitro (Lauterborn, Lynch et al. 2000; Legutko, Li et al. 2001) and
in vivo (Mackowiak, O'Neill et al. 2002). Intracellular actions of BDNF are mediated by
binding to Trk-B receptors. Un-differentiated SH-SY5Y cells express low levels of Trk-
B receptor protein and increase their expression significantly following differentiation
(Ruiz-Leon and Pascual 2003).
We therefore investigate the role of Trk receptors in the effect of LY404187 on
SH-SY5Y cells. Levels of Trk receptor protein were measured by Western blotting.
LY404187 in the presence of s-AMPA consistently enhanced Trk expression in four
separate replicate experiments, as measured by the intensity of a 140kDa band (Figure
3.1.15). Incubation with s-AMPA or LY404187 alone produced no increase in Trk
immunoreactivity. Equal loading was confirmed by the relative intensity of actin blots
across wells (42kDa band). The increase in Trk levels could be blocked with the addition





















Figure 3.1.15 The effect of LY404187 on Trk receptor expression
Data are presented as mean ±SEM fold increase in chemiluminescence normalised to
Vehicle+CNQX treated cells, (n=4). Representative Western blots showing Trk receptor
expression levels from control (upper) and CNQX (lOpM) treated cells (middle). Equal
loading was confirmed by blotting for fl-actin (lower).
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3.1.8 The effect of anti-BDNF IgG on LY404187-induced neurite growth
Increased Trk receptor expression suggests neurotrophin function is important in
this model and the role of BDNF on neurite growth was thus examined. Attempts to
monitor levels of BDNF protein by Western Blot and ELISA assays were unsuccessful
(data not shown). Evidence from the literature however indicates that SH-SY5Ys
expressed very low levels of BDNF protein (Olivieri, Otten et al. 2003).
Antibody sequestration is a common technique to investigate the physiological
role of neurotrophins (Barde, Edgar et al. 1982; Cohen-Cory and Fraser 1995; Tucker,
Meyer et al. 2001). The addition of an antibody against BDNF inhibited the increase in
neurite length induce by LY404187 and s-AMPA (ANOVA with Bonferroni post hoc
test, p<0.05). The antibody did not significantly alter the average neurite length of any
other treatment group (Figure 3.1.16) and control experiments were carried out to
determine the specificity of the BDNF antibody. Western blots identified a single band
at 14 kDa corresponding to BDNF (Figure 3.1.17). The growth of neurites over 72 hours
was unaltered following incubation of BDNF antibody and, crucially the addition of a
random rabbit IgG did not attenuate the increase in neurite length following the co-
incubation of LY404187 and s-AMPA These data implicate BDNF in the mechanisms
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Figure 3.1.16 The effect anti-BDNF IgG on LY404187-induced neurite
growth
(Upper) Data are presented as mean ±SEM neurite lengths. (n>450, p<0.05). (Lower)
The same data are presented as cumulative percentage (n>450, p<0.05). Co-incubation
with anti-BDNF mouse IgG (Ab BDNF) (1 jig/ml) attenuated neurite outgrowth
following co-incubation with s-AMPA (0.1pM) and LY404187 (0.1pM).
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Figure 3.1.17 Western blot showing specificity of anti-BDNF antibody
Western blot showing BDNF (14kDa) in untreated SH-SY5Y lysate. The specificity of
the antibody is evident as a single clear band was detected.
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3.2 The effect of LY404187 on neurite sprouting and neurogenesis in the
dentate gyrus of mice following unilateral entorhinal cortex lesions
3.2.1 Aims
The aim of this study was to establish a model of structural plasticity in vivo in
which to measure the effect of LY404187 neuronal sprouting. To this end I used
unilateral lesions of the entorhinal cortex which induce unilateral loss of synapses in the
molecular layer of the dentate gyrus (DG) of the hippocampus. Over time sprouting
from within the hippocampal formation leads to a recovery in the density of synapses in
the molecular layer.
3.2.2 Establishment of mouse model of ECL
To determine the appropriate time points at which to investigate the effects of
LY404187 on sprouting in the hippocampus a time course of the loss and recovery of
synaptophysin in the middle molecular layer of the DG in mice was performed. Using
the study by White et al. (2001) as a guide I analysed the ratio of optical densities
between hemispheres at 3, 7, 28 and 90 days post surgery.
Unilateral excitotoxic lesions of the entorhinal cortex failed to produce a
significant change in the ratio of ipsilateral and contralateral synaptophysin levels in the
middle molecular layer of the dentate gyrus. However there was a significant difference
between the average interhemispheric ratio at 3 and 7 days post surgery (Figures 3.2.1
and 3.2.2) (ANOVA, p<0.05). Interhemispheric ratio of synaptophysin optical densities:
3 days 0.995±0.028 and 7 days 0.899±0.059 p<0.05). No differences were seen between
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other time groups. This apparent contradiction with other published studies (White et al.
2001) is most likely due to problems with the dose of ibotenic acid used to produce the
lesions. In fact, although histological assessment of the lesion site revealed necrotic
tissue around the injection site and confirmed the correct placement of the syringe
(Figure 3.2.3), most animals in the 28 day recovery group displayed small lesions (data
not shown). These animals were all operated on at the same time indicating that a
faulty dose of ibotenic acid would have led to reduced lesions in this group. In


















Figure 3.2.1 Synaptophysin immunoreactivity in the dentate gyrus
7 days post-unilateral ECL there is a significant reduction in synaptophysin staining





















Figure 3.2.2 Ratio of inter-hemispheric synaptophysin levels
Ratios of optical density measurements along the middle molecular layer of the DG in
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Figure 3.2.3 Histological analysis of lesioned tissue
Photomicrographs showing the damage caused by unilateral ibotenate injections in the
entorhinal cortex. Lesioned tissue was pale and contained many densely stained
shrunken cell bodies (black arrow). Un-lesioned tissuefrom the contralateral
entorhinal cortex is shownfor comparison displaying intact neuropil and large cell
bodies (yellow arrow).
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3.2.3 The effect of LY404187 on lesion volumes and synaptophysin levels
following ECL
Following the pilot study in which we characterised the progression of synaptic
degeneration, I next carried out a new study on the effects of LY404187 reactive
sprouting following surgery. We hypothesised that the reactive sprouting in the dentate
gyrus would be enhanced following treatment with the AMPA potentiator LY404187.
The mice underwent unilateral lesion of the entorhinal cortex and were treated with
LY404187 twice daily (0.5 mg/kg s.c) for 14 and 28 days and the lesion size and the
extent of synaptophysin levels were measured in both hemispheres of the dentate gyrus.
One animal was excluded from further study due to its lesion extending rostrally into the
hippocampal formation (Figures 3.2.4 and 3.2.5). The average lesion volume across all
3 3
groups was 1.36 mm' with maximum and minimum volumes of 2.8 and 0.4 mm (Figure
3.2.6). There was no significant change in average lesion size following administration
of LY404187 0.5mg/kg, nor was there any difference between 14 and 28 day groups
(ANOVA, with Bonferroni post hoc test, p>0.05).
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Figure 3.2.4 Representative entorhinal cortex lesions
(overleaf) Lesion template from a representative animal (AR8) and from animal AR44
that was excluded from further study because of damage to the neocortex and
hippocampus. Red areas represent lesioned tissue. These areas were used for 3D




Figure 3.2.5 3-D Reconstructions of representative lesions
3D reconstruction oflesionsfrom animals AR8 (upper) and AR44 (lower). Figure shows





































Figure 3.2.6 Lesion volumes in the entorhinal cortex following chronic
administration of LY404187
(Upper) Data are presented as a scatter graph of the raw data. One animal (arrow) was
excluded from further study because its lesion spread rostrally into the hippocampal
formation and the volume was over twice the mean for that group. (Lower) Data are
presented as the mean ±SEM volumes for the animals included in further study.
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Once the lesions had been quantified and animals included or excluded from the
study we measured the primary end point of the study, synaptophysin immunoreactivity
in the dentate gyrus. 10 optical density readings were taken from 3 fields across the
dentate gyrus; dorsal, medial and ventral. Readings were also taken from the corpus
callosum and the average value was subtracted from the average from the dentate gyrus.
The experimenter was formally blinded against treatment groups and the codes were
broken after all data was collected. Figure 3.2.7 summarises the results of this study.
There was no significant difference between the ratio of ipsilateral to contralateral
synaptophysin immunoreactivity between animals dosed with LY404187 and animals
dosed with vehicle.
Larger lesions cause more profound loss of synapses and a subsequently greater
reduction in synaptophysin immunoreactivity in the dentate gyrus (van Groen 2001; van
Groen, Miettinen et al. 2003). Correlation analysis between the volume of the lesion and
synaptophysin immunoreactivity revealed a weak correlation between the two
parameters at 14 days post lesion but no correlation between lesion and synaptophysin
levels (Figure 3.2.8). 14days; vehicle r2= 0.242, LY404187 r=0.246. 28 days; vehicle











































Figure 3.2.7 Synaptophysin levels in the dentate gyrus following chronic
administration of LY404187
Synaptophysin labelling in the middle molecular layer of the dentate gyrus. (Upper) data
are presented as scatter graph of raw optical density ratios. (Lower) The same data are
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Figure 3.2.8 Correlation of lesion volume and synaptophysin levels
Data are presented as a scatter graph of lesion volume against synaptophysin levels for
14 day (upper) and 28 day (lower) treatment groups.
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3.2.4 The effect of LY404187 on the rate of neurogenesis in the dentate
gyrus following ECL
The second end point of the study was to monitor the rate of neurogenesis in the
dentate gyrus 14 and 28 days following ECL. The study was also aimed at detecting any
change induced by the administration of LY404187.
Currently there are multiple protocols to study the rate of neurogenesis in the
hippocampal formation. The most widely used method is the administration of the
uridine analogue BrdU. The compound is incorporated into newly synthesised DNA and
BrdU+ cells can be detected using simple immunological techniques. In the current
study I chose to count, in both hemispheres of the dentate gyrus at the level of the lateral
habenulae, the average number of BrdU positive cells per section using two adjacent
slides.
The detection of BrdU+ cells in the sub-granular region of dentate gyrus of tissue
sections with anti-BrdU antibody allowed clear and easily quantifiable detection of
newly generated cells (Figure 3.2.9).
The rate of neurogenesis, as measured by the number of cells incorporating
BrdU, did not change across time points in ipsilateral or contralateral hemispheres
(ANOVA, p>0.05). There was no change in the rate of neurogenesis between animals
administered LY404187 and animals administered vehicle (Figure 3.2.10) (ANOVA,
p>0.05). There was also no change in the ratio of ipsilateral to contralateral hemispheres
across all groups (Figure 3.2.11) (ANOVA, p>0.05).
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Figure 3.2.9 Detection of neurogenesis in hippocampus
BrdUf cells in the sub-granular layer of the dentate gyrus (yellow arrows) ofnormal
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Figure 3.2.10 Neurogenesis in the dentate gyrus following chronic
administration of LY404187
Data presented as mean ±SEM number ofBrdU+ cells in the sub-granular layer of the
dentate gyrus (n=5-9,).. I-ipsilateral, C- Contralateral. Open bars = Vehicle, Closed
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Figure 3.2.11 Ratio of Inter-hemispheric rates of neurogenesis
(Upper) Data presented as scatter graph of inter-hemispheric ratios in the rate of
neurogenesis. (Lower) Data presented as mean ±SEM of inter-heniispheric ratios in the
rate ofneurogenesis (n=5-9,).
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3.3 Biochemical changes following AMPA potentiation in vivo
3.3.1 Aims
The aim of the three studies presented in this section was to establish whether chronic
administration of an AMPA receptor potentiator, LY450108, could induce persistent
changes in three key areas related to the actions of AMPA potentiators in vivo.
First, AMPA potentiators are thought to mediate their intracellular actions through the
MAPK and CREB pathways. The level of phosphorylation of these proteins was
measured by immunohistochemistry and western blotting in the hippocampus. Second,
AMPA potentiators have been shown to be effective in classical animal models of
depression. They also have been shown to promote sprouting of synapses positive for
tyrosine hydroxylase, an enzyme required in the synthesis of dopamine. The levels of
noradrenaline, serotonin and dopamine and their principal metabolites were measured by
HPLC in the caudate nucleus, hippocampus and neo-cortex to determine whether long
term LY450108 administration could change their levels. Third, AMPA potentiators
have been shown to induce neurogenesis following chronic administration. The
correlation between neurogenesis in the expression mood disorders and the actions of
classical antidepressants has been well documented (Malberg, Eisch et al. 2000;
Santarelli, Saxe et al. 2003).
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Dosing protocol
The dosing protocols used in these studies were designed to allow the study of
acute, chronic and persistent changes following the administration of LY450108.
Animals were dosed twice daily for 3 days, 10 days and a final group had 10 day
LY450108 administration and a further 7 days vehicle doses. Each group had
compound and vehicle treatment groups of 6 animals each. Additionally, animals
received doses of BrdU i.p. prior to being culled. In the neurogenesis study (shown
below), 24 prior to being culled the animals were administered with 2 x lOOmg/kg
injections of BrdU i.p. In the neuronal development study animals are given 2
xlOOmg/kg injections of BrdU i.p 7 days before being culled (Except animals in the 3



















3.3.2 The effects of LY450108 on phosphorylation levels of ERK 1/2 and
CREB in the hippocampus
AMPA potentiation increases the opening time of AMPA receptors. This can induce the
direct induction of MAPKs and CREB through Lyn kinase and Ca2+ (through calcium
permeable AMPA receptors) and indirectly through the recruitment of NMDA receptors.
To investigate whether these pathways are induced in vivo I performed Western blots
and immuno-histochemical analysis of levels of the phosphorylated proteins.
pERK 1/2
Levels of pERK 1/2 were assessed by measuring the intensity of pERK 1/2
chemiluminescence as a ratio of native ERK1/2 levels. Western blots identify two bands
at 44 and 42 kDa. Equal loading was confirmed by the relative intensity of actin blots
across wells. Levels of native ERK 1/2 were unchanged across all treatment groups. 6
animals per group were used, equal loading was assessed by protein assay and all
measurements were blinded to treatment groups. Figure 3.3.1 shows a representative
blot for pERKl/2 and ERK 1/2 and average ratio in intensities. Statistical analysis
detected no significant change between treatment groups and time points (ANOVA
p>0.05).
Immunohistochemistry allowed a more quantative measure of pERK levels and
allowed localization of the positive cells (Figures 3.3.3-3.3.5)
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Figure 3.3.1 Levels of pERK 1/2 in the whole hippocampus following
chronic administration of LY450108
(Upper) Representative Erk 1/2 western blots from vehicle (left) and LY450108 (right)
showing pErk, native Erk and actin loading control (Lower) Data expressed as mean
±SEMfold change chemiluminescence levels ofpERK 1/2 expressed as a ratio of
chemiluminescence levels ofnative ERK 1/2. Levels of native ERK1/2 were unchanged





Figure 3.3.2 Detection of pErk 1/2+ve cells in the hippocampus
(Upper) Low power micrograph showing the stainingpattern ofpErk+ve cells (black
arrows) in the dentate gyrus. (Lower) At a higherpowerpositively stained cells (black
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Figure 3.3.3 pERK 1/2 immunopositive cells in the hippocampus following
3 days administration of LY450108
Data presented as mean ±SEM (n=6, p>0.05). The number of pERK l/2+ cells in four
regions of the hippocampus. There was no significant change in any region between
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Figure 3.3.4 pERK 1/2 immunopositive cells in the hippocampus following
10 days administration of LY450108
Data presented as mean ±SEM (n-6, p>0.05). The number of pERK l/2+ cells in four
regions of the hippoca?npus. There was no significant change in any region between
vehicle and drug treated groups following 10 days chronic administration of LY450108
(0.5mg/kg).
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Figure 3.3.5 pERK 1/2 immunopositive cells in the hippocampus following
17 days administration of LY450108
Data presented as mean ±SEM (n=6, p>0.05). The number of pERK l/2+ cells in four
regions of the hippocampus. There was no significant change in any region between




Measuring levels of pCREB by Western blotting was not possible due to the poor
quality of the antibody in Western blotting. In contrast, the detection of pCREB+ cells in
paraffin embedded tissue by imrnunohistochemistry revealed clearly labelled cells along
the dentate gyrus that were clearly quantifiable (Figure 3.3.6). Assessing the number of
cells in the CA1, CA2 and CA3 regions however was not performed due the high
background staining in this area, making the identification of positive cells impractical.
The results show no significant change in the number of pCREB cells across all groups




3.3.6 Detection of pCREB+ve cells in the hippocampus
(Upper) Low power micrograph showing the stainingpattern ofpCREB+ve cells (black
arrows) in the dentate gyrus. (Lower) At a higherpower intensely stained cells (black





















Figure 3.3.7 The number of pCREB+ cells in the dentate gyrus following
chronic administration of LY450108
Data are presented as a scatter graph of the number of pCREB+ cells in individual
mice (n=4-6, p>0.05) There was no change between vehicle and drug treated groups
following 3, 10 or 17 days of drug administration. veh= vehicle, LY=LY450108
(0.5mg/kg)
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3.3.3 The effect of LY450108 on monoamine levels in the hippocampus,
caudate nucleus and neocortex
All antidepressants in widespread clinical use are able to enhance central levels
of aminergic neurotransmitters. In this study the levels of 5-HT, NA and DA and their
principal metabolites were measured across three brain regions by HPLC.
High levels of DA, DOPAC and HVA were detected in striatal tissue. Levels of
5HT, NA and 5HIAA were negligible (data not shown). There was no statistical
difference between each of the detected compounds across treatment groups and time
points (Figure 3.3.8) (p>0.05).
Low levels of 5HT, 5HIAA and NA were detected in the hippocampus,
reflecting the prevalence of glutamatergic synapses in this structure. Negligible levels of
DA and HVA were detected (data not shown). There were no significant changes
between treatment groups and time points (Figure 3.3.9) p>0.05).
Approximately 10 times higher levels of 5HT and 5HIAA and NA were detected
in the cortex than in the hippocampus. There where no significant changes between
drug treatment groups at any time point (p>0.05). Due to technical problems the 3 and

























Figure 3.3.8 Monoamine levels in the caudate nucleus following
administration of LY450108
Data are presented as mean monoamine levels ±SEM (n=6, p>0.05). There were no













































Figure 3.3.9 Monoamine levels in the hippocampus following
administration of LY450108
Data are presented as mean monoamine levels ±SEM (n=6, p>0.05). There were no
























Figure 3.3.10 Monoamine levels in the neocortex following administration
of LY450108
Data are presented as mean monoamine levels +SEM (n=6-12, p>0.05). Open bars=
Vehicle, Closed Bars= LY450108 (0.5mg/kg)
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3.3.4 The effect of LY450108 on the rate of neurogenesis and neuronal
development in the hippocampus
The final end point of this study was the assessment of the rate of neurogenesis
and neuronal development in the hippocampus following LY450108 administration.
Animals were dosed with BrdU 24hrs, 3 days of 7 days prior to being culled (see
materials and methods). The rate of neurogenesis was assessed by counting the number
of BrdU+ cells present in the subgranular zone of the dentate gyrus. The average number
of cells per slide was unchanged across treatment groups and time points. There is a
non-significant increase (p=0.08) in LY450108 treated 17 day group (veh=9±1.6
LY450108=16±2.9) (Figure 3.3.11).
The differentiation of stem cells into neuronal cells was assessed using the
neuronal marker NeuN. BrdU+/NeuN+ positive cells could be identified at high power
as the diffuse, cytoplasmic staining of NeuN could easily be distinguished from the
nuclear staining of BrdU (Figure 3.3.12). The end point was the percentage of BrdU+
cells that were also NeuN+. Statistical analysis revealed no change between treatment
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Figure 3.3.11 Neurogenesis following chronic administration of LY450108
Data are presented as scatter graph of raw data of BrdU+ cells (n=4-6, p>0.05)
For each animal the average of two coronal sections through the hippocampus was
measured. There was no change between vehicle and drug treated groups following 3,
10 or 17 days ofdrug administration. veh= vehicle, LY-LY450108 (0.5mg/kg).
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Figure 3.3.12 Detection of neuronal development in the hippocampus
At high magnification cells stained positive for BrdU (brown) and NeuN (blue) can
easily be identified. Cells displayed intensely stained cell nucleus surrounded by blue





























Figure 3.3.13 Neuronal development following chronic administration of
LY450108
Data are presented as scatter graph of raw data of BrdU+ cells (n=4-6, p>0.05). For
each animal the average of two coronal sections through the hippocampus was
measured. There was no change between vehicle and drug treated groups following 3,




4.1 Neurite growth with LY404187
4.1.1 Summary
The data presented in Chapter 3.1 show that the AMPA receptor potentiator
LY404187 can increase the average length of neurites and the expression of the
cytoskeletal protein neurofilament in SH-SY5Y cells. Further experiments suggested
that the increase in neurite length was mediated in part by the neurotrophin BDNF.
4.1.2 Methodology
The primary endpoint of the studies presented in Chapter 3.1 was the change in
average neurite length in SH-SY5Y cells. The choice of SH-SY5Y cells as the model
system for these experiments was made on the basis of their human origin, their
established use in neurite growth studies and their availability. Pilot experiments were
also carried out in cerebellar granule cells and hippocampal neurons with the aim of
establishing a neuronal model in which to study the molecular mechanisms of AMPA
potentiation and neurite growth. The cerebellar granule cells were not pursued further,
as the density required to promote adequate cell survival and neurite growth did not
permit accurate measuring of neurite growth (data not shown). Dissociated hippocampal
neurons collected from E16-18 rats provided healthy, dispersed and neurite bearing cells
ideal for exploring the mechanisms of AMPA receptor mediated intracellular cascades.
However following several pilot experiments aimed at investigating down stream effects




AMPA receptor potentiators were conceived as compounds that could facilitate
the induction of LTP and were hypothesised to act as cognitive enhancers by promoting
memory formation (Granger, Staubli et al. 1993; Staubli, Rogers et al. 1994; Lynch
2004). Many compounds, termed AMPA potentiators, of various chemical classes have
indeed been shown to act as cognitive enhancers in a variety of animal and human
paradigms (Larson, Lieu et al. 1995; Granger, Deadwyler et al. 1996; Lynch, Granger et
al. 1997; Hampson, Rogers et al. 1998; Buccafusco, Weiser et al. 2004; Porrino, Daunais
et al. 2005). In these studies the effects of tested compounds have been short lived,
leaving no residual effect following withdrawal of compound, implying that cognitive
enhancement by AMPA potentiation may only have symptomatic improvement for
cognitively impaired individuals. However, more recent studies suggest that AMPA
potentiation may also have neurotrophic and neuroprotective properties (Dicou, Rangon
et al. 2003; O'Neill, Murray et al. 2004; O'Neill, Murray et al. 2005). In particular
studies carried out by O'Neill and colleagues suggest enhanced sprouting of
dopaminergic terminals in the rat striatum following 6-OHDA lesions.
The studies described in chapter 3.1 were aimed at investigating the mechanisms
of any structural changes induced by AMPA potentiation. Our findings demonstrate that
direct application of an AMPA receptor potentiator can induce BDNF-dependent
morphological plasticity.
A role of glutamate receptors in regulating neurite growth is well established but
varied. Glutamate application inhibits neurite growth in embryonic rat motor neurons
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through Ca2+ permeable AMPA receptors (Metzger, Wiese et al. 1998), whilst kainic
acid promotes neurite growth in DRG cells in the presence of corticosterone (Tsai, Chiu
et al. 2002) and AMPA receptor activity stabilises actin dynamics in growth cones of
developing axons (Chang and De Camilli 2001). The only evidence of an AMPA
potentiator inducing neurite growth, published over a decade ago, reported moderate
enhancement of neurite length in murine CGNs with the weak AMPA potentiator
aniracetam (Fushiki, Matsumoto et al. 1995). However a number of recent reviews have
supported the possibility that AMPA potentiation may be able to enhance structural
plasticity in the adult CNS (O'Neill, Bleakman et al. 2004; Alt, Nisenbaum et al. 2006).
To explore the effects of AMPA potentiation on structural plasticity we
developed an assay for the measurement of neuritic growth in vitro using the human SH-
SY5Y neuroblastoma cell line. SH-SY5Y cells possess biochemical characteristics
similar to dopaminergic cells, such as tyrosine-P-hydroxylase activity (Oyarce and
Fleming 1991) and are a common model for the investigation of neuronal differentiation
and neurite growth (Ivankovic-Dikic, Gronroos et al. 2000; Cui, Yang et al. 2003; Price,
Yamaji et al. 2003; Jamsa, Hasslund et al. 2004; Daniel, Mudge et al. 2005). They
express AMPA receptor subunit mRNA, Trk-B receptors and BDNF protein
(Christnacher and Sommer 1995; Ho, Eggert et al. 2002; Olivieri, Otten et al. 2003;
Ruiz-Leon and Pascual 2003).
Our results demonstrate that LY404187 in the presence of s-AMPA induced
neurite outgrowth in SH-SY5Y cells. The magnitude of the effect was comparable to
that induced by BDNF incubation and around half that induced by NGF and retinoic
acid. LY404187 thus compares favourably to classical neurite growth inducers,
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especially when considering that an allosteric modulator of an ion channel is being
compared to neurotrophins and a powerful differentiation factor. This growth was
dependent on AMPA receptors, as incubation with CNQX, a competitive AMPA
receptor antagonist attenuated the response.
In addition to monitoring neurite growth by morphometric analysis we also
investigated changes in neurofilament expression. The cytoskeletal protein
neurofilament has been widely used as an indicator of neurite growth and maturation
(Drejer and Honore 1988). We observed increases in expression following incubation
with LY404187 alone and co-incubation with s-AMPA and LY404187. In all
experiments the largest increase was seen with co-incubation of LY404187 and s-
AMPA. LY404187 has no intrinsic activity at AMPA receptors when assessed by
electrophysiological recordings of transfected cell lines and neuronal cells (Gates,
Ogden et al. 2001; Miu, Jarvie et al. 2001). However long term administration in cell
culture systems by other biarylproposulphonamides is able to elicit intracellular
responses when applied on their own. This is probably due to their ability to potentiate
AMPA receptors in the presence of low levels of glutamate present in the medium,
released by cells, in the case of glutamatergic neurons, or released into the medium
following cell death and lysis (Legutko, Li et al. 2001). Increased neurofilament
expression following incubation with LY404187, where no effect was seen on neurite
outgrowth, may therefore reflect the higher sensitivity of Western blot analysis
(Doherty, Dickson et al. 1984; Cambray-Deakin, Morgan et al. 1987; Encinas, Iglesias et
al. 2000). Taken together the NF-H expression and the neurite outgrowth data strongly
suggest that AMPA potentiation can promote structural changes in vitro.
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The link between synaptic activity and neurotrophin expression is well
established (Zafra, Hengerer et al. 1990; Ghosh, Carnahan et al. 1994; Tao, Finkbeiner
et al. 1998; Limatola 2004). In particular AMPA receptor activity can depolarise
membrane potentials recruiting VGCC and NMDA receptors which in turn increase
intracellular levels of [Ca2+];. Through the recruitment of a number of calcium sensitive
enzymes, including CaM and CaMKs this can lead to the phosphorylation of CREB and
the increased synthesis of BDNF (Carlezon, Duman et al. 2005) (Figure 3.11). As well
as gating Ca2+ ion flux through GluR2 lacking receptors AMPA receptors can recruit a
variety of second messenger molecules such as the non-receptor tyrosine kinase Lyn
(Hayashi, Umemori et al. 1999), FAK (Millan, Aguilar et al. 2001), PI(3)K (Millan,
Arias-Montano et al. 2004) and G-proteins (Wang, Small et al. 1997). Through these
they can recruit intracellular signalling cascades such as the MAP kinase pathways
(Wang and Durkin 1995; Hayashi, Umemori et al. 1999; Perkinton, Sihra et al. 1999;
Bahr, Bendiske et al. 2002) and enhance gene expression through the activation of
transcription factors such as c-fos and CREB (Sassone-Corsi, Visvader et al. 1988;
Sheng, McFadden et al. 1990; Rajadhyaksha, Barczak et al. 1999; Garcia, Anderson et
al. 2003; Fowler, Whalley et al. 2004).
CREB is expressed in all cells of the brain and is regulated by many complex
region, cell and signal specific pathways and is a key link in the chain of membrane to
nucleus signal transduction, crucial for sensing changes in the extracellular environment
and translating them into changes in gene transcription (Carlezon, Duman et al. 2005).
Phosphorylation of CREB can regulate the expression of a large set of genes the most
studied of which include BDNF, Tyrosine hydroxylase, Bcl-2, GluRl and c-fos (Zafra,
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Hengerer et al. 1990; Finkbeiner, Tavazoie et al. 1997; Shieh, Hu et al. 1998; Tao,
Finkbeiner et al. 1998). Due to its distribution and range of target genes CREB activity
has been implicated in mediating a number of processes related to memory, cognition,
the pathology and treatment of depression, addiction and anxiety (Nestler, Barrot et al.
2002; Scott, Bourtchuladze et al. 2002; Carlezon, Duman et al. 2005).
BDNF signals primarily through the tyrosine kinase receptor Trk-B (Glass, Nye
et al. 1991; Klein, Nanduri et al. 1991; Soppet, Escandon et al. 1991; Squinto, Stitt et al.
1991; Barbacid 1995). Western analysis for Trk receptor expression revealed that
LY404187 in the presence of AMPA can increase expression levels, suggesting an
increase in neurotrophin responsiveness. There is evidence for the production of BDNF
by SF1-SY5Y cells under basal conditions (Ruiz-Leon and Pascual 2003) and my results
strongly indicate that neurite growth associated with AMPA potentiation is dependent on
BDNF. BDNF has been identified over the past decade as a modulator of a number of
cellular processes including early CNS development (Legutko, Li et al. 2001), synaptic
transmission (Ernfors, Lee et al. 1994) and regeneration following brain injury
(Patterson, Abel et al. 1996; Schratt, Nigh et al. 2004). It has also been hypothesised
that increases in growth factors such as BDNF may lead to the beneficial effects of
AMPA potentiation in a range of animal models (Ebadi, Bashir et al. 1997). In the
present study I demonstrated that BDNF antibody-sequestration attenuates the increase
in neurite length following co-incubation with AMPA and LY404187 indicating that
BDNF is a potential downstream effector of neurite growth following AMPA receptor
potentiation. AMPA receptor potentiation has recently been shown to protect cells from
excitotoxic cell death via Lyn, ERK1/2, CREB and BDNF activity (Wu, Zhu et al.
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2004). A similar pathway is likely to be activated in our model to promote neurite
outgrowth (O'Neill, Bleakman et al. 2004).
Enhancing central plasticity, neuritic sprouting and regeneration are promising
therapeutic strategies for the treatment of a number of neurological conditions including
depression and Parkinson's disease (Manji, Quiroz et al. 2003; Fernandez-Espejo 2004;
Mueller, Mack et al. 2005). Reductions in volume and structural abnormalities in a
number of brain regions have been observed in humans with depression (Sheline 2003)
and reduced neurogenesis (D'Sa and Duman 2002), decreased levels of BDNF
(Angelucci, Brene et al. 2005) and plasticity imbalances (Peled 2005) have also been
implicated. Neuroprotective and neurotrophic strategies are being investigated for the
treatment for Parkinson's disease, focusing on the actions of the neurotrophins BDNF
and GDNF (Mamounas, Blue et al. 1995; Gash, Zhang et al. 1998; Fernandez-Espejo
2004). Biarylproposulphonamides have been demonstrated to enhance neurogenesis
(Bai, Bergeron et al. 2003), BDNF expression in vivo (Mackowiak, O'Neill et al. 2002),
sprouting of nigro-striatal dopamingergic terminals and show behavioural effects in
animal models of depression (Li, Tizzano et al. 2001) and Parkinson's disease (O'Neill,
Murray et al. 2004; O'Neill, Murray et al. 2005). Along with the present demonstration
that they can promote structural plasticity, biarylproposulphonamides show a favourable
profile for the treatment of a number of neurological conditions.
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4.1.4 Conclusions
Our results further highlight the long term neurotrophic effect of AMPA receptor
potentiation and support evidence that, in addition to transient cognitive enhancement
(O'Neill, Bleakman et al. 2004), AMPA receptor potentiators can promote downstream









Figure 4.1.1 Working hypothesis for the mechanisms of action of AMPA potentiators. Enhanced
periods of AMPA receptor activation promote the recruitment of NMDA and VGCC through increased
membrane depolarisation. Elevated levels of Ca2'activate the CaM-CaMK cascade which results in
phosphorylation of CREB. AMPA receptors can also directly recruit MAPK pathways and CREB
activation through non receptor tyrosine kinase Lyn. CREB regulates the expression ofa number ofgenes
including BDNF which is secreted and can act in an autocrine or paracrine fashion, through Trk-B
receptors to promote a number of neurotrophic responses including the neurite growth described in this
chapter.
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4.2 Neuronal sprouting in dentate gyrus following ECL
4.2.1 Summary
The data from this study indicate that 14 and 28 days of twice daily injections of
LY404187 (0.5mg/kg) had no effect on lesion volume or the ratio of synaptophysin
immunoreactivity between hemispheres in the molecular layer of the dentate gyrus
following ECL. Thus, my hypothesis that LY404187 would enhance the recovery of
synaptophysin immunoreactivity following lesioning was not supported in this study.
There are three major reasons for which this might be the case: the experiment was
flawed, through practical or statistical reasons; the dosing protocol of LY404187 chosen
was not able to induce the appropriate changes in brain levels of LY404187 or AMPA
potentiation may not be able, as hypothesised, to induce significant sprouting and
synapse formation in this paradigm.
4.2.2 Methodology
Unilateral ibotenic acid injections in the entorhinal cortex were successful in
producing excitotoxic lesions in the ventro-caudal portion of the entorhinal cortex.
Histological analysis revealed staining showing that the tissue was deeply necrotic and
contained many shrunken intensely stained cell bodies and multiple holes in the tissue
representing widespread and substantial tissue damage. 3D reconstruction of the lesion
site for the LY404187 study and quantification of the volume showed that the procedure
was highly reproducible both in terms of the location of the lesion and its volume. This
type of lesion leads to a loss of synapses in the ipsilateral middle molecular layer of the
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dentate gyrus. The pilot study revealed a significant difference in the ratio of
intrahemispheric synaptophysin O.D. between 3 and 7 days post lesion. Animals in the
28 days recovery group did not show significantly altered levels of synaptophysin. The
lesions themselves produced small changes in synaptophysin levels and there were no
changes in the overall O.D levels between hemispheres. This is in direct contrast to
published data that showed maximum loss in synaptophysin occurs 28 days following
ECL (White, Nicoll et al. 2001). Histological analysis of the entorhinal cortex from
animals in the study showed substantially smaller lesions in the 28 day group than in
other groups (data not shown). Animals from each group of all underwent surgery on the
same day could and the small lesions in the 28 days group could have been due to a
faulty batch of ibotenic acid used that day. In, the follow-up study which examined the
effects of LY404187 in the lesioned mice, mice from the same recovery groups were all
lesioned on to ensure that animals from any one group were not all lesioned on the same
day.
4.2.3 Discussion
LY404187 and other biarylproposulphonamides of its class readily diffuse across
the blood brain barrier and have been shown, at a concentration of (0.5mg/kg), to elevate
cerebral glucose utilisation in the brain of the rat (Fowler, Whalley et al. 2004). At this
dose LY404187 has also induced positive responses in a number of behavioural models
and was the optimum dose for promoting functional and histological recovery in a 6-
OHDA model of Parkinson's Disease (Quirk and Nisenbaum 2002; O'Neill, Murray et
al. 2004). Although the exact pharmacokinetics of LY404187 in mice are not known,
157
particularly those associated with chronic administration, given the available literature
the dose of 0.5mg/kg was judged to be sufficient to enhance central levels of BDNF.
Given that the surgery was a practical success and induced a substantial loss of
synaptophysin in the dentate gyrus and that the dosing regime was the appropriate one
based on the available literature on LY404187, we can conclude that AMPA potentiation
had no appreciable effect in the model for valid physiological reasons.
Firstly we can conclude that AMPA potentiation does not exacerbate the damage
caused by ibotenic acid lesions. One of the main areas of concern with AMPA
potentiators is the potential to induce excitotoxicity, indeed IDRA-21 had been shown to
exacerbate excitotoxic hippocampal injury in vivo (Yamada, Covey et al. 1998),
although this was probably due to non specific kainate receptor effect. However it
seems that AMPA potentiation can actually protect against excitotoxicity both in vitro
(Wu, Zhu et al. 2004) and ischemic damage in vivo (Dicou, Rangon et al. 2003).
Levels of synaptophysin immunoreactivity in the dentate gyrus show no change
across all groups indicating no significant effect on the replacement of lost synapses in
this area. The hypothesis for this study expanded on three principal observations from
the literature and from my own work. Experiments in rats using 6-OHDA lesion of the
nigro-striatal tract show enhanced TH immunoreactivity in the striatum following
AMPA potentiator administration. The authors suggest that this is due to the sprouting
of surviving dopaminergic terminals. The study also showed that AMPA potentiation
could act in a neurotrophic as well as neuroprotective manner, as effects were seen even
if treatment was delayed up to 16 days post surgery (O'Neill, Murray et al. 2004;
O'Neill, Murray et al. 2005). AMPA potentiators of a range of classes and potencies
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have been shown to enhance the expression of BDNF in vivo and in vitro, particularly in
the dentate gyrus (Legutko, Li et al. 2001; Mackowiak, O'Neill et al. 2002; Lauterborn,
Truong et al. 2003). Observations made from my work in vitro show that AMPA
potentiation can induce cytoskeletal change that is dependant on BDNF (Voss, Milne et
al. 2006). BDNF has wide ranging developmental, neurotrophic and homeostatic
properties and could be expected to enhance structural recovery following injury and
synaptic loss (Cohen-Cory and Fraser 1995; Binder 2004; Binder and Scharfman 2004;
Du and Poo 2004).
There are three major physiological reasons why the results of this experiment
did not confirm my hypothesis. First is the time course of the experiment. The time
points of 14 and 28 days were chosen because they represented the points at which there
was likely to be the highest levels of synaptic loss in the hippocampus (White, Nicoll et
al. 2001). At these time points it is reasonable to presume that any structural effect
would be apparent. However if one considers the natural progression of the lesion (7-28
days of degeneration followed by a prolonged period of regenerative sprouting), it could
be argued that trying to promote sprouting at such an early stage, when the synapses
themselves are still degenerating is physiologically impossible. The up-regulation of
BDNF might accelerate the sprouting process once begun, but might not be able, either
because the levels are too low or because they are not specific both topographically and
biologically to initiate the process. The issue of topography is a second important
consideration. Studies in vivo have repeatedly shown that AMPA potentiation up-
regulated BDNF expression predominantly in the dentate gyrus (Mackowiak, O'Neill et
al. 2002; Lauterborn, Truong et al. 2003). Elevation of BDNF messenger and protein in
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the cell bodies of the post synaptic cells may not be sufficient to promote sprouting and
the formation of new synapses onto that cell. The processes that regulate the formation
of new synapses are under intense investigation and it is still unclear what the role of the
post synaptic cell is in this process. Evidence has suggested that retrograde signalling of
BDNF has a homeostatic mechanism (Poo 2001). Therefore the enhanced levels of
BDNF present and secreted by the granule cells may promote the formation and
maintenance of synapses. However it is not clear whether AMPA potentiation enhances
the expression of BDNF in other regions of the brain from which the sprouting occurs.
These include the septum and commissural fibres. Assuming that BDNF does promote
the growth and sprouting of neurites then the presence of AMPA receptors on cells in
these areas could lead one to speculate that AMPA potentiation would indeed enhance
BDNF and sprouting/growth in this area. The issue of the distribution of AMPA
receptors in the regions of interest are an important issue in this study. Cells in the
hippocampus express high levels of AMPA receptors and would therefore respond to
AMPA potentiators, however what about the expression of AMPA receptors in other
regions? AMPA receptors are widespread throughout the mouse brain but are
concentrated in regions with high density of excitatory connections including the neo¬
cortex, hippocampal formation and dorso-lateral septum with lower levels in the
striatum (Monaghan, Yao et al. 1984; Keinanen, Wisden et al. 1990). One would expect
therefore that AMPA receptor potentiation in these areas would indeed enhance BDNF
in some of the areas which participate in the restoration of the synaptic density in the
dentate gyrus. However it should be noted that LY404187 has a 10 fold range on
selectivity across GluR subtypes and its actions in vivo will be largely determined by
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receptor stoichiometry. Finally it should be noted that the synaptophysin levels in the
undamaged, contralateral, hemisphere were not measured. It is not clear whether AMPA
potentiators are able to produce changes in undamaged tissue or are only able to promote
recovery following degeneration. It is possible therefore that the effects of LY404187 in
promoting the increase in ipsilateral synaptophysin levels were masked by contralateral
increases too.
Neurogenesis in the adult brain occurs at a substantial rate in the sub-ventricular
zone (SVZ) and the sub-granular layer of the dentate gyrus (SGL) (Gage 1998; Alvarez-
Buylla and Garcia-Verdugo 2002). There have been reports of new neurons being
generated in other brain regions but these reports remain largely unconfirmed and
probably reflect very low physiological levels of neurogenesis (Gould, Reeves et al.
1999; Magavi, Leavitt et al. 2000). The functional significance of adult neurogenesis in
the dentate gyrus is not fully understood (Kempermann, Wiskott et al. 2004), despite the
identification of numerous external and internal signals that regulate the rate of cell
proliferation and the specific cues that determine the development of newly generated
neurons and the extent to which they integrate into local circuits. These include;
environment enrichment (Kempermann, Gast et al. 2002), running (van Praag,
Kempermann et al. 1999) and social stress (Gould, McEwen et al. 1997), epilepsy
(Parent and Lowenstein 2002), certain brain traumas (Dash, Mach et al. 2001), steroids
(Gould 1994; Karten, Olariu et al. 2005) growth factors (Pencea, Bingaman et al. 2001)
and NMDA receptor activation (Cameron, McEwen et al. 1995). Glutamatergic input is
therefore important in regulating neurogenesis. Lesioning the entorhinal cortex in rats
and blocking NMDA receptors has been shown to increase the rate of neurogenesis
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(Cameron, McEwen et al. 1995). Lesions of the granule cell layer also induced
proliferation and the generation of new granule cell pre-cursors (Gould and Tanapat
1997). However electrical stimulation of the perforant path and hippocampal kindling
and kainate induce seizures both increase neurogenesis (Gray and Sundstrom 1998).
More recently studies have shown that lesions of both cortical and septal inputs into the
brain transiently decrease the rate of neurogenesis. Our model was aimed at monitoring
any permanent change in the rate of neurogenesis and whether this change was either
reversed or enhanced by the administration of LY404187. The data in this thesis reveal
that at the level of the lateral habenulae there is no change in the rate of neurogenesis
across all groups, both in response to the lesion over time and following the
administration of the AMPA potentiation. Most available data indicates that the effect of
de-afferentation of the DG is transient and occurs in the first week following the lesion.
If the change in proliferation rate is a response to the synaptic degeneration then at 14
and 28 days post lesion the degeneration of the synapses is complete and no effect would
be evident.
AMPA potentiators in other models have been shown to induce cell proliferation
following both acute and chronic dosing. The active isomer of LY404187, LY451646,
was able to enhance cell proliferation up to 45% following 21 days of administration
(Bai, Bergeron et al. 2003). The difference here could be due to species differences in
availability of the compound. There are also differences in the method for measuring
proliferation between the two studies. Our use of 50mg/kg is the most commonly used
dose (Gould and Gross 2002). However there were only 4-9 BrdU+cells per section due
to the thinness of the tissue. The experiment therefore was likely to be insufficiently
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powered. We determined therefore to use higher doses of BrdU in subsequent
experiments (see below)
4.2.4 Conclusion
This study has shown that, under the present dosing protocol, LY404187 was
unable to induce significant synaptogenesis in the molecular layer of the DG and alter
the rate of neurogenesis. Although the study does not support my initial hypothesis the
study was carried out correctly and still addresses important issues pertaining to the
ability of AMPA potentiators to induce in vivo structural plasticity that are worthy of
further investigation.
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4.3 Biochemical changes associated with AMPA potentiation
4.3.1 Summary
The studies described in Chapter 3.3 were aimed at investigating the ability of
the AMPA potentiator LY450108 (0.5mg/kg) to induce persistent changes in a number
of relevant biochemical parameters. Each study had three groups of animals. The first
group received LY450108 (0.5mg/kg) twice daily for three days, the second for ten days
and the final group received ten days of compound and seven days of vehicle doses. All
groups included vehicle-dosed controls. The studies all reveal little or no change in the
measured end points across time points and treatment groups. There was no significant
change in the levels of phosphorylated ERK1/2, CREB, the rate of neurogenesis of
neuronal development and the levels of the principal monoaminergic neurotransmitters
across multiple brain regions. There are a number of reasons for this outcome,
insufficient dosing of LY450108, lack of sensitivity of the techniques and an inaccurate
hypothesis.
4.3.2 Adequacy of LY450108 treatment regimen
The dose of LY450108 used in the studies (0.5mg/kg) was selected because of
the efficacy seen at a similar dose with AMPA potentiators from the same family as
LY450108 in a number of in vivo models. LY450108 has been shown to increase
BDNF protein and mRNA in cortical neurons and potentiate synapses at comparable
concentrations to LY404187 in vitro (V. Lakics 2006). Histological and behavioural
studies in rats following 6-OHDA lesions of the cortico-striatal tracts show that
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LY450108 (0.5mg/kg) induces significant recovery in both endpoints with comparable
potency to LY404108 and LY540430 (Murray, Whalley et al. 2003). Other AMPA
potentiators of the same class have been shown to be active in animal models of
depression (Li, Tizzano et al. 2001), induce BDNF expression in vivo following acute
and chronic exposure (Mackowiak, O'Neill et al. 2002) and promote structural recovery
in vivo at the same dose of 0.5 mg/kg (Quirk and Nisenbaum 2002; O'Neill, Murray et
al. 2004). However all these studies were carried out in rats and currently there is no
available data on the pharmacokinetics of LY450108 in mice. It is possible therefore
that the brain availability of LY450108 in these studies is significantly different from
those seen in rats (MJ O'Neill personal communication). The activity of AMPA
potentiators in vivo has a pronounced bell shaped dose response curve. In fact, although
0.5mg/kg of LY404187's active isomer LY451646 increased BDNF and Trk-B mRNA
in the hippocampus following seven days dosing, higher doses were ineffective and
lower doses caused a decrease in BDNF and Trk-B expression (Mackowiak, O'Neill et
al. 2002).
4.3.3 Methodology
If LY450108 0.5mg/kg is a high enough dose to penetrate the brain in sufficient
concentration then the temporal aspect of experimental design must be reviewed. The
design was aimed at identifying whether AMPA potentiator administration could induce
long term plastic changes in a number of biophysical measures. There is limited data
regarding the long term effects of AMPA potentiators in vivo. The principal evidence
for choosing the time course of the studies monitoring the histological and behavioural
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improvements associated with AMPA potentiation was from data obtained with an
animal model of Parkinson's disease (MJ O'Neill, personal communication). What
these studies consistently reveal is that behavioural recovery, as measured by the rate of
turning following apomorphine administration, is only apparent following approximately
ten days administration of AMPA potentiator (Murray, Whalley et al. 2003). Other
studies using CX516, show that the improved performance in a short term memory task
following 10 days administration have been shown to persist for 7 days following
withdrawal of treatment (Hampson, Rogers et al. 1998; Hampson, Rogers et al. 1998).
The choice of 3, 10 and 17 days time points were chosen to identify changes that had not
occurred following 3 days administration but had developed by 10 days and showed
some evidence of persisting 7 days following withdrawal of treatment.
If LY450108 at 0.5mg/kg is sufficient to produce prolonged potentiation of
central glutamatergic synapses triggering multiple downstream cascades, then there is a
possibility the techniques used to assess the different endpoints may not be appropriate
or sensitive enough to detect these changes.
Western blotting techniques are excellent measures of large on/off changes in
protein expression. They are among the most widely used techniques in biology but are
not ideal for revealing subtle changes in protein levels. They are semi-quantative
techniques and do not generate raw data that is amenable to standard statistical
evaluation. No change was detected in the levels of phosphorylated ERK 1/2 when
assessed using Western blots. It is possible that Western blotting is not sensitive enough
to detect a change in expression that is likely to be subtle (see below) and restricted to
certain cell types within the hippocampus. For this reason a second measure of protein
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expression using immunohistochemistry was incorporated into the experimental design.
This technique holds a number of advantages over standard Western blotting. First it
allows accurate identification of individual positive cells while Western blots were
carried out on protein extracted from the whole hippocampus. Using the protocol
described, only a percentage of cells were stained positive for pERK and pCREB which
allowed for a more quantitative approach as individual positive cells can be counted.
The experiment was designed with two parallel end points to give support to any
positive findings but also to ensure the largest chance of detecting a change in
expression.
Peripheral administration of the uridine analogue BrdU is an established way to
measure neurogenesis in vivo (Gage, Kempermann et al. 1998; Kempermann and Gage
2000). The BrdU dose we used (2x lOOmg/kg doses 24hours prior to cull) was larger
than that used in many other studies because it gives a larger number of positive cells in
the thin section used in this study (Gould and Gross 2002). The double labelling of
newly generated cells with other markers is also a commonly used technique. There are
a range of neuronal markers that can be used to identify cells at multiple stages of
development including NeuN, Doublecortin and Nestin. The neuronal marker NeuN
however remains the most widely used (Kempermann, Wiskott et al. 2004). In this
study, double labelled cells were often identified in the granular layer of the
hippocampus showing that the cells had migrated and were potentially being integrated
into the hippocampal circuitry (Kempermann and Gage 2000; van Praag, Schinder et al.
2002). The identification of newly divided cells in the hippocampus by this technique is
well established and is amenable to accurate quantification. As such I am satisfied the
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results give an accurate reflection of both the rate of neurogenesis and neuronal
development.
HPLC allows rapid separation and accurate quantitative resolution of levels of
the components of a mixture. In this case the technique was used to measure levels of
the principal aminergic neurotransmitters and their main metabolites. The
electrochemical detection system used is highly sensitive and can allow the detection of
picograms of the desired compounds. The reproducibility and reliability of the
technique is borne out not only by tight distribution of the data but by the similarity with
results from other groups. Levels obtained for DA (~15ng/mg) in the striatum, 5HT
(~0.5ng/mg) and NA (~0.4ng/mg) in the hippocampus and NA (~0.5ng/mg) in the neo
cortex are almost identical to those found in a recent study (Chourbaji, Hellweg et al.
2004).
4.3.4 Discussion
The intellectual basis of this study was the neurotrophin hypothesis of depression
and the potential benefit AMPA potentiators may have in the treatment of this condition
(Duman, Heninger et al. 1997; Manji, Quiroz et al. 2003; Castren 2005; Alt, Nisenbaum
et al. 2006). Recent basic and clinical studies have implicated the neurotrophin BDNF
and its receptor Trk-B in mediating dendritic structural integrity in the hippocampus and
neurogenesis, both of which are believed to be reduced in depressed patients and are
manipulated by common antidepressants (Manji, Quiroz et al. 2003; Peled 2005).
Recent work by O'Neill and colleagues has suggested that AMPA potentiators may be
able to promote structural plasticity in vivo and LY404187 has been shown to enhance
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the rate of neurogenesis (Bai, Bergeron et al. 2003). AMPA potentiators have also been
shown to be active in animal models of depression (Bai, Li et al. 2001; Quirk and
Nisenbaum 2002). The study was aimed at identifying the effects of LY450108 on two
potential indicators of antidepressant properties: the rate of neurogenesis and the levels
of monoaminergic neurotransmitters across the brain (Bunney and Davis 1965;
Schildkraut 1965; Brown and Gershon 1993; D'Sa and Duman 2002; Santarelli, Saxe et
al. 2003).
BDNF expression is regulated by AMPA receptors through the activation of
ERK 1/2 and the transcription factor CREB (see above section 4.1.3) (Finkbeiner,
Tavazoie et al. 1997; Shieh, Hu et al. 1998; Tao, Finkbeiner et al. 1998). Although
AMPA potentiators have been hypothesised to act though MAPK and CREB in vivo
(O'Neill, Bleakman et al. 2004) this has yet to be demonstrated. The data in this study
show no significant change in the level of phosphorylation of either of these proteins.
One reason for this could be that the animals were culled 18 hours following the final
dose. Levels of other biarylpropylsulphonamides typically have a short half-life, plasma
levels returning to baseline levels within 18 hours (O'Neill, Murray et al. 2005) and it is
likely that any direct activation of MAPK and CREB would be over by this time. The
reason for this delay was to identify enhanced expression due to the action of BDNF.
Rates of neurogenesis have been shown to be significantly altered by chronic
antidepressant administration (Malberg, Eisch et al. 2000) and by both acute and chronic
administration of AMPA receptor potentiator (Bai, Bergeron et al. 2003). Levels of
neurogenesis were unaltered across treatment groups and time points in this study. Given
the sensitivity of the method and the previous demonstration of an enhancement of
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neurogenesis by an AMPA potentiator it is likely that the main cause of a lack of
detectable change is a problem of insufficient dosage.
The most commonly prescribed antidepressants inhibit the re-uptake of
aminergic neurotrasmitters (mainly 5-HT but also NA and DA) (Nestler, Barrot et al.
2002). If LY450108 had been shown to enhance levels of monoamines, this would have
provided support for their potential as effective antidepressants. However the lack of any
effect as shown in this study does not preclude a possible benefit in this condition.
Firstly SSRIs and SNRIs act to enhance synaptic levels of neurotransmitter, while in the
study the total levels have been measured. It is possible that AMPA receptor
potentiation may modulate the release of neurotransmitter. Secondly the neurotrophin
hypothesis of depression places the role of CREB and BDNF downstream of
antidepressants (Duman et al 2000). AMPA potentiators, able to directly enhance levels
of BDNF, following acute administration, may be able to bypass mechanisms by which
common antidepressants work, possibly even bypassing the therapeutic lag associated
with SSRIs.
4.3.5 Conclusions
In the absence of extensive pharmacokinetic data for LY450108 in mice it cannot
be concluded with any certainty that this experiment has yielded neutral results due to
insufficient dosing. However, given the well established in vivo actions of other
biarylpropylsulphonamides in a range of biochemical, behavioural and physiological
paradigms in multiple species it is likely that this is the case. It might be expected that
even with a suboptimal dose, repeated exposure to AMPA potentiator may induce
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measurable effects in one of the study's endpoints. However due to the indirect
measures used in this study and the fact that the animals were not all normal healthy
adults it is possible that any effect would be negligible.
Despite the obvious disappointment with the results the issues raised in this
study; the persistence of AMPA potentiator action and the potential for inducing forms
of plasticity relevant to novel therapeutic mechanisms for the treatment of depression,




The evidence presented in this thesis suggests that AMPA potentiation can
induce structural plasticity in vitro following 3 days exposure to LY404187. However
much of the study has yielded inconclusive results. By its very nature AMPA
potentiation does not induce large, dramatic developmental and neurotrophic changes in
cells. Long-term changes induced by AMPA receptors are likely to be due to the
downstream actions of neurotrophins up-regulated by repeated AMPA receptor
activation (Limatola 2004; O'Neill, Bleakman et al. 2004). The multiple effects of
BDNF and other neurotrophins are thus diluted temporally and topographically and it is
understandable that the in vivo studies yielded neutral results. The evidence showing
neurotrophin-mediated mechanisms of structural development in vitro (Voss, Milne et
al. 2006) is not easily transferred to an in vivo system. The magnitude of the effect seen
in vitro was relatively small and was detectable only through well powered and
statistically sound analysis. Extrapolating these data to an in vivo system, with its
increased inherent variability and the multiple cell types, systems and different
biochemical environment has proved unsuccessful. There is also data suggesting that
BDNF expression is refractory followed repeated exposure to AMPA potentiators
(Lauterborn, Truong et al. 2003). However, data using biarylpropylsulphonamides has
repeatedly shown that they can have biological effects following chronic exposure
(Mackowiak, O'Neill et al. 2002; Bai, Bergeron et al. 2003).
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There is the strong possibility that the chosen dose of 0.5mg/kg of LY450108
was insufficient to reach adequate concentrations in the brain of mice. Unfortunately
there was neither the time nor the technical expertise to develop a full pharmacokinetic
profile for LY450108 in mice and the dose was chosen from a large body of literature
describing the effects of other AMPA potentiators in a range of pre-clinical models.
Despite the disappointment of neutral results I believe the experiments in this
thesis were consistently well designed and executed. The demonstration that LY404187
can induce structural plasticity in vitro represents a novel observation with important
implications for the potential therapeutic applications of AMPA potentiators.
4.4.2 Recent advances in compound development
Two reports have recently appeared in the literature describing new generations
of positive AMPA modulators and cognitive enhancers (Romanelli, Galeotti et al. 2006;
Zarrinmayeh, Tromiczak et al. 2006). Romanelli et al. reported the development of
aniracetam derivatives that exhibit potencies 4 orders of magnitude higher than
traditional AMPAkines. As well as facilitating synaptic transmission they improved
performance in memory tasks and enhanced acetylcholine release in rat hippocampal
slices; data that holds obvious promise in the treatment of Alzheimer's disease and other
cognitive disorders. Zarrinmayeh et al reported the generation of a whole family of
novel AMPA receptors potentiators, the most potent of which, LY2059346, displayed
low nanomolar EC50 at recombinant GluRl-4 subunits.
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4.4.3 Clinical trials
The absence of clinical data on the efficacy of AMPA potentiators in treating
neurological conditions and cognitive impairment means that it is too early to judge the
success of AMPA potentiator development. AMPA potentiation is being studied
principally for the development of clinically effective drugs. Therefore it is clear that
the future of AMPA potentiators lies in the clinic rather than the laboratory. Following
the publication of a number of reports describing the early development and key
properties of a series of AMPA potentiators, there has been fewer recent reports
regarding their development. Currently there are a number of clinical trials for the use
of AMPA potentiators in neurological conditions. Organon currently has compounds in
both Phase I and Phase II trials for the treatment of schizophrenia and mild cognitive
impairment (website 2006). Servier Pharmaceuticals have an AMPA modulator SI8986
(Lebrun, Pilliere et al. 2000) in Phase II clinical trials (clinical gov.net). Cortex
pharmaceuticals, the company set up by Gary Lynch to develop clinical AMPA
potentiators, recently had one of it's compounds CX717 (Porrino, Daunais et al. 2005)
put on clinical hold by the FDA following concerns regarding the toxicity of the
compound. This hold has recently been lifted prompting a resumption of clinical trials
(Cortex pharmaceuticals web site 2006). Lilly Neuroscience's compounds LY450108
and LY451395 have both passed Phase I studies (Jhee, Chappell et al. 2006).
4.4.4 Future directions
The primary concern regarding the development of AMPA potentiators is their
selectivity. Early publications contained results of in depth screening at a variety of
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receptor subtypes and splice variants. Recent generations of AMPA potentiators show a
wide range of selectivity and affinity across all GluR subtypes (Zarrinmayeh, Tromiczak
et al. 2006). This pool of compounds, coupled with a more sophisticated knowledge of
the receptors distribution across different areas of the brain could allow the development
of a range of disease-tailored compounds. Compounds could be developed specifically
for cognitive enhancement, working on the hippocampus to facilitate the formation of
long term memories, or a compound working specifically in the basal ganglia to promote
neurotrophic effects in Parkinson's disease or for the limbic system in mood disorders.
One important caveat with this, as with all notions of tailor made drugs is that as the
costs associated with the development of multiple compounds increases the number of
patients that will benefit from each drug is reduced.
4.4.5 Conclusions
The positive modulation of AMPA receptors has been shown to facilitate the
formation of memories, enhance the rate of neurogenesis, induce the expression of
BDNF and promote structural plasticity in pre-clinical models. These features make
AMPA potentiators clinically relevant in a number of conditions that display deficits in
one or more of these areas.
AMPA potentiators have been developed from first principals to clinical trials in
little over a decade. The challenge of the next ten years is to realise the undoubted
potential of these compounds to treat some of the most common neurological conditions.
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Abstract
Positive allosteric modulation of AMPA receptor function has therapeutic potential in a number of psychiatric disorders and neurodegener¬
ative diseases. AMPA receptor potentiators can induce neurite sprouting in vivo. Using a strategy of combined morphological and biochemical
analyses, we investigated the effect of the AMPA receptor potentiator LY404187 on neurite growth in the SH-SY5Y human neuroblastoma cell
line. LY404187 (0.1 — 10 pM) increased average neurite length and neurofilament expression when co-administered with s-AMPA. Co-incuba-
tion with s-AMPA and LY404187 also increased Trk receptor expression. All actions of LY404187 were sensitive to AMPA receptor blockade by
the selective antagonist CNQX (10 pM). Antibody sequestration of BDNF attenuated neurite growth following AMPA receptor potentiator ad¬
ministration, suggesting that LY404187 increases neurite length in vitro by a BDNF mediated mechanism. AMPA receptor potentiation activates
multiple intracellular neurochemical cascades and the present report identifies BDNF as one key mediator of the neurotrophic effects of AMPA
receptor potentiation.
© 2006 Elsevier Ltd. All rights reserved.
Keywords: LY404187; AMPA potentiators; BDNF; Neuroplasticity
1. Introduction
Glutamate receptor dysfunction has been implicated in a
variety of neurological disorders including depression, schizo¬
phrenia and Parkinson's Disease (Chase and Oh, 2000; Paul
and Skolnick, 2003; Tuominen et al., 2005). AMPA receptors
mediate the majority of excitatory neurotransmission at central
mammalian synapses (Hollmann and Heinemann, 1994) and
regulate many developmental, neurotrophic and cognitive pro¬
cesses (Collingridge and Singer, 1990; Limatola, 2004). The
modulation of AMPA receptor activity is thus being actively
investigated as a possible treatment for a variety of cognitive
* Corresponding author. Tel.: +44 (0) 131 242 6181; fax: +44 (0) 131 242
9371.
E-mail address: o.p.voss@sms.ed.ac.uk (O.P. Voss).
and neurodegenerative conditions (Lynch, 2004; O'Neill
et al., 2004a). Due to the rapid desensitisation of AMPA recep¬
tors (Dingledine et al., 1999) and their involvement in excito-
toxic cell death (Choi, 1992) direct AMPA receptor agonists
are not desirable pharmaceutical agents. Consequently a num¬
ber of compounds, which act as positive allosteric modulators,
with no intrinsic agonist activity, have been developed (Larson
et al., 1995; Arai et al., 1996; Sekiguchi et al., 1997; Ornstein
et al., 2000; Buccafusco et al., 2004). These compounds have
been shown to enhance synaptic transmission in vitro and in
vivo (Gates et al., 2001; Vandergriff et al., 2001), facilitate
the induction of LTP (Staubli et al., 1992; Arai et al., 2004),
increase BDNF expression in vivo and in vitro (Legutko
et al., 2001; Mackowiak et al., 2002; Lauterborn et al.,
2003) and promote memory formation in animals and in hu¬
mans (Staubli et al., 1994; Granger et al., 1996; Ingvar
et al., 1997; Buccafusco et al., 2004).
0028-3908/$ - see front matter © 2006 Elsevier Ltd. All rights reserved,
doi: 10.1016/j .neuropharm.2006.09.001
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The biarylpropylsulphonamide family of AMPA receptor
potentiators (Ornstein et al., 2000) have recently been shown
to be beneficial in a rodent model of Parkinson's Disease,
demonstrating histological and behavioural improvements
(O'Neill et al., 2004b, 2005). In this study the authors con¬
cluded that enhanced survival and sprouting of dopaminergic
cells mediated these benefits and it has been hypothesised
that enhanced central levels of BDNF underlie this form of
structural plasticity (O'Neill et al., 2004a).
In the present study we set out to test the hypothesis that
AMPA receptor potentiation could induce morphological plas¬
ticity. Using a sensitive neurite growth assay, we demonstrate
that the AMPA receptor potentiator LY404187 (Quirk and
Nisenbaum, 2002) significantly increases neurite length and
expression of the cytoskeletal protein neurofilament in the
SH-SY5Y human neuroblastoma cell line and that this in¬
crease is mediated by the neurotrophin BDNF. Our data sup¬
port the hypothesis that compounds which are able to
enhance central levels of neurotrophins, such as AMPA poten¬
tiators, are able to promote structural plasticity and may be
useful in the treatment of neurological disorders.
2. Methods
All reagents were purchased from Sigma (Poole, UK), unless otherwise
stated.
2.1. Cell culture
SH-SY5Y cells (ECACC No. 94030304) were cultured in Dulbecco's mod¬
ified Eagle's medium (DMEM) with 10% heat-inactivated foetal calf serum
(FCS) (Gibco), 2 mM L-glutamine and 1% penicillin/streptomycin mix. Cells
were cultured for up to 6 weeks (~ passage 20 in accordance with ECACC
guidelines). In neurite growth experiments, cells were plated in NUNC 6-well
dishes at a density of 1 x 105 cells/well 24 h prior to testing. Medium was re¬
placed with fresh DMEM (2% FCS, 2 mM L-glutamine) and drugs applied
for 72 h. In Western blot experiments cells were seeded at a density of
1 x 106 per 9 cm dish and again incubated in DMEM (2% FCS, 2 mM L-gluta-
mine) containing drug treatment for 72 h. Cells were treated with s-AMPA,
LY404187 (Eli Lilly), CNQX and Ab-BDNF (1:200, N-20, sc-546, Santa
Cruz) or vehicle (1:10,000 Ethanol). All drugs were stored at —20 °C in
10 mM stock aliquots and fresh dilutions were made on each experimental day.
2.2. Neurite growth assay
Cells were fixed with ice-cold 4% paraformaldehyde in Phosphate Buff¬
ered Saline (PBS) for 2 h at 4 °C, washed and stored in PBS. Phase-contrast
images (200 x magnification) were obtained from each well (Leitz Laborlux
microscope with Polaroid CCD camera running Polaroid DMC2 software).
The experimenter, blinded to treatment group, selected fields at random. Digi¬
tised images of dispersed, neurite bearing cells were captured and morphomet¬
ry analysis was performed using Image J software (NIH). The system was
checked for image compression and calibrated before use by taking horizontal
and vertical images (200x) of a standard graticule. Neurites were traced man¬
ually and the length calculated. All process shorter than 20 pm (average width
of cell body) were not included in further analysis. For all groups, unless other¬
wise specified, between 300 and 450 neurites were collected from 10 separate
wells over 4 experimental days.
As the data were not distributed normally, all measurements of neurite
length were analysed by Kruskall—Wallis analysis of variance on ranks, fol¬
lowed by comparison to vehicle using Dunn's method. In all cases statistical
significance was set at p < 0.05. For BDNF antibody and CNQX studies addi¬
tional, multiple Mann—Whitney comparisons were run as a post-hoc test
following analysis of variance. In this study p values were corrected for mul¬
tiple comparisons using the Bonferroni procedure.
2.3. Western blotting
After 72 h incubation, SH-SY5Y cells were washed with ice-cold PBS and
lysed in 500 pi NP40 lysis buffer (150 mM NaCl; 50 mM Tris—HC1 pH 7.4;
10 mM EDTA; 0.6% Nonidet P40; 1 mM Na3V04; 10% glycerol; lOpg/ml
pepstatin; 1 mM phenyl methyl sulfonyl fluoride). Cell lysates were incubated
on ice for 30min before removing cell debris by centrifugation (15,300 g/
10 min/4 °C) and protein concentrations determined using a modified Lowry
method (Bio-Rad D2 Protein Assay kit; Bio-Rad Laboratories, Hemel Hemp¬
stead, UK). In Western blot experiments, 10 pg of protein in standard loading
buffer (25 mM Tris-HCl (pH 6.8); 0.8% SDS; 1% 2-mercaptoethanol; 4%
glycerol; 0.01% bromophenol blue) was loaded on a 4—12% Tris glycine
gel and separated by SDS-PAGE (200 mV for 45 min). Proteins were trans¬
ferred to a PVDF membrane (Millipore (UK) Ltd, Watford, UK), and mem¬
brane incubated in Tris Buffered Saline (TBS)-Tween (50 mM Tris—HC1;
150 mM NaCl; 0.05% v/v Tween-20) containing 5% albumin w/v for 1 h. Se¬
quentially membranes were probed with primary antibody; neurofilament
(1:2000 anti-200kDa Neurofilament Heavy — Ab7795, Abeam), Trk (1:500,
B-3 sc-7268, SantaCruz), (5-actin (1:5000, Sigma, UK) and peroxidase-conju-
gated IgG (1:30,000; Sigma, UK) and then detected with Enhanced Chemilu-
minescence Detection system (ECL plus; Amersham Biosciences UK Ltd.,
Little Chalfont, UK). Between each step membranes were washed three times
for 5 min with TBS-T\veen. Chemiflourescence levels were corrected for
background and normalised to levels for control cells. Data were analysed
by Kruskal—Wallis analysis of variance on Ranks with multiple comparisons
using Dunn's method. In all cases significance was set at p < 0.05.
3. Results
3.1. Neurite growth assay
Power calculations revealed that approximately 350 neu¬
rites were required to detect a 5 pm increase in neurite length
using a power of 80% and p value of 0.05.
3.2. AMPA potentiation increases neurite length and
neurofilament expression
As an assessment of structural plasticity, neurite growth in the
human neuroblastoma line SH-SY5Y was measured (Fig. la).
Cells exposed to s-AMPA (0.1—10 pM) alone exhibited no sig¬
nificant change in neurite length (Fig. 2 left). Pilot studies con¬
firmed that higher concentrations of s-AMPA (100 pM)
induced cell death (data not shown). LY404187 (0.1 — 10 pM)
alone failed to produce any significant increase in average neu¬
rite length over the concentration range examined, although a de¬
crease in neurite length was observed at 10 pM (Fig. 2 centre).
However, when co-administered with s-AMPA (0.1 pM),
LY404187 (0.1 — 1 pM) produced a significant, concentration
dependant increase in neurite length (Fig. 2 right). Frequency
distribution analysis reveals that the shift in neurite distribution
was more pronounced in shorter neurites, explaining the numer¬
ically subtle increases in average neurite length (Fig. 1 b). AMPA
potentiator-induced neurite growth was sensitive to AMPA re¬
ceptor blockade as it was significantly blocked by co-incubation
with CNQX (10 pM) (Fig. 3).
The increase in average neurite length induced by AMPA and
LY404187, was compared to that induced by the classical
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Neurite Length
Fig. 1. Measuring neurite growth in vitro, a) Following 72 h incubation each
SH-SY5Y cell develops 2—3 neuritic processes. 64 fields containing approxi¬
mately 200 neurite bearing cells were acquired for each treatment (approxi¬
mately 400 neurites per treatment) and used for morphological analysis
(Scale bar 100 pm). b) Frequency distribution analysis of the length of neu¬
rites. The distribution profile of neurites following incubation with vehicle,
AMPA and LY404187 alone were similar. Incubation with LY404187
(0.1 pM) together with AMPA (0.1 pM) produced a significant increase in
neurite length and this was reflected by an increase in the median length
(41.8 pm to 46.3 pm), reflecting a reduction in neurites 20—40 pm and an in¬
crease in neurites between 40 pm—80 pm. There was no change in the per¬
centage of neurites measuring above 80 pm. Data represents >400 neurites
collected over 4 independent experimental days.
differentiating factors BDNF (lOng/ml), NGF (lOng/ml) and
retinoic acid (RA 100 nM) (Fig. 4). Because each compound
was prepared in a different vehicle, relative increases were used
to assess neurite growth. Co-incubation of AMPA and
LY404187 induced approximately a 10% increase in neurite
length which was comparable to that produced by BDNF. NGF
and RA increased average neurite length by around 20—30%.
As an alternative, surrogate marker for neuritic develop¬
ment and growth western blots for neurofilament heavy chain
(NF-H) were performed. LY404187 (0.1 pM) produced occa¬
sional, small increases in NF-H expression that were blocked
by CNQX (data not shown). These effects were likely due to
the presence of low levels of glutamate in the media following
72 h incubation. Co-treatment with LY404187 (0.1 pM) and s-
AMPA (0.1 pM) however induced robust increases in immu-
noreactivity for NF-H (Veh = 0.75 ± 0.2 SEM, A + LY:
2.7 ± 0.6 SEM) that were significantly blocked by the addition
of the AMPA receptor blocker CNQX (10 pM) (CNQX +
AMPA + LY = 0.4 ± 0.2) (Fig. 5).
Taken together these data strongly indicate significant mor¬
phological plasticity induced by AMPA receptor potentiation.
3.3. AMPA potentiation enhances Trk receptor
expression
Neurotrophins have been strongly implicated as mediators
of the beneficial effects seen with administration of AMPA po¬
tentiators. As an indicator of enhanced neurotrophic activity
Trk receptor expression was next monitored by western blot¬
ting. Co-incubation with AMPA (0.1 pM) and LY404187
(0.1 pM) produces robust increases in immunoreactivity,
(Veh = 0.8 ± 0.1 A + LY = 3.8 ± 0.8 SEM), which are sig¬
nificantly blocked by co-incubation with CNQX (10 pM)
(CNQX + AMPA + LY = 0.57 ± 0.3) (Fig. 6).
3.4. Antibody sequestration of BDNF blocks increase in
neurite length following AMPA potentiation
with LY404187
BDNF is the main neurotrophin thought to mediate the ac¬
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Fig. 2. AMPA potentiation increases neurite length. Incubation for 72 h with either (left) s-AMPA (0.1 — 10 pM) or (centre) LY404187 (0.1 — 10 pM) alone pro¬
duced no significant change in neurite length. Co-administration of s-AMPA (0.1 pM) and the AMPA potentiator LY404187 (0.1 — 1 pM) however, significantly
increased average neurite length (right). Data are presented as the mean neurite length ± SEM of 400—500 neurites for each treatment. (Veh = vehicle
*,#=/?< 0.05.)






Fig. 3. AMPA receptor blockade attenuates increase in neurite length. Incuba¬
tion of SH-SY5Y with CNQX (10 pM) attenuated the increase in neurite
length following co-incubation with s-AMPA (0.1 pM) and LY404187
(0.1 pM). Data are presented as the mean average length db SEM of 300—
400 neurites. * = p < 0.05.
of neurite growth was investigated. The addition of BDNF an¬
tibody (1 pg/ml) attenuated the increase in average neurite
length induced by co-administration of s-AMPA (0.1 pM)
and LY404187 (0.1 pM) (Fig. 7). Importantly, 72 h incubation
with another rabbit-raised antibody (anti-Rat IgG) did not in¬
hibit the increase in average neurite length induced by AMPA
potentiation that the effect of the anti-BDNF antibody was
specific to the sequestration of BDNF and not a non-specific
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Fig. 4. Comparison between AMPA potentiation and neurotrophins. BDNF
(10 ng/ml), NGF (10 ng/ml) and retinoic acid (RA) (0.1 pM) treatment are com¬
pared to AMPA (0.1 pM) + LY404187 (0.1 pM) (A + LY) by their ability to
enhance neurite length. Graphs represent average percentage increase ± SEM
of 4 independent experiments. Data are expressed as percentage change from
multiple vehicle treatments (appropriate for each compound). Individual values
AMPA + LY: (veh = 65.9 pm ± 2.1, A + LY = 71.9 pm ± 1.5) BDNF:
(veh = 64.2 pm ± 1.7, BDNF = 75.5 pm ± 2.2) NGF: (veh = 48.3 pm ± 3.1,
NGF = 58.6 pm ± 1.9) RA: (veh = 52.3 pm ± 3.3, RA = 66.7 pm ± 2.3).
Statistical significance was assessed by Student r-tests on the average lengths
from each experiment * = p < 0.05. Graph shows the distribution of >400

















Fig. 5. AMPA receptor potentiation increases neurofilament expression, (a)
Representative Western blots showing neurofilament heavy chain expression
levels from control (upper) and CNQX (10 pM) treated cells (middle).
Equal loading was confirmed by blotting for (3-actin (lower). AMPA
(0.1 pM) + LY404187. (b) Mean fold increase in chemiluminescence normal¬
ised to Vehicle + CNQX treated cells ± SEM of 4 independent experiments.
* = p < 0.05.
4. Discussion
AMPA receptor potentiators have been shown to act as cog¬
nitive enhancers in a variety of animal and human paradigms
(Black, 2005), and have been hypothesised to act by facilitating
the induction of LTP (Lynch, 2004). However, more recent
studies suggest that AMPA potentiation may have neurotrophic
and neuroprotective properties (Dicou et al., 2003; O'Neill
et al., 2004b, 2005). In this study we aimed to directly test
the hypothesis that AMPA potentiation can induce structural
plasticity. Our findings demonstrate that direct application of
an AMPA receptor potentiator can induce neurite growth in
SH-SY5Ys that is attenuated by AMPA receptor blockade.
We showed that this increase is comparable to that induced
by the more traditional neurotrophic agents BDNF, NGF and
retinoic acid. As an alternative measure of plasticity we demon¬
strated that the expression of the cytoskeletal protein neurofila¬
ment is enhanced in an AMPA receptor mediated fashion
following AMPA potentiation. We then showed that Trk recep¬
tor expression is also enhanced, implicating the actions of


















Fig. 6. AMPA receptor potentiation increases Trk receptor expression, (a) Rep¬
resentative Western blots showing Trk receptor expression levels from control
(upper) and CNQX (10 pM) (middle) treated cells. Equal loading was con¬
firmed by blotting for (3-actin (lower), (b) Mean fold increase normalised to
Vehicle + CNQX treated cells ± SEM of 4 independent experiments.
* = p < 0.05.
VEHICLE
Fig. 7. Antibody sequestration of BDNF attenuates increase in neurite length.
Co-incubation with anti-BDNF mouse IgG (Ab BDNF) (1 pg/ml) attenuated
neurite outgrowth following co-incubation with s-AMPA (0.1 pM) and
LY404187 (0.1 pM). Data are presented as mean neurite length of 400—500
neurites ± SEM. * = p < 0.05.
neurotrophins. We finally showed that neurite growth promoted
by AMPA potentiation is dependent of BDNF. Our results sup¬
port our initial hypothesis and shed light into the mechanisms of
AMPA potentiator mediated effects.
Enhancing central plasticity, neuritic sprouting and regener¬
ation are promising therapeutic strategies for the treatment of
a number of neurological conditions (Manji et al., 2003; Fer-
nandez-Espejo, 2004; Mueller et al., 2005). Reductions in vol¬
ume and structural abnormalities have been observed in
a number of brain regions in humans with depression (Sheline,
2003). Reduced rates of neurogenesis (D'Sa and Duman,
2002), decreased levels of BDNF (Angelucci et al., 2005)
and plasticity imbalances (Peled, 2005) have all been impli¬
cated. Neuroprotective and neurotrophic strategies are also be¬
ing investigated for the treatment for Parkinson's disease,
focusing on the actions of the neurotrophins BDNF and
GDNF (Mamounas et al., 1995; Gash et al., 1998; Fernan-
dez-Espejo, 2004). Compounds that are able to enhance cen¬
tral levels of neurotrophins and promote structural plasticity
and regeneration would be well placed as potential therapeutic
agents in each of these conditions (O'Neill et al., 2004a). Biar-
ylproposulphonamides have been demonstrated to enhance
neurogenesis (Bai et al., 2003), BDNF expression in vivo
(Mackowiak et al., 2002), sprouting of nigro-striatal dopamin-
gergic terminals and show behavioural effects in animal
models of depression (Li et al., 2001) and Parkinson's disease
(O'Neill et al., 2004b, 2005). Our data extend these findings,
demonstrating the ability of AMPA receptor potentiation to
enhance neuritic growth in vitro, supporting the notion that
LY404187, and related compounds have favourable profiles
for the treatment of a range of neurological conditions.
SH-SY5Y cells possess biochemical characteristics similar
to dopaminergic cells, such as tyrosine- [^-hydroxylase activity
(Oyarce and Fleming, 1991) and are a common model for the
investigation of neuronal differentiation and neurite growth
(Ivankovic-Dikic et al., 2000; Cui et al., 2003; Price et al.,
2003; Jamsa et al., 2004; Daniel et al., 2005). Our results dem¬
onstrate that LY404187 in the presence of s-AMPA induced
neurite outgrowth in SH-SY5Y cells. The magnitude of the ef¬
fect was comparable to that induced by BDNF incubation and
around half that induced by NGF and retinoic acid. LY404187
thus compares favourably to classical neurite growth inducers,
especially when considering that an allosteric modulator of an
ion channel is being compared to neurotrophins and a powerful
differentiation factor. This growth was dependent on AMPA
receptors, as incubation with CNQX, a competitive AMPA re¬
ceptor antagonist (Drejer and Honore, 1988) attenuated the
response. The EC50 of LY404187 ranges from 0.15 pM at re¬
combinant GluR2 receptors (Miu et al., 2001) and 1.3 pM for
native AMPA receptors on isolated cortical rat neurons (Quirk
and Nisenbaum, 2002). At >10x these concentrations
LY404187 reduced the average length of neurites. This was
most likely due to a non-specific effect of the compound fol¬
lowing 72 h incubation in vitro. A full pharmacological profile
of the compound can be found elsewhere (Quirk and Nisen¬
baum, 2002), and this non-specific effect was not investigated
further.
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In addition to monitoring neurite growth by morphometric
analysis, we also measured changes in neurofilament expres¬
sion. The cytoskeletal protein neurofilament has been widely
used as an indicator of neurite growth and maturation (Doherty
et al., 1984; Encinas et al., 2000). In agreement with our neu¬
rite growth data expression levels were robustly enhanced by
AMPA potentiation and this was significantly blocked by co-
incubation with the AMPA receptor antagonist CNQX. The
combination of these two observations strongly suggests ro¬
bust morphological plasticity following AMPA receptor
potentiation.
Having tested our central hypothesis we subsequently ex¬
plored the mechanisms mediating neurite growth. AMPA re¬
ceptor activation can activate numerous intracellular cascades
and it is unclear which is associated with the beneficial effects
of AMPA receptor potentiation. Enhanced BDNF expression
has been seen following AMPA potentiation in a number of sys¬
tems (Lauterborn et al., 2000; Legutko et al., 2001; Mackowiak
et al., 2002; Lauterborn et al., 2003). BDNF has been identified
over the past decade as a modulator of a number of cellular pro¬
cesses including early CNS development (Ernfors et al., 1994),
synaptic transmission (Patterson et al., 1996; Schratt et al.,
2004) and regeneration following brain injury (Ebadi et al.,
1997). It has also been hypothesised that increases in growth
factors such as BDNF may lead to the beneficial effects of
AMPA potentiation in a range of animal models (O'Neill
et al., 2004a). Due to its role in promoting neuronal growth
and survival its role in our system was investigated further.
The link between AMPA receptor activity and neurotro-
phins is well established (Zafra et al., 1990; Limatola,
2004). AMPA receptors can recruit a variety of second mes¬
senger molecules such as the non-receptor tyrosine kinase
Lyn (Hayashi et al., 1999) FAK and PI(3)K (Millan et al.,
2004). Through these they can recruit intracellular signalling
cascades such as the MAP kinase pathways (Wang and
Durkin, 1995; Perkinton et al., 1999; Bahr et al., 2002).
AMPA receptor activation can induce the phosphorylation of
CREB, thus regulating, among other genes, the expression of
BDNF (Zafra et al., 1990; Finkbeiner et al., 1997; Shieh
et al., 1998; Tao et al., 1998). BDNF signals primarily through
the tyrosine kinase receptor Trk-B (Glass et al., 1991; Klein
et al., 1991; Soppetetal., 1991; Squinto et al., 1991; Barbacid,
1995). Western analysis for TrK receptor expression revealed
that LY404187 in the presence of AMPA can increase expres¬
sion levels, suggesting an increase in neurotrophin responsive¬
ness. To directly implicate BDNF as a mediator of neurite
growth we demonstrated that BDNF antibody-sequestration at¬
tenuated the increase in neurite length following co-incubation
with AMPA and LY404187. Addition of the antibody had no
effect on the average length of vehicle treated cells demon¬
strating that the attenuated growth is due to the actions of
the antibody on BDNF. Our results therefore implicated
BDNF as a potential downstream effector of neurite growth
following AMPA receptor potentiation.
Our results further highlight the long term neurotrophic ef¬
fect of AMPA receptor potentiation and support evidence that,
in addition to transient cognitive enhancement (Larson et al.,
1995; Ingvar et al., 1997; Lynch, 2004), AMPA receptor po¬
tentiators can promote downstream plasticity, via the actions
of neurotrophins, that may be beneficial for the treatment of
chronic neurodegenerative disorders.
References
Angelucci, F., Brene, S., Mathe, A.A., 2005. BDNF in schizophrenia, depres¬
sion and corresponding animal models. Mol. Psychiatry 10, 345—352.
Arai, A., Guidotti, A., Costa, E., Lynch, G., 1996. Effect of the AMPA receptor
modulator IDRA 21 on LTP in hippocampal slices. Neuroreport 7, 2211—
2215.
Arai, A.C., Xia, Y.F., Suzuki, E., 2004. Modulation of AMPA receptor kinetics
differentially influences synaptic plasticity in the hippocampus. Neurosci-
ence 123, 1011-1024.
Bahr, B.A., Bendiske, J., Brown, Q.B., Munirathinam, S., Caba, E., Rudin, M.,
Urwyler, S., Sauter, A., Rogers, G., 2002. Survival signaling and selective
neuroprotection through glutamatergic transmission. Exp. Neurol. 174,
37-47.
Bai, F., Bergeron, M., Nelson, D.L., 2003. Chronic AMPA receptor potentiator
(LY451646) treatment increases cell proliferation in adult rat hippocam¬
pus. Neuropharmacology 44, 1013—1021.
Barbacid, M., 1995. Structural and functional properties of the TRK family of
neurotrophin receptors. Ann. N.Y. Acad. Sci. 766, 442—458.
Black, M.D., 2005. Therapeutic potential of positive AMPA modulators and
their relationship to AMPA receptor subunits. A review of preclinical
data. Psychopharmacology (Berl) 179, 154—163.
Buccafusco, J.J., Weiser, T., Winter, K., Klinder, K., Terry, A.V., 2004. The
effects of IDRA 21, a positive modulator of the AMPA receptor, on de¬
layed matching performance by young and aged rhesus monkeys. Neuro¬
pharmacology 46, 10—22.
Chase, T.N., Oh, J.D., 2000. Striatal dopamine- and glutamate-mediated dys-
regulation in experimental parkinsonism. Trends Neurosci. 23, S86—S91.
Choi, D.W., 1992. Excitotoxic cell death. J. Neurobiol. 23, 1261—1276.
Collingridge, G.L., Singer, W., 1990. Excitatory amino acid receptors and syn¬
aptic plasticity. Trends Pharmacol. Sci. 11, 290—296.
Cui, S.S., Yang, C.P., Bowen, R.C., Bai, O., Li, X.M., Jiang, W., Zhang, X.,
2003. Valproic acid enhances axonal regeneration and recovery of motor
function after sciatic nerve axotomy in adult rats. Brain Res. 975, 229—
236.
Daniel, E.D., Mudge, A.W., Maycox, PR., 2005. Comparative analysis of the
effects of four mood stabilizers in SH-SY5Y cells and in primary neurons.
Bipolar Disord. 7, 33—41.
Dicou, E., Rangon, C.M., Guimiot, F., Spedding, M., Gressens, P., 2003. Pos¬
itive allosteric modulators of AMPA receptors are neuroprotective against
lesions induced by an NMDA agonist in neonatal mouse brain. Brain Res.
970, 221-225.
Dingledine, R., Borges, K., Bowie, D., Traynelis, S.F., 1999. The glutamate
receptor ion channels. Pharmacol. Rev. 51, 7—61.
Doherty, P., Dickson, J.G., Flanigan, T.P., Walsh, F.S., 1984. Quantitative eval¬
uation of neurite outgrowth in cultures of human foetal brain and dorsal
root ganglion cells using an enzyme-linked immunoadsorbent assay for
human neurofilament protein. J. Neurochem. 42, 1116—1122.
Drejer, J., Honore, T., 1988. New quinoxalinediones show potent antagonism
of quisqualate responses in cultured mouse cortical neurons. Neurosci.
Lett. 87, 104-108.
D'Sa, C., Duman, R.S., 2002. Antidepressants and neuroplasticity. Bipolar
Disord. 4, 183-194.
Ebadi, M., Bashir, R.M., Heidrick, M.L., Hamada, F.M., Refaey, H.E.,
Hamed, A., Helal, G., Baxi, M.D., Cerutis, D.R., Lassi, N.K., 1997. Neuro¬
trophins and their receptors in nerve injury and repair. Neurochem. Int. 30,
347-374.
Encinas, M., Iglesias, M., Liu, Y., Wang, H., Muhaisen, A., Cena, V.,
Gallego, C., Cornelia, J.X., 2000. Sequential treatment of SH-SY5Y cells
with retinoic acid and brain-derived neurotrophic factor gives rise to fully
596 O P. Voss et al. / Neuropharmacology 52 (2007) 590—597
differentiated, neurotrophic factor-dependent, human neuron-like cells. J.
Neurochem. 75, 991 — 1003.
Ernfors, P., Lee, K.F., Jaenisch, R., 1994. Mice lacking brain-derived neurotro¬
phic factor develop with sensory deficits. Nature 368, 147—150.
Fernandez-Espejo, E., 2004. Pathogenesis of Parkinson's disease: prospects of
neuroprotective and restorative therapies. Mol. Neurobiol. 29, 15—30.
Finkbeiner, S., Tavazoie, S.F., Maloratsky, A., Jacobs, K.M., Harris, K.M.,
Greenberg, M.E., 1997. CREB: a major mediator of neuronal neurotrophin
responses. Neuron 19, 1031 — 1047.
Gash, D.M., Zhang, Z., Gerhardt, G., 1998. Neuroprotective and neurorestor-
ative properties of GDNF. Ann. Neurol. 44, S121—S125.
Gates, M., Ogden, A., Bleakman, D., 2001. Pharmacological effects of AMPA
receptor potentiators LY392098 and LY404187 on rat neuronal AMPA re¬
ceptors in vitro. Neuropharmacology 40, 984—991.
Glass, D.J., Nye, S.H., Hantzopoulos, P., Macchi, M.J., Squinto, S.P.,
Goldfarb, M., Yancopoulos, G.D., 1991. TrkB mediates BDNF/NT-3-
dependent survival and proliferation in fibroblasts lacking the low affinity
NGF receptor. Cell 66, 405-413.
Granger, R., Deadwyler, S., Davis, M., Moskovitz, B., Kessler, M., Rogers, G.,
Lynch, G., 1996. Facilitation of glutamate receptors reverses an age-asso¬
ciated memory impairment in rats. Synapse 22, 332—337.
Hayashi, T., Umemori, H., Mishina, M., Yamamoto, T., 1999. The AMPA re¬
ceptor interacts with and signals through the protein tyrosine kinase Lyn.
Nature 397, 72-76.
Hollmann, M., Heinemann, S., 1994. Cloned glutamate receptors. Annu. Rev.
Neurosci. 17, 31 — 108.
Ingvar, M., Ambros-Ingerson, J., Davis, M., Granger, R., Kessler, M.,
Rogers, G.A., Schehr, R.S., Lynch, G., 1997. Enhancement by an ampa-
kine of memory encoding in humans. Exp. Neurol. 146, 553—559.
Ivankovic-Dikic, I., Gronroos, E., Blaukat, A., Barth, B.U., Dikic, I., 2000.
Pyk2 and FAK regulate neurite outgrowth induced by growth factors and
integrins. Nat. Cell Biol. 2, 574—581.
Jamsa, A., Hasslund, K., Cowburn, R.F., Backstrom, A., Vasange, M., 2004.
The retinoic acid and brain-derived neurotrophic factor differentiated
SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphor¬
ylation. Biochem. Biophys. Res. Commun. 319, 993—1000.
Klein, R., Nanduri, V., Jing, S.A., Lamballe, F., Tapley, P., Bryant, S., Cordon-
Cardo, C., Jones, K.R., Reichardt, L.F., Barbacid, M., 1991. The trkB ty¬
rosine protein kinase is a receptor for brain-derived neurotrophic factor and
neurotrophin-3. Cell 66, 395—403.
Larson, J., Lieu, T., Petchpradub, V., LeDuc, B., Ngo, H., Rogers, G.A.,
Lynch, G., 1995. Facilitation of olfactory learning by a modulator of
AMPA receptors. J. Neurosci. 15, 8023—8030.
Lauterborn, J.C., Lynch, G., Vanderklish, P., Arai, A., Gall, C.M., 2000. Pos¬
itive modulation of AMPA receptors increases neurotrophin expression by
hippocampal and cortical neurons. J. Neurosci. 20, 8—21.
Lauterborn, J.C., Truong, G.S., Baudry, M., Bi, X., Lynch, G., Gall, C.M.,
2003. Chronic elevation of brain-derived neurotrophic factor by ampa-
kines. J. Pharmacol. Exp. Ther. 307, 297—305.
Legutko, B., Li, X., Skolnick, P., 2001. Regulation of BDNF expression in pri¬
mary neuron culture by LY392098, a novel AMPA receptor potentiator.
Neuropharmacology 40, 1019—1027.
Li, X., Tizzano, J.P., Griffey, K., Clay, M., Lindstrom, T., Skolnick, P., 2001.
Antidepressant-like actions of an AMPA receptor potentiator (LY392098).
Neuropharmacology 40, 1028—1033.
Limatola, C., 2004. Neurotrophic effects of AMPA. Cerebellum 3, 2—10.
Lynch, G., 2004. AMPA receptor modulators as cognitive enhancers. Curr.
Opin. Pharmacol. 4, 4—11.
Mackowiak, M., O'Neill, M.J., Hicks, C.A., Bleakman, D., Skolnick, P., 2002.
An AMPA receptor potentiator modulates hippocampal expression of
BDNF: an in vivo study. Neuropharmacology 43, 1—10.
Mamounas, L.A., Blue, M.E., Siuciak, J.A., Altar, C.A., 1995. Brain-derived
neurotrophic factor promotes the survival and sprouting of serotonergic
axons in rat brain. J. Neurosci. 15, 7929—7939.
Manji, H.K., Quiroz, J.A., Sporn, J., Payne, J.L., Denicoff, K., Gray, A.N.,
2003. Enhancing neuronal plasticity and cellular resilience to develop
novel, improved therapeutics for difficult-to-treat depression. Biol. Psychi¬
atry 53, 707-742.
Millan, A., Arias-Montano, J.A., Mendez, J.A., Hernandez-Kelly, L.C., Ortega, A.,
2004. Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors
signaling complexes in Bergmann glia. J. Neurosci. Res. 78, 56—63.
Miu, P., Jarvie, K.R., Radhakrishnan, V., Gates, M.R., Ogden, A.,
Ornstein, PL., Zarrinmayeh, H., Ho, K., Peters, D., Grabell, J.,
Gupta, A., Zimmerman, D.M., Bleakman, D., 2001. Novel AMPA receptor
potentiators LY392098 and LY404187: effects on recombinant human
AMPA receptors in vitro. Neuropharmacology 40, 976—983.
Mueller, B.K., Mack, H., Teusch, N., 2005. Rho kinase, a promising drug tar¬
get for neurological disorders. Nat. Rev. Drug Discov. 4, 387—398.
O'Neill, M.J., Bleakman, D., Zimmerman, D.M., Nisenbaum, E.S., 2004a.
AMPA receptor potentiators for the treatment of CNS disorders. Curr.
Drug Targets CNS Neurol. Disord. 3, 181—194.
O'Neill, M.J., Murray, T.K., Whalley, K., Ward, M.A., Hicks, C.A.,
Woodhouse, S., Osborne, D.J., Skolnick, P., 2004b. Neurotrophic actions
of the novel AMPA receptor potentiator, LY404187, in rodent models of
Parkinson's disease. Eur. J. Pharmacol. 486, 163—174.
O'Neill, M.J., Murray, T.K., Clay, M.P., Lindstrom, T., Yang, C.R.,
Nisenbaum, E.S., 2005. LY503430: pharmacology, pharmacokinetics, and
effects in rodent models of Parkinson's disease. CNS Drug Rev. 11, 77—96.
Ornstein, PL., Zimmerman, D.M., Arnold, M.B., Bleisch, T.J., Cantrell, B.,
Simon, R., Zarrinmayeh, H., Baker, S.R., Gates, M., Tizzano, J.P.,
Bleakman, D., Mandelzys, A., Jarvie, K.R., Ho, K., Deverill, M.,
Kamboj, R.K., 2000. Biarylpropylsulfonamides as novel, potent potentia¬
tors of 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)-propanoic acid
(AMPA) receptors. J. Med. Chem. 43, 4354—4358.
Oyarce, A.M., Fleming, P.J., 1991. Multiple forms of human dopamine beta-
hydroxylase in SH-SY5Y neuroblastoma cells. Arch. Biochem. Biophys.
290, 503-510.
Patterson, S.L., Abel, T., Deuel, T.A., Martin, K.C., Rose, J.C., Kandel, E.R.,
1996. Recombinant BDNF rescues deficits in basal synaptic transmission
and hippocampal LTP in BDNF knockout mice. Neuron 16, 1137—1145.
Paul, I.A., Skolnick, P., 2003. Glutamate and depression: clinical and preclin¬
ical studies. Ann. N.Y. Acad. Sci. 1003, 250—272.
Peled, A., 2005. Plasticity imbalance in mental disorders the neuroscience of
psychiatry: implications for diagnosis and research. Med. Hypotheses 65,
947-952.
Perkinton, M.S., Sihra, T.S., Williams, R.J., 1999. Ca(2+)-permeable AMPA
receptors induce phosphorylation of cAMP response element-binding pro¬
tein through a phosphatidylinositol 3-kinase-dependent stimulation of the
mitogen-activated protein kinase signaling cascade in neurons. J. Neurosci.
19, 5861-5874.
Price, R.D., Yamaji, T., Matsuoka, N., 2003. FK506 potentiates NGF-induced
neurite outgrowth via the Ras/Raf/MAP kinase pathway. Br. J. Pharmacol.
140, 825-829.
Quirk, J.C., Nisenbaum, E.S., 2002. LY404187: a novel positive allosteric
modulator of AMPA receptors. CNS Drug Rev. 8, 255—282.
Schratt, G.M., Nigh, E.A., Chen, W.G., Hu, L., Greenberg, M.E., 2004. BDNF
regulates the translation of a select group of mRNAs by a mammalian tar¬
get of rapamycin-phosphatidylinositol 3-kinase-dependent pathway during
neuronal development. J. Neurosci. 24, 9366—9377.
Sekiguchi, M., Fleck, M.W., Mayer, M.L., Takeo, J., Chiba, Y., Yamashita, S.,
Wada, K., 1997. A novel allosteric potentiator of AMPA receptors: 4—2-
(phenylsulfonylamino)ethylthio—2,6-difluoro-phenoxyaceta mide. J. Neu¬
rosci. 17, 5760-5771.
Sheline, Y.I., 2003. Neuroimaging studies of mood disorder effects on the
brain. Biol. Psychiatry 54, 338—352.
Shieh, P.B., Hu, S.C., Bobb, K., Timmusk, T., Ghosh, A., 1998. Identification
of a signaling pathway involved in calcium regulation of BDNF expres¬
sion. Neuron 20, 727—740.
Soppet, D., Escandon, E., Maragos, J., Middlemas, D.S., Reid, S.W., Blair, J.,
Burton, L.E., Stanton, B.R., Kaplan, D.R., Hunter, T., et al., 1991. The
neurotrophic factors brain-derived neurotrophic factor and neurotrophin-
3 are ligands for the trkB tyrosine kinase receptor. Cell 65, 895—903.
Squinto, S.P., Stitt, T.N., Aldrich, T.H., Davis, S., Bianco, S.M., Radziejewski, C.,
Glass, D.J., Masiakowski, P., Furth, M.E., Valenzuela, D.M., et al., 1991.
trkB encodes a functional receptor for brain-derived neurotrophic factor
and neurotrophin-3 but not nerve growth factor. Cell 65, 885—893.
O P. Voss et al. / Neuropharmacology 52 (2007) 590—597 597
Staubli, U., Ambros-Ingerson, J., Lynch, G., 1992. Receptor changes and LTP:
an analysis using aniracetam, a drug that reversibly modifies glutamate
(AMPA) receptors. Hippocampus 2, 49—57.
Staubli, U., Rogers, G., Lynch, G., 1994. Facilitation of glutamate receptors
enhances memory. Proc. Natl. Acad. Sci. U.S.A. 91, 777—781.
Tao, X., Finkbeiner, S., Arnold, D.B., Shaywitz, A.J., Greenberg, M.E., 1998.
Ca2+ influx regulates BDNF transcription by a CREB family transcription
factor-dependent mechanism. Neuron 20, 709—726.
Tuominen, H.J., Tiihonen, J., Wahlbeck, K., 2005. Glutamatergic drugs for
schizophrenia: a systematic review and meta-analysis. Schizophr. Res.
72, 225-234.
Vandergriff, J., Huff, K., Bond, A., Lodge, D., 2001. Potentiation of responses
to AMPA on central neurones by LY392098 and LY404187 in vivo. Neu¬
ropharmacology 40, 1003—1009.
Wang, Y., Durkin, J.P., 1995. alpha-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid, but not W-methyl-D-aspartate, activates mitogen-acti-
vated protein kinase through G-protein beta gamma subunits in rat
cortical neurons. J. Biol. Chem. 270, 22783—22787.
Zafra, F., Hengerer, B., Leibrock, J., Thoenen, H., Lindholm, D., 1990. Activ¬
ity dependent regulation of BDNF and NGF mRNAs in the rat hippocam¬
pus is mediated by non-NMDA glutamate receptors. Embo J. 9, 3545—
3550.
References:
Abemayor, E. and N. Sidell (1989). "Human neuroblastoma cell lines as models for the
in vitro study of neoplastic and neuronal cell differentiation." Environ Health
Perspect 80: 3-15.
Adams, A. E., D. I. Johnson, et al. (1990). "CDC42 and CDC43, two additional genes
involved in budding and the establishment of cell polarity in the yeast
Saccharomyces cerevisiae." J Cell Biol 111(1): 131-42.
Adlerz, L., M. Beckman, et al. (2003). "Accumulation of the amyloid precursor-like
protein APLP2 and reduction of APLP1 in retinoic acid-differentiated human
neuroblastoma cells upon curcumin-induced neurite retraction." Brain Res Mol
Brain Res 119(1): 62-72.
Alt, A., E. S. Nisenbaum, et al. (2006). "A role for AMPA receptors in mood disorders."
Biochem Pharmacol.
Alvarez-Buylla, A. and J. M. Garcia-Verdugo (2002). "Neurogenesis in adult
subventricular zone." J Neurosci 22(3): 629-34.
Angelucci, F., S. Brene, et al. (2005). "BDNF in schizophrenia, depression and
corresponding animal models." Mol Psychiatry 10(4): 345-52.
Anisman, H. and R. M. Zacharko (1992). "Depression as a consequence of inadequate
neurochemical adaptation in response to stressors." Br J Psychiatry SuppK 15):
36-43.
Arai, A., A. Guidotti, et al. (1996). "Effect of the AMPA receptor modulator IDRA 21
on LTP in hippocampal slices." Neuroreport 7(13): 2211-5.
Arai, A., M. Kessler, et al. (1996). "Effects of a centrally active benzoylpyrrolidine drug
on AMPA receptor kinetics." Neuroscience 75(2): 573-85.
Arai, A. C., M. Kessler, et al. (2000). "Effects of the potent ampakine CX614 on
hippocampal and recombinant AMPA receptors: interactions with cyclothiazide
and GYKI 52466." Mol Pharmacol 58(4): 802-13.
Arai, A. C., Y. F. Xia, et al. (2002). "Benzamide-type AMPA receptor modulators form
two subfamilies with distinct modes of action." J Pharmacol Exp Ther 303(3):
1075-85.
Armstrong, N. and E. Gouaux (2000). "Mechanisms for activation and antagonism of an
AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand
binding core." Neuron 28(1): 165-81.
Armstrong, N., Y. Sun, et al. (1998). "Structure of a glutamate-receptor ligand-binding
core in complex with kainate." Nature 395(6705): 913-7.
Bahr, B. A., J. Bendiske, et al. (2002). "Survival signaling and selective neuroprotection
through glutamatergic transmission." Exp Neurol 174(1): 37-47.
Bai, F., M. Bergeron, et al. (2003). "Chronic AMPA receptor potentiator (LY451646)
treatment increases cell proliferation in adult rat hippocampus."
Neuropharmacology 44(8): 1013-21.
Bai, F., X. Li, et al. (2001). "Intra- and interstrain differences in models of "behavioral
despair"." Pharmacol Biochem Behav 70(2-3): 187-92.
181
Bamdad, M., D. Voile, et al. (2004). "Alpha 1 beta 1 -integrin is an essential signal for
neurite outgrowth induced by thrombospondin type 1 repeats of SCO-spondin."
Cell Tissue Res 315(1): 15-25.
Bannerman, D. M., J. N. Rawlins, et al. (2006). "The drugs don't work-or do they?
Pharmacological and transgenic studies of the contribution of NMDA and GluR-
A-containing AMPA receptors to hippocampal-dependent memory."
Psychopharmacology (Berl) 188(4): 552-66.
Barbacid, M. (1995). "Structural and functional properties of the TRK family of
neurotrophin receptors." Ann N Y Acad Sci 766: 442-58.
Barde, Y. A., D. Edgar, et al. (1982). "Purification of a new neurotrophic factor from
mammalian brain." Embo J 1(5): 549-53.
Bast, T., B. M. da Silva, et al. (2005). "Distinct contributions of hippocampal NMDA
and AMPA receptors to encoding and retrieval of one-trial place memory." J
Neurosci 25(25): 5845-56.
Baumbarger, P. J., M. Muhlhauser, et al. (2001). "Positive modulation of alpha-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal
cortical pyramidal neurons by a novel allosteric potentiator." J Pharmacol Exp
Ther 298(1): 86-102.
Benke, T. A., A. Luthi, et al. (1998). "Modulation of AMPA receptor unitary
conductance by synaptic activity." Nature 393(6687): 793-7.
Bertolino, M., M. Baraldi, et al. (1993). "Modulation of AMPA/kainate receptors by
analogues of diazoxide and cyclothiazide in thin slices of rat hippocampus."
Receptors Channels 1(4): 267-78.
Berton, O., C. A. McClung, et al. (2006). "Essential role of BDNF in the mesolimbic
dopamine pathway in social defeat stress." Science 311(5762): 864-8.
Berton, O. and E. J. Nestler (2006). "New approaches to antidepressant drug discovery:
beyond monoamines." Nat Rev Neurosci 7(2): 137-51.
Beyer, J. L. and K. R. Krishnan (2002). "Volumetric brain imaging findings in mood
disorders." Bipolar Disord 4(2): 89-104.
Bibel, M. and Y. A. Barde (2000). "Neurotrophins: key regulators of cell fate and cell
shape in the vertebrate nervous system." Genes Dev 14(23): 2919-37.
Binder, D. K. (2004). "The role of BDNF in epilepsy and other diseases of the mature
nervous system." Adv Exp Med Biol 548: 34-56.
Binder, D. K. and H. E. Scharfman (2004). "Brain-derived neurotrophic factor." Growth
Factors 22(3): 123-31.
Biscoe, T. J., R. H. Evans, et al. (1977). "D-alpha-Aminoadipate as a selective
antagonist of amino acid-induced and synaptic excitation of mammalian spinal
neurones." Nature 270(5639): 743-5.
Bredt, D. S. and R. A. Nicoll (2003). "AMPA receptor trafficking at excitatory
synapses." Neuron 40(2): 361-79.
Brown, A. S. and S. Gershon (1993). "Dopamine and depression." J Neural Transm Gen
Sect 91(2-3): 75-109.
Buccafusco, J. J., T. Weiser, et al. (2004). "The effects of IDRA 21, a positive modulator
of the AMPA receptor, on delayed matching performance by young and aged
rhesus monkeys." Neuropharmacology 46(1): 10-22.
182
Bunney, W. E., Jr. and J. M. Davis (1965). "Norepinephrine in depressive reactions. A
review." Arch Gen Psychiatry 13(6): 483-94.
Burnashev, N., H. Monyer, et al. (1992). "Divalent ion permeability of AMPA receptor
channels is dominated by the edited form of a single subunit." Neuron 8(1): 189-
98.
Burnette, W. N. (1981). ""Western blotting": electrophoretic transfer of proteins from
sodium dodecyl sulfate—polyacrylamide gels to unmodified nitrocellulose and
radiographic detection with antibody and radioiodinated protein A." Anal
Biochem 112(2): 195-203.
Cambray-Deakin, M. A., A. Morgan, et al. (1987). "Sequential appearance of
cytoskeletal components during the early stages of neurite outgrowth from
cerebellar granule cells in vitro." Brain Res 465(1-2): 197-207.
Cameron, H. A., B. S. McEwen, et al. (1995). "Regulation of adult neurogenesis by
excitatory input and NMDA receptor activation in the dentate gyrus." J Neurosci
15(6): 4687-92.
Carlezon, W. A., Jr., R. S. Duman, et al. (2005). "The many faces of CREB." Trends
Neurosci 28(8): 436-45.
Carlier, M. F., V. Laurent, et al. (1997). "Actin depolymerizing factor (ADF/cofilin)
enhances the rate of filament turnover: implication in actin-based motility." J
Cell Biol 136(6): 1307-22.
Castren, E. (2005). "Is mood chemistry?" Nat Rev Neurosci 6(3): 241-6.
Cavazzini, M., T. Bliss, et al. (2005). "Ca2+ and synaptic plasticity." Cell Calcium 38(3-
4): 355-67.
Chang, S. and P. De Camilli (2001). "Glutamate regulates actin-based motility in axonal
filopodia." Nat Neurosci 4(8): 787-93.
Chen, A. C., Y. Shirayama, et al. (2001). "Expression of the cAMP response element
binding protein (CREB) in hippocampus produces an antidepressant effect." Biol
Psychiatry 49(9): 753-62.
Chen, B., D. Dowlatshahi, et al. (2001). "Increased hippocampal BDNF
immunoreactivity in subjects treated with antidepressant medication." Biol
Psychiatry 50(4): 260-5.
Chen, L., D. M. Chetkovich, et al. (2000). "Stargazin regulates synaptic targeting of
AMPA receptors by two distinct mechanisms." Nature 408(6815): 936-43.
Chilton, J. K. (2006). "Molecular mechanisms of axon guidance." Dev Biol 292(1): 13-
24.
Choi, D. W. (1992). "Excitotoxic cell death." J Neurobiol 23(9): 1261-76.
Chourbaji, S., R. Hellweg, et al. (2004). "Mice with reduced brain-derived neurotrophic
factor expression show decreased choline acetyltransferase activity, but regular
brain monoamine levels and unaltered emotional behavior." Brain Res Mol Brain
Res 121(1-2): 28-36.
Christnacher, A. and B. Sommer (1995). "Alternative splicing of AMPA receptor
subunits: regulation in clonal cell lines." FEBS Lett 373(1): 93-6.
Cline, H. T. and M. Constantine-Paton (1989). "NMDA receptor antagonists disrupt the
retinotectal topographic map." Neuron 3(4): 413-26.
Cohen-Cory, S. and S. E. Fraser (1995). "Effects of brain-derived neurotrophic factor on
optic axon branching and remodelling in vivo." Nature 378(6553): 192-6.
183
Collingridge, G. L. and T. V. Bliss (1995). "Memories of NMDA receptors and LTP."
Trends Neurosci 18(2): 54-6.
Collingridge, G. L. and J. T. Isaac (2003). "Functional roles of protein interactions with
AMPA and kainate receptors." Neurosci Res 47(1): 3-15.
Collingridge, G. L., S. J. Kehl, et al. (1983). "Excitatory amino acids in synaptic
transmission in the Schaffer collateral-commissural pathway of the rat
hippocampus." J Physiol 334: 33-46.
Conover, J. C., J. T. Erickson, et al. (1995). "Neuronal deficits, not involving motor
neurons, in mice lacking BDNF and/or NT4." Nature 375(6528): 235-8.
Conrad, C. D., L. A. Galea, et al. (1996). "Chronic stress impairs rat spatial memory on
the Y maze, and this effect is blocked by tianeptine pretreatment." Behav
Neurosci 110(6): 1321-34.
Coppen, A. (1967). "The biochemistry of affective disorders." Br J Psychiatry 113(504):
1237-64.
Corcoran, J. and M. Maden (1999). "Nerve growth factor acts via retinoic acid synthesis
to stimulate neurite outgrowth." Nat Neurosci 2(4): 307-8.
Cotman, C. W. and N. C. Berchtold (2002). "Exercise: a behavioral intervention to
enhance brain health and plasticity." Trends Neurosci 25(6): 295-301.
Crowley, C., S. D. Spencer, et al. (1994). "Mice lacking nerve growth factor display
perinatal loss of sensory and sympathetic neurons yet develop basal forebrain
cholinergic neurons." Cell 76(6): 1001-11.
Cui, S. S., C. P. Yang, et al. (2003). "Valproic acid enhances axonal regeneration and
recovery of motor function after sciatic nerve axotomy in adult rats." Brain Res
975(1-2): 229-36.
Curtis, D. R., J. W. Phillis, et al. (1959). "Chemical excitation of spinal neurones."
Nature 183(4661): 611-2.
Curtis, D. R., J. W. Phillis, et al. (1959). "The depression of spinal neurones by gamma-
amino-n-butyric acid and beta-alanine." J Physiol 146(1): 185-203.
Curtis, D. R. and J. C. Watkins (1960). "The excitation and depression of spinal
neurones by structurally related amino acids." J Neurochem 6: 117-41.
da Silva, J. S. and C. G. Dotti (2002). "Breaking the neuronal sphere: regulation of the
actin cytoskeleton in neuritogenesis." Nat Rev Neurosci 3(9): 694-704.
Daniel, E. D., A. W. Mudge, et al. (2005). "Comparative analysis of the effects of four
mood stabilizers in SH-SY5Y cells and in primary neurons." Bipolar Disord
7(1): 33-41.
Dash, P. K., S. A. Mach, et al. (2001). "Enhanced neurogenesis in the rodent
hippocampus following traumatic brain injury." J Neurosci Res 63(4): 313-9.
Davies, J., A. A. Francis, et al. (1981). "2-Amino-5-phosphonovalerate (2APV), a potent
and selective antagonist of amino acid-induced and synaptic excitation."
Neurosci Lett 21(1): 77-81.
Day, M., R. Langston, et al. (2003). "Glutamate-receptor-mediated encoding and
retrieval of paired-associate learning." Nature 424(6945): 205-9.
Deitch, J. S. and E. W. Rubel (1984). "Afferent influences on brain stem auditory nuclei
of the chicken: time course and specificity of dendritic atrophy following
deafferentation." J Comp Neurol 229(1): 66-79.
184
Di Ciano, P., R. N. Cardinal, et al. (2001). "Differential involvement of NMDA,
AMPA/kainate, and dopamine receptors in the nucleus accumbens core in the
acquisition and performance of pavlovian approach behavior." J Neurosci
21(23): 9471-7.
Dickson, B. J. (2002). "Molecular mechanisms of axon guidance." Science 298(5600):
1959-64.
Dicou, E., C. M. Rangon, et al. (2003). "Positive allosteric modulators of AMPA
receptors are neuroprotective against lesions induced by an NMDA agonist in
neonatal mouse brain." Brain Res 970(1-2): 221-5.
Dingledine, R., K. Borges, et al. (1999). "The glutamate receptor ion channels."
Pharmacol Rev 51(1): 7-61.
Doherty, P., J. G. Dickson, et al. (1984). "Quantitative evaluation of neurite outgrowth
in cultures of human foetal brain and dorsal root ganglion cells using an enzyme-
linked immunoadsorbent assay for human neurofilament protein." J Neurochem
42(4): 1116-22.
Dong, H., R. J. O'Brien, et al. (1997). "GRIP: a synaptic PDZ domain-containing protein
that interacts with AMPA receptors." Nature 386(6622): 279-84.
Dong, H., P. Zhang, et al. (1999). "Characterization of the glutamate receptor-interacting
proteins GRIP1 and GRIP2." J Neurosci 19(16): 6930-41.
Drejer, J. and T. Honore (1988). "New quinoxalinediones show potent antagonism of
quisqualate responses in cultured mouse cortical neurons." Neurosci Lett 87(1-
2): 104-8.
Drevets, W. C., W. Bogers, et al. (2002). "Functional anatomical correlates of
antidepressant drug treatment assessed using PET measures of regional glucose
metabolism." Eur Neuropsychopharmacol 12(6): 527-44.
Drevets, W. C., J. L. Price, et al. (2002). "Glucose metabolism in the amygdala in
depression: relationship to diagnostic subtype and plasma Cortisol levels."
Pharmacol Biochem Behav 71(3): 431-47.
D'Sa, C. and R. S. Duman (2002). "Antidepressants and neuroplasticity." Bipolar Disord
4(3): 183-94.
Du, J. L. and M. M. Poo (2004). "Rapid BDNF-induced retrograde synaptic
modification in a developing retinotectal system." Nature 429(6994): 878-83.
Duggan, A. W. (1974). "The differential sensitivity to L-glutamate and L-aspartate of
spinal interneurones and Renshaw cells." Exp Brain Res 19(5): 522-8.
Duman, R. S., G. R. Heninger, et al. (1997). "A molecular and cellular theory of
depression." Arch Gen Psychiatry 54(7): 597-606.
Duman, R. S., J. Malberg, et al. (2000). "Neuronal plasticity and survival in mood
disorders." Biol Psychiatry 48(8): 732-9.
Eaton, S., P. Auvinen, et al. (1995). "CDC42 and Racl control different actin-dependent
processes in the Drosophila wing disc epithelium." J Cell Biol 131(1): 151-64.
Ebadi, M., R. M. Bashir, et al. (1997). "Neurotrophins and their receptors in nerve injury
and repair." Neurochem Int 30(4-5): 347-74.
Encinas, M., M. Iglesias, et al. (2000). "Sequential treatment of SH-SY5Y cells with
retinoic acid and brain-derived neurotrophic factor gives rise to fully
differentiated, neurotrophic factor-dependent, human neuron-like cells." J
Neurochem 75(3): 991-1003.
185
Ernfors, P., J. Bengzon, et al. (1991). "Increased levels of messenger RNAs for
neurotrophic factors in the brain during kindling epileptogenesis." Neuron 7(1):
165-76.
Ernfors, P., K. F. Lee, et al. (1994). "Mice lacking brain-derived neurotrophic factor
develop with sensory deficits." Nature 368(6467): 147-50.
Ernfors, P., K. F. Lee, et al. (1994). "Lack of neurotrophin-3 leads to deficiencies in the
peripheral nervous system and loss of limb proprioceptive afferents." Cell 77(4):
503-12.
Erreger, K., P. E. Chen, et al. (2004). "Glutamate receptor gating." Crit Rev Neurobiol
16(3): 187-224.
Evans, R. H., A. A. Francis, et al. (1978). "Mg2+-like selective antagonism of excitatory
amino acid-induced responses by alpha, epsilon-diaminopimelic acid, D-alpha-
aminoadipate and HA-966 in isolated spinal cord of frog and immature rat."
Brain Res 148(2): 536-42.
Fernandez-Espejo, E. (2004). "Pathogenesis of Parkinson's disease: prospects of
neuroprotective and restorative therapies." Mol Neurobiol 29(1): 15-30.
Finkbeiner, S. (2000). "Calcium regulation of the brain-derived neurotrophic factor
gene." Cell Mol Life Sci 57(3): 394-401.
Finkbeiner, S., S. F. Tavazoie, et al. (1997). "CREB: a major mediator of neuronal
neurotrophin responses." Neuron 19(5): 1031-47.
Fowler, J. H., K. Whalley, et al. (2004). "The AMPA receptor potentiator LY404187
increases cerebral glucose utilization and c-fos expression in the rat." J Cereb
Blood Flow Metab 24(10): 1098-109.
Frey, U. and R. G. Morris (1997). "Synaptic tagging and long-term potentiation." Nature
385(6616): 533-6.
Frey, U. and R. G. Morris (1998). "Synaptic tagging: implications for late maintenance
of hippocampal long-term potentiation." Trends Neurosci 21(5): 181-8.
Fukata, Y., A. V. Tzingounis, et al. (2005). "Molecular constituents of neuronal AMPA
receptors." J Cell Biol 169(3): 399-404.
Fushiki, S., K. Matsumoto, et al. (1995). "Neurite outgrowth of murine cerebellar
granule cells can be enhanced by aniracetam with or without alpha-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)." Neurosci Lett 199(3):
171-4.
Gage, F. H. (1998). "Stem cells of the central nervous system." Curr Opin Neurobiol
8(5): 671-6.
Gage, F. H., G. Kempermann, et al. (1998). "Multipotent progenitor cells in the adult
dentate gyrus." J Neurobiol 36(2): 249-66.
Gallo, V., L. M. Upson, et al. (1992). "Molecular cloning and development analysis of a
new glutamate receptor subunit isoform in cerebellum." J Neurosci 12(3): 1010-
23.
Garcia, M. M., A. T. Anderson, et al. (2003). "Morphine induction of c-fos expression in
the rat forebrain through glutamatergic mechanisms: role of non-n-methyl-D-
aspartate receptors." Neuroscience 119(3): 787-94.
Gash, D. M., Z. Zhang, et al. (1998). "Neuroprotective and neurorestorative properties of
GDNF." Ann Neurol 44(3 Suppl 1): S121-5.
186
Gates, M., A. Ogden, et al. (2001). "Pharmacological effects of AMPA receptor
potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in
vitro." Neuropharmacology 40(8): 984-91.
Gentry, J. J., P. A. Barker, et al. (2004). "The p75 neurotrophin receptor: multiple
interactors and numerous functions." Prog Brain Res 146: 25-39.
Ghosh, A., J. Carnahan, et al. (1994). "Requirement for BDNF in activity-dependent
survival of cortical neurons." Science 263(5153): 1618-23.
Gilbody, S., T. Sheldon, et al. (2006). "Should we screen for depression?" Bmi
332(7548): 1027-30.
Gillespie, L. N. (2003). "Regulation of axonal growth and guidance by the neurotrophin
family of neurotrophic factors." Clin Exp Pharmacol Physiol 30(10): 724-33.
Glantz, L. A., J. H. Gilmore, et al. (2006). "Apoptotic mechanisms and the synaptic
pathology of schizophrenia." Schizophr Res 81(1): 47-63.
Glass, D. J., S. H. Nye, et al. (1991). "TrkB mediates BDNF/NT-3-dependent survival
and proliferation in fibroblasts lacking the low affinity NGF receptor." Cell
66(2): 405-13.
Gold, B. G. (1997). "FK506 and the role of immunophilins in nerve regeneration." Mol
Neurobiol 15(3): 285-306.
Gomperts, S. N., A. Rao, et al. (1998). "Postsynaptically silent synapses in single neuron
cultures." Neuron 21(6): 1443-51.
Gould, E. (1994). "The effects of adrenal steroids and excitatory input on neuronal birth
and survival." Ann N Y Acad Sci 743: 73-92; discussion 92-3.
Gould, E. and C. G. Gross (2002). "Neurogenesis in adult mammals: some progress and
problems." J Neurosci 22(3): 619-23.
Gould, E., B. S. McEwen, et al. (1997). "Neurogenesis in the dentate gyrus of the adult
tree shrew is regulated by psychosocial stress and NMDA receptor activation." J
Neurosci 17(71: 2492-8.
Gould, E., A. J. Reeves, et al. (1999). "Neurogenesis in the neocortex of adult primates."
Science 286(5439): 548-52.
Gould, E. and P. Tanapat (1997). "Lesion-induced proliferation of neuronal progenitors
in the dentate gyrus of the adult rat." Neuroscience 80(2): 427-36.
Granger, R., S. Deadwyler, et al. (1996). "Facilitation of glutamate receptors reverses an
age-associated memory impairment in rats." Synapse 22(4): 332-7.
Granger, R., U. Staubli, et al. (1993). "A drug that facilitates glutamatergic transmission
reduces exploratory activity and improves performance in a learning-dependent
task." Synapse 15(4): 326-9.
Gray, W. P. and L. E. Sundstrom (1998). "Kainic acid increases the proliferation of
granule cell progenitors in the dentate gyrus of the adult rat." Brain Res 790(1-2):
52-9.
Hampson, R. E., G. Rogers, et al. (1998). "Facilitative effects of the ampakine CX516
on short-term memory in rats: correlations with hippocampal neuronal activity."
J Neurosci 18(7): 2748-63.
Hampson, R. E., G. Rogers, et al. (1998). "Facilitative effects of the ampakine CX516
on short-term memory in rats: enhancement of delayed-nonmatch-to-sample
performance." J Neurosci 18(7): 2740-7.
187
Hashimoto, K., M. Fukaya, et al. (1999). "Impairment of AMPA receptor function in
cerebellar granule cells of ataxic mutant mouse stargazer." J Neurosci 19(14):
6027-36.
Hayashi, T. (1954). "Effects of sodium glutamate on the nervous system." Keio J. Med.
3: 183-192.
Hayashi, T., H. Umemori, et al. (1999). "The AMPA receptor interacts with and signals
through the protein tyrosine kinase Lyn." Nature 397(6714): 72-6.
Hebb, D. O. (1949). The Organisation of behaviour. New York, John Wiley.
Henley, J. (2001). "Proteins involved in the synaptic organization of AMPA (alpha-
amino-3-hydroxy-5-methylisoxazolepropionate) receptors." Biochem Soc Trans
29(Pt 4): 485-8.
Ho, R., A. Eggert, et al. (2002). "Resistance to chemotherapy mediated by TrkB in
neuroblastomas." Cancer Res 62(22): 6462-6.
Hollmann, M. and S. Heinemann (1994). "Cloned glutamate receptors." Annu Rev
Neurosci 17: 31-108.
Hollmann, M., A. O'Shea-Greenfield, et al. (1989). "Cloning by functional expression of
a member of the glutamate receptor family." Nature 342(6250): 643-8.
Holsboer, F., A. Gerken, et al. (1986). "Human corticotropin-releasing hormone in
depression—correlation with thyrotropin secretion following thyrotropin-
releasing hormone." Biol Psychiatry 21(7): 601-11.
Honey, G. D., R. A. Honey, et al. (2005). "Impairment of specific episodic memory
processes by sub-psychotic doses of ketamine: the effects of levels of processing
at encoding and of the subsequent retrieval task." Psvchopharmacology (Berl)
181(3): 445-57.
Honore, T., S. N. Davies, et al. (1988). "Quinoxalinediones: potent competitive non-
NMDA glutamate receptor antagonists." Science 241(4866): 701-3.
Houamed, K. M., J. L. Kuijper, et al. (1991). "Cloning, expression, and gene structure of
a G protein-coupled glutamate receptor from rat brain." Science 252(5010):
1318-21.
Howe, C. L. (2003). "Depolarization of PC12 cells induces neurite outgrowth and
enhances nerve growth factor-induced neurite outgrowth in rats." Neurosci Lett
351(1): 41-5.
Hubel, D. H. and T. N. Wiesel (1970). "The period of susceptibility to the physiological
effects of unilateral eye closure in kittens." J Physiol 206(2): 419-36.
Hubel, D. H., T. N. Wiesel, et al. (1977). "Plasticity of ocular dominance columns in
monkey striate cortex." Philos Trans R Soc Lond B Biol Sci 278(961): 377-409.
Hume, R. I., R. Dingledine, et al. (1991). "Identification of a site in glutamate receptor
subunits that controls calcium permeability." Science 253(5023): 1028-31.
Ingvar, M., J. Ambros-Ingerson, et al. (1997). "Enhancement by an ampakine of
memory encoding in humans." Exp Neurol 146(2): 553-9.
Isaacson, J. S. and R. A. Nicoll (1991). "Aniracetam reduces glutamate receptor
desensitization and slows the decay of fast excitatory synaptic currents in the
hippocampus." Proc Natl Acad Sci U S A 88(23): 10936-40.
Ito, I., S. Tanabe, et al. (1990). "Allosteric potentiation of quisqualate receptors by a
nootropic drug aniracetam." J Physiol 424: 533-43.
188
Ivankovic-Dikic, I., E. Gronroos, et al. (2000). "Pyk2 and FAK regulate neurite
outgrowth induced by growth factors and integrins." Nat Cell Biol 2(9): 574-81.
Jamsa, A., K. Hasslund, et al. (2004). "The retinoic acid and brain-derived neurotrophic
factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like
tau phosphorylation." Biochem Biophys Res Commun 319(3): 993-1000.
Javitt, D. C. (2004). "Glutamate as a therapeutic target in psychiatric disorders." Mol
Psychiatry 9(11): 984-97, 979.
Jhee, S. S., A. S. Chappell, et al. (2006). "Multiple-dose plasma pharmacokinetic and
safety study of LY450108 and LY451395 (AMPA receptor potentiators) and
their concentration in cerebrospinal fluid in healthy human subjects." J Clin
Pharmacol 46(4): 424-32.
Jin, R., T. G. Banke, et al. (2003). "Structural basis for partial agonist action at
ionotropic glutamate receptors." Nat Neurosci 6(8): 803-10.
Johnson, D. I. and J. R. Pringle (1990). "Molecular characterization of CDC42, a
Saccharomyces cerevisiae gene involved in the development of cell polarity." J
Cell Biol 111(1): 143-52.
Johnson, S. A., N. T. Luu, et al. (1999). "Synergistic interactions between ampakines
and antipsychotic drugs." J Pharmacol Exp Ther 289(1): 392-7.
Jones, E. G. (1999). "Colgi, Cajal and the Neuron Doctrine." J Hist Neurosci 8(2): 170-
8.
Jones, M. V. and G. L. Westbrook (1996). "The impact of receptor desensitization on
fast synaptic transmission." Trends Neurosci 19(3): 96-101.
Jordan, G. R., J. McCulloch, et al. (2005). "Regionally selective and dose-dependent
effects of the ampakines Org 26576 and Org 24448 on local cerebral glucose
utilisation in the mouse as assessed by 14C-2-deoxyglucose autoradiography."
Neuropharmacology 49(2): 254-64.
Karten, Y. J., A. Olariu, et al. (2005). "Stress in early life inhibits neurogenesis in
adulthood." Trends Neurosci 28(4): 171-2.
Katz, L. C. and C. J. Shatz (1996). "Synaptic activity and the construction of cortical
circuits." Science 274(5290): 1133-8.
Kawahara, Y., K. Ito, et al. (2004). "GluR4c, an alternative splicing isoform of GluR4, is
abundantly expressed in the adult human brain." Brain Res Mol Brain Res 127(1-
2): 150-5.
Keinanen, K., W. Wisden, et al. (1990). "A family of AMPA-selective glutamate
receptors." Science 249(4968): 556-60.
Kempermann, G. and F. H. Gage (2000). "Neurogenesis in the adult hippocampus."
Novartis Found Svmp 231: 220-35; discussion 235-41, 302-6.
Kempermann, G., D. Gast, et al. (2002). "Neuroplasticity in old age: sustained fivefold
induction of hippocampal neurogenesis by long-term environmental enrichment."
Ann Neurol 52(2): 135-43.
Kempermann, G., L. Wiskott, et al. (2004). "Functional significance of adult
neurogenesis." Curr Opin Neurobiol 14(2): 186-91.
Kessler, M. and A. C. Arai (2006). "Use of [3H]fluorowillardiine to study properties of
AMPA receptor allosteric modulators." Brain Res 1076(1): 25-41.
Klein, R., V. Nanduri, et al. (1991). "The trkB tyrosine protein kinase is a receptor for
brain-derived neurotrophic factor and neurotrophin-3." Cell 66(2): 395-403.
189
Kohler, M., H. C. Kornau, et al. (1994). "The organization of the gene for the
functionally dominant alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic
acid receptor subunit GluR-B." J Biol Chem 269(26): 17367-70.
Kolodkin, A. L. (1996). "Growth cones and the cues that repel them." Trends Neurosci
19(11): 507-13.
Konur, S. and A. Ghosh (2005). "Calcium signaling and the control of dendritic
development." Neuron 46(3): 401-5.
Korey, C. A. and D. Van Vactor (2000). "From the growth cone surface to the
cytoskeleton: one journey, many paths." J Neurobiol 44(2): 184-93.
Krogsgaard-Larsen, P., T. Honore, et al. (1980). "New class of glutamate agonist
structurally related to ibotenic acid." Nature 284(5751): 64-6.
Lakics, V., Ryder, J. W., Stewart, T. R. , Shou J., Boess, F. G., Merchant, K. M.
(2006). Cellular pathways associated with activation of AMPA receptors by
allosteric modulators: relevance to pleiotropic neuropharmacology of AMPA
potentiators. Neuroscience 2006, Washington, Society for Neuroscience.
Larner, A. J. (1995). "Axonal sprouting and synaptogenesis in temporal lobe epilepsy:
possible pathogenetic and therapeutic roles of neurite growth inhibitory factors."
Seizure 4(4): 249-58.
Larson, J., T. Lieu, et al. (1995). "Facilitation of olfactory learning by a modulator of
AMPA receptors." J Neurosci 15(12): 8023-30.
Lauterborn, J. C., G. Lynch, et al. (2000). "Positive modulation of AMPA receptors
increases neurotrophin expression by hippocampal and cortical neurons." J
Neurosci 20(11: 8-21.
Lauterborn, J. C., G. S. Truong, et al. (2003). "Chronic elevation of brain-derived
neurotrophic factor by ampakines." J Pharmacol Exp Ther 307(1): 297-305.
Lazarova-Bakarova, M. B. and M. G. Genkova-Papasova (1989). "Influence of
nootropic drugs on the memory-impairing effect of clonidine in albino rats."
Methods Find Exp Clin Pharmacol 11(4): 235-9.
Lebrun, C., E. Pilliere, et al. (2000). "Effects of S 18986-1, a novel cognitive enhancer,
on memory performances in an object recognition task in rats." Eur J Pharmacol
401(2): 205-12.
Lee, C. R. and P. Benfield (1994). "Aniracetam. An overview of its pharmacodynamic
and pharmacokinetic properties, and a review of its therapeutic potential in senile
cognitive disorders." Drugs Aging 4(3): 257-73.
Legutko, B., X. Li, et al. (2001). "Regulation of BDNF expression in primary neuron
culture by LY392098, a novel AMPA receptor potentiator." Neuropharmacology
40(8): 1019-27.
Lendvai, B., E. A. Stern, et al. (2000). "Experience-dependent plasticity of dendritic
spines in the developing rat barrel cortex in vivo." Nature 404(6780): 876-81.
Lessmann, V., K. Gottmann, et al. (2003). "Neurotrophin secretion: current facts and
future prospects." Prog Neurobiol 69(5): 341-74.
Letts, V. A., R. Felix, et al. (1998). "The mouse stargazer gene encodes a neuronal
Ca2+-channel gamma subunit." Nat Genet 19(4): 340-7.
Levi-Montalcini, R. (1987). "The nerve growth factor 35 years later." Science
237(4819): 1154-62.
190
Levi-Montalcini, R. and V. Hamburger (1951). "Selective growth stimulating effects of
mouse sarcoma on the sensory and sympathetic nervous system of the chick
embryo." J Exp Zool 116(2): 321-61.
Levine, E. S., C. F. Dreyfus, et al. (1995). "Brain-derived neurotrophic factor rapidly
enhances synaptic transmission in hippocampal neurons via postsynaptic tyrosine
kinase receptors." Proc Natl Acad Sci USA 92(17): 8074-7.
Li, X., J. P. Tizzano, et al. (2001). "Antidepressant-like actions of an AMPA receptor
potentiator (LY392098)." Neuropharmacology 40(8): 1028-33.
Li, Z., L. Van Aelst, et al. (2000). "Rho GTPases regulate distinct aspects of dendritic
arbor growth in Xenopus central neurons in vivo." Nat Neurosci 3(3): 217-25.
Limatola, C. (2004). "Neurotrophic effects of AMPA." Cerebellum 3(1): 2-10.
Lindvall, O., Z. Kokaia, et al. (2004). "Stem cell therapy for human neurodegenerative
disorders-how to make it work." Nat Med 10 Suppl: S42-50.
Lledo, P. M., M. Alonso, et al. (2006). "Adult neurogenesis and functional plasticity in
neuronal circuits." Nat Rev Neurosci 7(3): 179-93.
Lodge, D. and N. A. Anis (1982). "Effects of phencyclidine on excitatory amino acid
activation of spinal interneurones in the cat." Eur J Pharmacol 77(2-3): 203-4.
Lohof, A. M., N. Y. Ip, et al. (1993). "Potentiation of developing neuromuscular
synapses by the neurotrophins NT-3 and BDNF." Nature 363(6427): 350-3.
Lohof, A. M., M. Quillan, et al. (1992). "Asymmetric modulation of cytosolic cAMP
activity induces growth cone turning." J Neurosci 12(4): 1253-61.
Luine, V., M. Villegas, et al. (1994). "Repeated stress causes reversible impairments of
spatial memory performance." Brain Res 639(1): 167-70.
Luo, L. (2000). "Rho GTPases in neuronal morphogenesis." Nat Rev Neurosci 1(3):
173-80.
Lynch, G. (2004). "AMPA receptor modulators as cognitive enhancers." Curr Opin
Pharmacol 4(1): 4-11.
Lynch, G., R. Granger, et al. (1997). "Evidence that a positive modulator of AMPA-type
glutamate receptors improves delayed recall in aged humans." Exp Neurol
145(1): 89-92.
Lynch, G., D. Muller, et al. (1988). "Long-term potentiation: persisting problems and
recent results." Brain Res Bull 21(3): 363-72.
Lynch, M. A. (2004). "Long-term potentiation and memory." Physiol Rev 84(1): 87-136.
Mackowiak, M., M. J. O'Neill, et al. (2002). "An AMPA receptor potentiator modulates
hippocampal expression of BDNF: an in vivo study." Neuropharmacology 43(1):
1-10.
Magavi, S. S., B. R. Leavitt, et al. (2000). "Induction of neurogenesis in the neocortex of
adult mice." Nature 405(6789): 951-5.
Malberg, J. E. and R. S. Duman (2003). "Cell proliferation in adult hippocampus is
decreased by inescapable stress: reversal by fluoxetine treatment."
Neuropsychopharmacology 28(9): 1562-71.
Malberg, J. E., A. J. Eisch, et al. (2000). "Chronic antidepressant treatment increases
neurogenesis in adult rat hippocampus." J Neurosci 20(24): 9104-10.
Malenka, R. C. (2003). "Synaptic plasticity and AMPA receptor trafficking." Ann N Y
Acad Sci 1003: 1-11.
191
Malenka, R. C. and M. F. Bear (2004). "LTP and LTD: an embarrassment of riches."
Neuron 44(1): 5-21.
Mamounas, L. A., M. E. Blue, et al. (1995). "Brain-derived neurotrophic factor
promotes the survival and sprouting of serotonergic axons in rat brain." J
Neurosci 15(12): 7929-39.
Manji, H. K., J. A. Quiroz, et al. (2003). "Enhancing neuronal plasticity and cellular
resilience to develop novel, improved therapeutics for difficult-to-treat
depression." Biol Psychiatry 53(8): 707-42.
Marenco, S., M. F. Egan, et al. (2002). "Preliminary experience with an ampakine
(CX516) as a single agent for the treatment of schizophrenia: a case series."
Schizophr Res 57(2-3): 221-6.
Masu, M., Y. Tanabe, et al. (1991). "Sequence and expression of a metabotropic
glutamate receptor." Nature 349(6312): 760-5.
Mayer, M. L. and L. Vyklicky, Jr. (1989). "Concanavalin A selectively reduces
desensitization of mammalian neuronal quisqualate receptors." Proc Natl Acad
SciUS A 86(4): 1411-5.
McCulloch, R. M., G. A. Johnston, et al. (1974). "The differential sensitivity of spinal
interneurones and Renshaw cells to Kainate and N-methyl-D-aspartate." Exp
Brain Res 21(5): 515-8.
McEwen, B. S. (1999). "Stress and hippocampal plasticity." Annu Rev Neurosci 22:
105-22.
McEwen, B. S. and R. M. Sapolsky (1995). "Stress and cognitive function." Curr Qpin
Neurobiol 5(2): 205-16.
McLennan, H. (1983). "Receptors for the excitatory amino acids in the mammalian
central nervous system." Prog Neurobiol 20(3-4): 251-71.
McLennan, H., R. D. Fluffman, et al. (1968). "Patterns of excitation of thalamic
neurones by amino-acids and by acetylcholine." Nature 219(5152): 387-8.
Messenger, M., Murray, T., Ward, M., O'Neill, M.J. (2006). AMPA receptor potentiator-
mediated regeneration of the nigrostriatal tract:mechanistic studies in teh 6-
OHDA model of Parkinson's Disease. Neuroscience 2006, Washington DC.
Metzger, F., S. Wiese, et al. (1998). "Effect of glutamate on dendritic growth in
embryonic rat motoneurons." J Neurosci 18(5): 1735-42.
Meyer, G. and E. L. Feldman (2002). "Signaling mechanisms that regulate actin-based
motility processes in the nervous system." J Neurochem 83(3): 490-503.
Millan, A., P. Aguilar, et al. (2001). "Glutamate activates PP125(FAK) through
AMPA/kainate receptors in Bergmann glia." J Neurosci Res 66(4): 723-9.
Millan, A., J. A. Arias-Montano, et al. (2004). "Alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors signaling complexes in Bergmann glia." J
Neurosci Res 78(1): 56-63.
Miserendino, M. J., C. B. Sananes, et al. (1990). "Blocking of acquisition but not
expression of conditioned fear-potentiated startle by NMDA antagonists in the
amygdala." Nature 345(6277): 716-8.
Mitchison, T. and M. Kirschner (1988). "Cytoskeletal dynamics and nerve growth."
Neuron 1(9): 761-72.
192
Miu, P., K. R. Jarvie, et al. (2001). "Novel AMPA receptor potentiators LY392098 and
LY404187: effects on recombinant human AMPA receptors in vitro."
Neuropharmacology 40(8): 976-83.
Monaghan, D. T. and C. W. Cotman (1982). "The distribution of [3H]kainic acid
binding sites in rat CNS as determined by autoradiography." Brain Res 252(1):
91-100.
Monaghan, D. T., D. Yao, et al. (1984). "Distribution of [3HJAMPA binding sites in rat
brain as determined by quantitative autoradiography." Brain Res 324(1): 160-4.
Moriyoshi, K., M. Masu, et al. (1991). "Molecular cloning and characterization of the rat
NMDA receptor." Nature 354(6348): 31-7.
Morris, B. J., S. M. Cochran, et al. (2005). "PCP: from pharmacology to modelling
schizophrenia." Curr Opin Pharmacol 5(1): 101-6.
Morris, R. G., E. Anderson, et al. (1986). "Selective impairment of learning and
blockade of long-term potentiation by an N-methyl-D-aspartate receptor
antagonist, AP5." Nature 319(6056): 774-6.
Mueller, B. K., H. Mack, et al. (2005). "Rho kinase, a promising drug target for
neurological disorders." Nat Rev Drug Discov 4(5): 387-98.
Muller, D., M. Joly, et al. (1988). "Contributions of quisqualate and NMDA receptors to
the induction and expression of LTP." Science 242(4886): 1694-7.
Muller, D. and G. Lynch (1988). "Long-term potentiation differentially affects two
components of synaptic responses in hippocampus." Proc Natl Acad Sci USA
85(23): 9346-50.
Murray, T. K., K. Whalley, et al. (2003). "LY503430, a novel alpha-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid receptor potentiator with functional,
neuroprotective and neurotrophic effects in rodent models of Parkinson's
disease." J Pharmacol Exp Ther 306(2): 752-62.
Nakagawa, S., J. E. Kim, et al. (2002). "Regulation of neurogenesis in adult mouse
hippocampus by cAMP and the cAMP response element-binding protein." J
Neurosci 22(9): 3673-82.
Nakagawa, T., Y. Cheng, et al. (2005). "Structure and different conformational states of
native AMPA receptor complexes." Nature 433(7025): 545-9.
Nakanishi, N., N. A. Shneider, et al. (1990). "A family of glutamate receptor genes:
evidence for the formation of heteromultimeric receptors with distinct channel
properties." Neuron 5(5): 569-81.
Nakanishi, S. (1992). "Molecular diversity of glutamate receptors and implications for
brain function." Science 258(5082): 597-603.
Nestler, E. J., M. Barrot, et al. (2002). "Neurobiology of depression." Neuron 34(1): 13-
25.
Nibuya, M., S. Morinobu, et al. (1995). "Regulation of BDNF and trkB mRNA in rat
brain by chronic electroconvulsive seizure and antidepressant drug treatments." J
Neurosci 15(11): 7539-47.
Nibuya, M., E. J. Nestler, et al. (1996). "Chronic antidepressant administration increases
the expression of cAMP response element binding protein (CREB) in rat
hippocampus." J Neurosci 16(7): 2365-72.
Nicoletti, F., M. J. Iadarola, et al. (1986). "Excitatory amino acid recognition sites
coupled with inositol phospholipid metabolism: developmental changes and
193
interaction with alpha 1-adrenoceptors." Proc Natl Acad Sci U S A 83(6): 1931-
5.
Nicoletti, F., J. L. Meek, et al. (1986). "Coupling of inositol phospholipid metabolism
with excitatory amino acid recognition sites in rat hippocampus." J Neurochem
46(1): 40-6.
Nicoll, R. A. and R. C. Malenka (1999). "Expression mechanisms underlying NMDA
receptor-dependent long-term potentiation." Ann N Y Acad Sci 868: 515-25.
Nicoll, R. A., S. Tomita, et al. (2006). "Auxiliary subunits assist AMPA-type glutamate
receptors." Science 311(5765): 1253-6.
Nikolic, M. (2002). "The role of Rho GTPases and associated kinases in regulating
neurite outgrowth." Int J Biochem Cell Biol 34(7): 731-45.
Olivieri, G., U. Otten, et al. (2003). "Beta-amyloid modulates tyrosine kinase B receptor
expression in SHSY5Y neuroblastoma cells: influence of the antioxidant
melatonin." Neuroscience 120(3): 659-65.
Olney, J. W. and O. L. Ho (1970). "Brain damage in infant mice following oral intake of
glutamate, aspartate or cysteine." Nature 227(5258): 609-11.
Olverman, H. J., A. W. Jones, et al. (1984). "L-glutamate has higher affinity than other
amino acids for [3H]-D-AP5 binding sites in rat brain membranes." Nature
307(5950): 460-2.
O'Neill, M. J., D. Bleakman, et al. (2004). "AMPA receptor potentiators for the
treatment of CNS disorders." Curr Drug Targets CNS Neurol Disord 3(3): 181-
94.
O'Neill, M. J., T. K. Murray, et al. (2005). "LY503430: pharmacology,
pharmacokinetics, and effects in rodent models of Parkinson's disease." CNS
Drug Rev 11(1): 77-96.
O'Neill, M. J., T. K. Murray, et al. (2004). "Neurotrophic actions of the novel AMPA
receptor potentiator, LY404187, in rodent models of Parkinson's disease." Eur J
Pharmacol 486(2): 163-74.
Omstein, P. L., D. M. Zimmerman, et al. (2000). "Biarylpropylsulfonamides as novel,
potent potentiators of 2-amino-3- (5-methyl-3-hydroxyisoxazol-4-yl)- propanoic
acid (AMPA) receptors." J Med Chem 43(23): 4354-8.
Oyarce, A. M. and P. J. Fleming (1991). "Multiple forms of human dopamine beta-
hydroxylase in SH-SY5Y neuroblastoma cells." Arch Biochem Biophvs 290(2):
503-10.
Paavilainen, V. O., E. Bertling, et al. (2004). "Regulation of cytoskeletal dynamics by
actin-monomer-binding proteins." Trends Cell Biol 14(7): 386-94.
Packard, M. G. and L. A. Teather (1997). "Double dissociation of hippocampal and
dorsal-striatal memory systems by posttraining intracerebral injections of 2-
amino-5-phosphonopentanoic acid." Behav Neurosci 111(3): 543-51.
Parent, J. M. and D. H. Lowenstein (2002). "Seizure-induced neurogenesis: are more
new neurons good for an adult brain?" Prog Brain Res 135: 121-31.
Partin, K. M., D. Bowie, et al. (1995). "Structural determinants of allosteric regulation in
alternatively spliced AMPA receptors." Neuron 14(4): 833-43.
Patterson, S. L., T. Abel, et al. (1996). "Recombinant BDNF rescues deficits in basal
synaptic transmission and hippocampal LTP in BDNF knockout mice." Neuron
16(6): 1137-45.
194
Peled, A. (2005). "Plasticity imbalance in mental disorders the neuroscience of
psychiatry: implications for diagnosis and research." Med Hypotheses 65(5):
947-52.
Pencea, V., K. D. Bingaman, et al. (2001). "Infusion of brain-derived neurotrophic factor
into the lateral ventricle of the adult rat leads to new neurons in the parenchyma
of the striatum, septum, thalamus, and hypothalamus." J Neurosci 21(17): 6706-
17.
Perkinton, M. S., T. S. Sihra, et al. (1999). "Ca(2+)-permeable AMPA receptors induce
phosphorylation of cAMP response element-binding protein through a
phosphatidylinositol 3-kinase-dependent stimulation of the mitogen-activated
protein kinase signaling cascade in neurons." J Neurosci 19(14): 5861-74.
Poo, M. M. (2001). "Neurotrophins as synaptic modulators." Nat Rev Neurosci 2(1): 24-
32. ' ~
Porrino, L. J., J. B. Daunais, et al. (2005). "Facilitation of task performance and removal
of the effects of sleep deprivation by an ampakine (CX717) in nonhuman
primates." PLoS Biol 3(9): e299.
Post, R. M. (1992). "Transduction of psychosocial stress into the neurobiology of
recurrent affective disorder." Am J Psychiatry 149(8): 999-1010.
Price, R. D., T. Oe, et al. (2005). "A Simple, Flexible, Nonfluorescent System for the
Automated Screening of Neurite Outgrowth." J Biomol Screen.
Price, R. D., T. Yamaji, et al. (2003). "FK506 potentiates NGF-induced neurite
outgrowth via the Ras/Raf/MAP kinase pathway." Br J Pharmacol 140(5): 825-9.
Priel, A., A. Kolleker, et al. (2005). "Stargazin reduces desensitization and slows
deactivation of the AMPA-type glutamate receptors." J Neurosci 25(10): 2682-6.
Prince, J. A. and L. Oreland (1997). "Staurosporine differentiated human SH-SY5Y
neuroblastoma cultures exhibit transient apoptosis and trophic factor
independence." Brain Res Bull 43(6): 515-23.
Quirk, J. C. and E. S. Nisenbaum (2002). "LY404187: a novel positive allosteric
modulator of AMPA receptors." CNS Drug Rev 8(3): 255-82.
Quirk, J. C. and E. S. Nisenbaum (2003). "Multiple molecular determinants for allosteric
modulation of alternatively spliced AMPA receptors." J Neurosci 23(34): 10953-
62.
Raisman, G. (1969). "Neuronal plasticity in the septal nuclei of the adult rat." Brain Res
14(1): 25-48.
Rajadhyaksha, A., A. Barczak, et al. (1999). "L-Type Ca(2+) channels are essential for
glutamate-mediated CREB phosphorylation and c-fos gene expression in striatal
neurons." J Neurosci 19(15): 6348-59.
Rajan, I. and H. T. Cline (1998). "Glutamate receptor activity is required for normal
development of tectal cell dendrites in vivo." J Neurosci 18(19): 7836-46.
Ramm, P., Y. Alexandrov, et al. (2003). "Automated screening of neurite outgrowth." J
Biomol Screen 8(1): 7-18.
Redmond, L., A. H. Kashani, et al. (2002). "Calcium regulation of dendritic growth via
CaM kinase IV and CREB-mediated transcription." Neuron 34(6): 999-1010.
Reisel, D., D. M. Bannerman, et al. (2005). "GluR-A-dependent synaptic plasticity is
required for the temporal encoding of nonspatial information." Behav Neurosci
119(5): 1298-306.
195
Ridley, A. J. and A. Hall (1992). "The small GTP-binding protein rho regulates the
assembly of focal adhesions and actin stress fibers in response to growth
factors." Cell 70(31: 389-99.
Ridley, A. J., H. F. Paterson, et al. (1992). "The small GTP-binding protein rac regulates
growth factor-induced membrane ruffling." Cell 70(3): 401-10.
Rios, J. C., G. Repetto, et al. (2003). "Tribromophenol induces the differentiation of SH-
SY5Y human neuroblastoma cells in vitro." Toxicol In Vitro 17(5-6): 635-41.
Robbins, T. W. and E. R. Murphy (2006). "Behavioural pharmacology: 40+ years of
progress, with a focus on glutamate receptors and cognition." Trends Pharmacol
Sri 27(3): 141-8.
Rodriguez-Tebar, A. and Y. A. Barde (1988). "Binding characteristics of brain-derived
neurotrophic factor to its receptors on neurons from the chick embryo." J
Neurosci 8(9): 3337-42.
Romanelli, M. N., N. Galeotti, et al. (2006). "Pharmacological characterization of
DM232 (unifxram) and DM235 (sunifiram), new potent cognition enhancers."
CNS Drug Rev 12(1): 39-52.
Ronn, L. C., I. Ralets, et al. (2000). "A simple procedure for quantification of neurite
outgrowth based on stereological principles." J Neurosci Methods 100(1-2): 25-
32.
Rowland, L. M., R. S. Astur, et al. (2005). "Selective cognitive impairments associated
with NMDA receptor blockade in humans." Neuropsvchopharmacology 30(3):
633-9.
Rubin, R. T., J. J. Phillips, et al. (1995). "Adrenal gland volume in major depression.
Increase during the depressive episode and decrease with successful treatment."
Arch Gen Psychiatry 52(3): 213-8.
Ruiz-Leon, Y. and A. Pascual (2003). "Induction of tyrosine kinase receptor b by
retinoic acid allows brain-derived neurotrophic factor-induced amyloid precursor
protein gene expression in human SH-SY5Y neuroblastoma cells." Neuroscience
120(4): 1019-26.
Sachar, E. J. and M. Baron (1979). "The biology of affective disorders." Annu Rev
Neurosci 2: 505-17.
Sakimura, K., H. Bujo, et al. (1990). "Functional expression from cloned cDNAs of
glutamate receptor species responsive to kainate and quisqualate." FEBS Lett
272(1-2): 73-80.
Sanchez, S., C. L. Sayas, et al. (2001). "The inhibition of phosphatidylinositol-3-kinase
induces neurite retraction and activates GSK3." J Neurochem 78(3): 468-81.
Santarelli, L., M. Saxe, et al. (2003). "Requirement of hippocampal neurogenesis for the
behavioral effects of antidepressants." Science 301(5634): 805-9.
Sassone-Corsi, P., J. Visvader, et al. (1988). "Induction of proto-oncogene fos
transcription through the adenylate cyclase pathway: characterization of a
cAMP-responsive element." Genes Dev 2(12A): 1529-38.
Schildkraut, J. J. (1965). "The catecholamine hypothesis of affective disorders: a review
of supporting evidence." Am J Psychiatry 122(5): 509-22.
Schmitt, W. B., R. Sprengel, et al. (2005). "Restoration of spatial working memory by
genetic rescue of GluR-A-deficient mice." Nat Neurosci 8(3): 270-2.
196
Schratt, G. M., E. A. Nigh, et al. (2004). "BDNF regulates the translation of a select
group of mRNAs by a mammalian target of rapamycin-phosphatidylinositol 3-
kinase-dependent pathway during neuronal development." J Neurosci 24(33):
9366-77.
Schurov, I. L., S. McNulty, et al. (1999). "Glutamatergic induction of CREB
phosphorylation and Fos expression in primary cultures of the suprachiasmatic
hypothalamus in vitro is mediated by co-ordinate activity of NMDA and non-
NMDA receptors." J Neuroendocrinol 11(1): 43-51.
Schwab, M. E. (2002). "Increasing plasticity and functional recovery of the lesioned
spinal cord." Prog Brain Res 137: 351-9.
Scott, R., R. Bourtchuladze, et al. (2002). "CREB and the discovery of cognitive
enhancers." J Mol Neurosci 19(1-2): 171-7.
Segal, R. A. (2003). "Selectivity in neurotrophin signaling: theme and variations." Annu
Rev Neurosci 26: 299-330.
Segal, R. A. and M. E. Greenberg (1996). "Intracellular signaling pathways activated by
neurotrophic factors." Annu Rev Neurosci 19: 463-89.
Shea, T. B., C. M. Cressman, et al. (1995). "Enhancement of neurite outgrowth
following calpain inhibition is mediated by protein kinase C." J Neurochem
65(2): 517-27.
Sheline, Y. I. (2003). "Neuroimaging studies of mood disorder effects on the brain."
Biol Psychiatry 54(3): 338-52.
Sheng, M., G. McFadden, et al. (1990). "Membrane depolarization and calcium induce
c-fos transcription via phosphorylation of transcription factor CREB." Neuron
4(4): 571-82.
Shepherd, T. A., J. A. Aikins, et al. (2002). "Design and synthesis of a novel series of
1,2-disubstituted cyclopentanes as small, potent potentiators of 2-amino-3-(3-
hydroxy-5-methyl-isoxazol-4-yl)propanoic acid (AMPA) receptors." J Med
Chem 45(10): 2101-11.
Shi, S., Y. Hayashi, et al. (2001). "Subunit-specific rules governing AMPA receptor
trafficking to synapses in hippocampal pyramidal neurons." Cell 105(3): 331-43.
Shieh, P. B., S. C. Hu, et al. (1998). "Identification of a signaling pathway involved in
calcium regulation of BDNF expression." Neuron 20(4): 727-40.
Shinozaki, H. and S. Konishi (1970). "Actions of several anthelmintics and insecticides
on rat cortical neurones." Brain Res 24(2): 368-71.
Shinozaki, H. and I. Shibuya (1974). "A new potent excitant, quisqualic acid: effects on
crayfish neuromuscular junction." Neuropharmacology 13(7): 665-72.
Shirayama, Y., A. C. Chen, et al. (2002). "Brain-derived neurotrophic factor produces
antidepressant effects in behavioral models of depression." J Neurosci 22(8):
3251-61.
Simpson, P. B., J. I. Bacha, et al. (2001). "Retinoic acid evoked-differentiation of
neuroblastoma cells predominates over growth factor stimulation: an automated
image capture and quantitation approach to neuritogenesis." Anal Biochem
298(2): 163-9.
Siuciak, J. A., D. R. Lewis, et al. (1997). "Antidepressant-like effect of brain-derived
neurotrophic factor (BDNF)." Pharmacol Biochem Behav 56(1): 131-7.
197
Skolnick, P. (2002). "Modulation of glutamate receptors: strategies for the development
of novel antidepressants." Amino Acids 23(1-3): 153-9.
Skolnick, P., B. Legutko, et al. (2001). "Current perspectives on the development of
non-biogenic amine-based antidepressants." Pharmacol Res 43(5): 411-23.
Sladeczek, F., J. P. Pin, et al. (1985). "Glutamate stimulates inositol phosphate formation
in striatal neurones." Nature 317(6039): 717-9.
Sommer, B., K. Keinanen, et al. (1990). "Flip and flop: a cell-specific functional switch
in glutamate-operated channels of the CNS." Science 249(4976): 1580-5.
Sommer, B., M. Kohler, et al. (1991). "RNA editing in brain controls a determinant of
ion flow in glutamate-gated channels." Cell 67(1): 11-9.
Song, I. and R. L. Huganir (2002). "Regulation of AMPA receptors during synaptic
plasticity." Trends Neurosci 25(11): 578-88.
Soppet, D., E. Escandon, et al. (1991). "The neurotrophic factors brain-derived
neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase
receptor." CeH 65(5): 895-903.
Sperry, R. W. (1963). "Chemoaffinity in the Orderly Growth of Nerve Fiber Patterns
and Connections." Proc Natl Acad Sci USA 50: 703-10.
Squinto, S. P., T. N. Stitt, et al. (1991). "trkB encodes a functional receptor for brain-
derived neurotrophic factor and neurotrophin-3 but not nerve growth factor."
Cell 65(5): 885-93.
Staubli, U., Y. Perez, et al. (1994). "Centrally active modulators of glutamate receptors
facilitate the induction of long-term potentiation in vivo." Proc Natl Acad Sci U
S A 91(23): 11158-62.
Staubli, U., G. Rogers, et al. (1994). "Facilitation of glutamate receptors enhances
memory." Proc Natl Acad Sci U S A 91(2): 777-81.
Stewart, R. J., B. Chen, et al. (2001). "Abnormalities in the cAMP signaling pathway in
post-mortem brain tissue from the Stanley Neuropathology Consortium." Brain
Res Bull 55(5): 625-9.
Strakowski, S. M., C. M. Adler, et al. (2002). "Volumetric MRI studies of mood
disorders: do they distinguish unipolar and bipolar disorder?" Bipolar Disord
4(2): 80-8.
Stringer, J. L., L. J. Greenfield, et al. (1983). "Blockade of long-term potentiation by
phencyclidine and sigma opiates in the hippocampus in vivo and in vitro." Brain
Res 280(1): 127-38.
Sugiyama, H., 1. Ito, et al. (1987). "A new type of glutamate receptor linked to inositol
phospholipid metabolism." Nature 325(6104): 531-3.
Sun, Y., R. Olson, et al. (2002). "Mechanism of glutamate receptor desensitization."
Nature 417(6886): 245-53.
Suter, D. M. and P. Forscher (1998). "An emerging link between cytoskeletal dynamics
and cell adhesion molecules in growth cone guidance." Curr Opin Neurobiol
8(1): 106-16.
Tao, X., S. Finkbeiner, et al. (1998). "Ca2+ influx regulates BDNF transcription by a
CREB family transcription factor-dependent mechanism." Neuron 20(4): 709-26.
Tessier-Lavigne, M. and C. S. Goodman (1996). "The molecular biology of axon
guidance." Science 274(5290): 1123-33.
198
Teter, B. and J. W. Ashford (2002). "Neuroplasticity in Alzheimer's disease." J Neurosci
Res 70(3): 402-37.
Tomita, S., H. Adesnik, et al. (2005). "Stargazin modulates AMPA receptor gating and
trafficking by distinct domains." Nature.
Tomita, S., H. Adesnik, et al. (2005). "Stargazin modulates AMPA receptor gating and
trafficking by distinct domains." Nature 435(7045): 1052-8.
Tomita, S., M. Sekiguchi, et al. (2006). "Stargazin controls the pharmacology of AMPA
receptor potentiators." Proc Natl Acad Sci USA.
Troller, U., A. Raghunath, et al. (2004). "A possible role for pl90RhoGAP in
PKCepsilon-induced morphological effects." Cell Signal 16(2): 245-52.
Tsai, S. Y., P. Y. Chiu, et al. (2002). "Synergistic effects of corticosterone and kainic
acid on neurite outgrowth in axotomized dorsal root ganglion." Neuroscience
114(1): 55-67.
Tucholski, J. and G. V. Johnson (2003). "Tissue transglutaminase directly regulates
adenylyl cyclase resulting in enhanced cAMP-response element-binding protein
(CREB) activation." J Biol Chem 278(29): 26838-43.
Tucker, K. L., M. Meyer, et al. (2001). "Neurotrophins are required for nerve growth
during development." Nat Neurosci 4(1): 29-37.
Tuominen, H. J., J. Tiihonen, et al. (2005). "Glutamatergic drugs for schizophrenia: a
systematic review and meta-analysis." Schizophr Res 72(2-3): 225-34.
Turetsky, D., E. Garringer, et al. (2005). "Stargazin modulates native AMPA receptor
functional properties by two distinct mechanisms." J Neurosci 25(32): 7438-48.
V. Lakics, J. W. R., T. R. Stewart, J. Shou, F. G. Boess, K. M. Merchant (2006).
Cellular pathways associated with activation of AMPA receptors by allosteric
modulators: relevance to pleiotropic neuropharmacology of AMPA potentiators.
Neuroscience 2006, Washington, Society for Neuroscience.
van Groen, T. (2001). "Entorhinal cortex of the mouse: cytoarchitectonical
organization." Hippocampus 11(4): 397-407.
van Groen, T., P. Miettinen, et al. (2003). "The entorhinal cortex of the mouse:
organization of the projection to the hippocampal formation." Hippocampus
13(1): 133-49.
van Praag, H., G. Kempermann, et al. (1999). "Running increases cell proliferation and
neurogenesis in the adult mouse dentate gyrus." Nat Neurosci 2(3): 266-70.
van Praag, H., A. F. Schinder, et al. (2002). "Functional neurogenesis in the adult
hippocampus." Nature 415(6875): 1030-4.
Vandergriff, J., K. Huff, et al. (2001). "Potentiation of responses to AMPA on central
neurones by FY392098 and LY404187 in vivo." Neuropharmacology 40(8):
1003-9.
Verdoorn, T. A., N. Burnashev, et al. (1991). "Structural determinants of ion flow
through recombinant glutamate receptor channels." Science 252(5013): 1715-8.
Vollmayr, B., C. Simonis, et al. (2003). "Reduced cell proliferation in the dentate gyrus
is not correlated with the development of learned helplessness." Biol Psychiatry
54(10): 1035-40.
Voss, O. P., S. Milne, et al. (2006). "Molecular mechanisms of neurite growth with
AMPA receptor potentiation." Neuropharmacology.
199
Wang, G. X. and M. M. Poo (2005). "Requirement of TRPC channels in netrin-1-
induced chemotropic turning of nerve growth cones." Nature 434(7035): 898-
904.
Wang, Y. and J. P. Durkin (1995). "alpha-Amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid, but not N-methyl-D-aspartate, activates mitogen-
activated protein kinase through G-protein beta gamma subunits in rat cortical
neurons." J Biol Chem 270(39): 22783-7.
Wang, Y., D. L. Small, et al. (1997). "AMPA receptor-mediated regulation of a Gi-
protein in cortical neurons." Nature 389(6650): 502-4.
Watanabe, Y., E. Gould, et al. (1992). "Tianeptine attenuates stress-induced
morphological changes in the hippocampus." Eur J Pharmacol 222(1): 157-62.
Watkins, J. C. (2000). "1-glutamate as a central neurotransmitter: looking back."
Biochem Soc Trans 28(4): 297-309.
Watkins, J. C. and R. H. Evans (1981). "Excitatory amino acid transmitters." Annu Rev
Pharmacol Toxicol 21: 165-204.
website, O. (2006).
Werner, P., M. Voigt, et al. (1991). "Cloning of a putative high-affinity kainate receptor
expressed predominantly in hippocampal CA3 cells." Nature 351(6329): 742-4.
White, F., J. A. Nicoll, et al. (2001). "Impaired neuronal plasticity in transgenic mice
expressing human apolipoprotein E4 compared to E3 in a model of entorhinal
cortex lesion." Neurobiol Pis 8(4): 611-25.
Wiesel, T. N. and D. H. Hubel (1963). "Effects of Visual Deprivation on Morphology
and Physiology of Cells in the Cats Lateral Geniculate Body." J Neurophvsiol
26: 978-93.
Wong, E. H., J. A. Kemp, et al. (1986). "The anticonvulsant MK-801 is a potent N-
methyl-D-aspartate antagonist." Proc Natl Acad Sci USA 83(18): 7104-8.
Wong, R. O. and A. Ghosh (2002). "Activity-dependent regulation of dendritic growth
and patterning." Nat Rev Neurosci 3(10): 803-12.
Wu, G. Y. and H. T. Cline (1998). "Stabilization of dendritic arbor structure in vivo by
CaMKII." Science 279(5348): 222-6.
Wu, G. Y., K. Deisseroth, et al. (2001). "Activity-dependent CREB phosphorylation:
convergence of a fast, sensitive calmodulin kinase pathway and a slow, less
sensitive mitogen-activated protein kinase pathway." Proc Natl Acad Sci U S A
98(5): 2808-13.
Wu, X., D. Zhu, et al. (2004). "AMPA protects cultured neurons against glutamate
excitotoxicity through a phosphatidylinositol 3-kinase-dependent activation in
extracellular signal-regulated kinase to upregulate BDNF gene expression." J
Neurochem 90(4): 807-18.
Xia, J., X. Zhang, et al. (1999). "Clustering of AMPA receptors by the synaptic PDZ
domain-containing protein PICK1." Neuron 22(1): 179-87.
Xiao, P., U. Staubli, et al. (1991). "Selective effects of aniracetam across receptor types
and forms of synaptic facilitation in hippocampus." Hippocampus 1(4): 373-80.
Yamada, K. A., D. F. Covey, et al. (1998). "The diazoxide derivative IDRA 21 enhances
ischemic hippocampal neuron injury." Ann Neurol 43(5): 664-9.
200
Yamada, K. A. and S. M. Rothman (1992). "Diazoxide blocks glutamate desensitization
and prolongs excitatory postsynaptic currents in rat hippocampal neurons." J
Physiol 458: 409-23.
Yamada, K. A. and C. M. Tang (1993). "Benzothiadiazides inhibit rapid glutamate
receptor desensitization and enhance glutamatergic synaptic currents." J
Neurosri 13(9): 3904-15.
Yamazaki, M., T. Ohno-Shosaku, et al. (2004). "A novel action of stargazin as an
enhancer of AMPA receptor activity." Neurosci Res 50(4): 369-74.
Zafra, F., B. Hengerer, et al. (1990). "Activity dependent regulation of BDNF and NGF
mRNAs in the rat hippocampus is mediated by non-NMDA glutamate
receptors." Embo J 9(11): 3545-50.
Zarrinmayeh, H., E. Tromiczak, et al. (2006). "A novel class of positive allosteric
modulators of AMPA receptors: design, synthesis, and structure-activity
relationships of 3-biphenyl-4-yl-4-cyano-5-ethyl-1 -methyl-1 H-pyrrole-2-
carboxylic acid, LY2059346." Bioorg Med Chem Lett 16(19): 5203-6.
Zhang, D. X. and W. B. Levy (1992). "Ketamine blocks the induction of LTP at the
lateral entorhinal cortex-dentate gyrus synapses." Brain Res 593(1): 124-7.
Zivkovic, I., D. M. Thompson, et al. (1995). "7-Chloro-3-methyl-3-4-dihydro-2H-l,2,4
benzothiadiazine S,S-dioxide (IDRA 21): a benzothiadiazine derivative that
enhances cognition by attenuating DL-alpha-amino-2,3-dihydro-5-methyl-3-oxo-
4-isoxazolepropanoic acid (AMPA) receptor desensitization." J Pharmacol Exp
Ther 272(1): 300-9.
201
